タイトル:

出版社:

ISBN:

著者:

キーワード:

カテゴリー:

発行年:

～

検索条件をクリア

書籍詳細

未契約

書籍名	血液凝固 ―止血と血栓・下
出版社	宇宙堂八木書店
発行日	1983-12-10
著者	福武勝博(編集) 山中學(編集)
ISBN
ページ数	577
版刷巻号	第1版
分野	臨床医学：内科血液
閲覧制限	未契約

本書は現代凝血学の総輯的なものとしてその出版はまさに時宜をえたものであろう。上巻は総論的な内容を主として取り上げ、下巻は臨床の実際に直結する内容である。(序より)

目次

表紙
閲覧
分担執筆者
閲覧
序
閲覧
目次
閲覧
第2編各論
閲覧
- 1. 出血性疾患
- 2. 血栓性疾患
第3編検査法
閲覧
- 1. 止血検査用試剤の調整法
- 2.凝固因子の純化
- 3. 検査手技
索引
閲覧
奥付
閲覧

参考文献

第2編各論

P.7 掲載の参考文献

1) Cream, J. J., et al.:Schonlein-Henoch purpura in the adult. Quart. J. Med., 39:461-484, 1970.
pubmed

2) Gray, N. E., et al.:The Schonlein-Henoch syndrome. Ann. Int. Med., 72:229-234, 1970.

3) Allen, D. M., et a.:Anaphylactoid purpura in children (Schonlein-Henoch syndrome). Amer. J. Dis. Child., 99:833-854, 1960.

4) Meadow, S. R., et al.:Schonlein-Henoch nephritis. Quart. J. Med., 41:241-258, 1972.
pubmed

5) Ballard, H. S., et al.:Renal manifestation of the Henoch-Schonlein syndrome in adults. Amer. J. Med., 491:328-335, 1970.

6) Ratnoff, O. S. and Agle, D. P.:Psychogenic purpura a reevaluation of the syndrome of autoerythrocyte sensitization. Medicine, 47:475-500, 1966.

7) McKusick, V. A.:Heritable disorders of connective tissue. 3rd ed., St. Louis:The C. V. Mosby Co., 1965.

8) Wintrobe, M. M.:Clinical Hematology. 8th ed., Philadelphia:Lea & Febiger, 1981. p. 1072-1089.

P.34 掲載の参考文献

1) Wakisaka, G.:Idiopathic thrombocytopenic purpura as observed from the viewpoint of auto. immune disease. Acta Haematol Jap., 25:341, 1962.

2) Wakisaka, G.:Studies on platelet antibodies in idiopathic thrombocytopenic purpura and experimental thrombocytopenias. Acta Haematol. Jap., 27:663, 1964.

3) 脇坂行一, 安永幸二郎:免疫栓球減少症. 日血全書, 4巻. 東京:丸善, 1965. p. 667.

4) 安永幸二郎:免疫血小板減少症. 第17回日本医学会総会学術講演集-196年の医学-, 第II巻, 1967. p.351.

5) 安永幸二郎:血小板抗体の臨床. 医学のあゆみ, 68:676, 1969.

6) 安永幸二郎:特発性血小板減少性紫斑病. 臨床血液, 13:504, 1972.

7) Baldini, M.:Idiopathic thrombocytopenic purpura. N. Engl. J. Med., 274:1245, 1301, 1360, 1966.

8) Davey, M. G.:The survival and destruction of human platelets. Basel and New York:S. Karger, 1966.

9) Aster, R. H., Keene, W. R.:Sites of platelet destruction in idiopathic thrombocytopenic purpura. Br. J. Haematol., 16:61, 1969.
pubmed

10) Harrington, W. J., Sprague, C C., Minnich, V., Moore, C. V., Aulvin, R. C., Dubach, R.:Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura. Ann. Intern. Med., 38:433, 1953.
pubmed

11) Sauer, A. J., Van Loghem, J. J.:Platelet autoantibodies and haemorrhagic disease in the new-born. Vox Sang, 5:45, 1955.

12) Jones, T. G., Goldsmith, K. L. G., Anderson, I. M.:Maternal and neonatal platelet antibodies in a case of congenital thrombocytopenia. Lancet, ii:1008, 1961.

13) Harrington, W. J., Hollingsworth, J. W., Minnich, V., Moore, C. V.:Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. Lab. Clin. Med., 38:1, 1951.
pubmed

14) Furukawa, H.:Serological studies on human platelet antibodies. Acta Haematol.Jap., 30:372, 1967.

15) Schulman, N. R., Marder, VJ., Weinrach, R. S.:similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia or idiopathic purpura. Physiologic, serologic and isotope studies. Ann. N. Y. Acad. Sci., 124:499, 1965.

16) Karpatkin, S., Strick, N., Siskind, G. W.:Detection of splenic antiplatelet antibody synthesis in (idiopathic) autoimmune thrombocytopenic purpura (ATP). Clin. Res., 19:422, 1971.

17) McMillan, R., Longmire, R., Yelenosky, R., Craddock, C. G.:Platelet binding antibodies produced in vitro by idiopathic thrombocytopenic purpura (ITP) spleens. J. Clin. Invest., 50:65, 1971.

18) Harker, L. A., Finch, C A.:Thrombokinetics in man. J. Clin. Invest., 48:963, 1969.

19) Harker, L. A,:Thrombokinetics in idiopathic thrombocytopenic purpura. Br. J. Haematot., 19:95, 1970.

20) 安永幸二郎:特発性血小板減少性紫斑病 (ITP). 臨床病理, 23:256, 1975.
Medical*Online

21) Doan, C. A., Bouroncle, B. A., Wiseman, B. K.:Idiopathic and secondary thrombocytopenic purpura. Clinical studies and evaluation of 381 cases over a period of 28 years. Ann. Intern. Med., 53:861, 1960.

22) Meyers, M. C.:Results of treatment in 71 patients with idiopathic thrombocytopenic purpura. Am. J. Med. Sci., 242:295, 1961.
pubmed

23) Ehrlich, L., Schwartz, S. O.:Splenomegaly in thrombocytopenic purpura. Am. J. Med. Sci., 221:158, 1951.
pubmed

24) Evans, R. S., Takahashi, K., Duane, R. T., Payne, T., Liu, C. K.:Primary thrombocytopenic purpura and acquired hemolytic anemia. Arch. Intern. Med., 87:48, 1951.

25) Dameshek, W., Miller, E. B.:The megakaryocytes in idiopathic thrombocytopenic purpura:A form of hypersp|enism. Blood, 1:27, 1946.

26) Stefanini, M., Mele, R. H.:The significance of platelet antibodies:With special reference to platelet agglutinins. Acta Haematol., 20:195, 1958.
pubmed

27) Jacklin, H. N., Fur, F. W., Losner, E. L.:Studies on the causes of false positive results in the laboratory detection of platelet agg (utinins in thrombocytopenic purpura. Am. J. Clin. Path., 36:95, 1961.

28) Dausset, J., Colombani, J., Colombani, M.:Study of leukopenias and thrombocytopenias by the direct antiglobulin consumption test on leukocytes and/or platelets. Blood, 18:672, 1961.
pubmed

29) Sauer, A. J., Von Loghem, JJ.:A study on the occurrence of platelet autoantibodies. Vox Sang, 4:120, 1954.

30) Tullis, J. L.:Identification and significance of platelet antibodies. N. Engl. J. Med., 225:541, 1956.

31) Aster, R. H.:A platelet membrane defect in paroxysmal nocturnal hemoglobururia (PNH):Usefulness in detecting platelet antibodies in thrombocytopenic purpura. J. Clin. Invest., 47:2, 1968.

32) Harrington, W. J., Minnich, V., Arimura, G.:The autoimmune thrombocytopenias. Progr. Hematol., 1:166, 1956.

33) 安永幸二郎, 大熊稔, 山田-正, 鯉江捷夫, 神谷忠, 石黒順造, 高橋武昭, 緒方完治, 蔵本淳, 武富嘉亮, 井原章裕:特発性血小板減少性紫斑病症例における血小板抗体の検出について-血小板抗体検査方法による比較と検査施設問の比較. 厚生省特定疾患, 「特発性血小板減少性紫斑病」調査研究班, 昭和49年度研究業績報告書, 1975, p.330,

34) Dixson, R., Rosse, W., Ebbert, L.:Quantitative determination of antibody in idiopathic throm-bocytopenic purpura. New Engl. J. Med., 292:230, 1975.

35) Luiken, G. A., McMillan, R., Lightsey, A. L, Gordon, P., Zevely, S" Schulman, I., Gribble, J., Longmire, R.L.:Platelet-associated IgG in immune thrombocytopenic purpura. Blood, 50:317, 1977

36) McMillan, R., Tani, P., Masson, D.:The demonstration of antibody binding to platelet associated antigens in patients with immune thrombocytopenic purpura. Blood, 56:993, 1980.

37) Mueller-Echardt, C., Mahn, I., Schulz, G., Mueller-Eckhardt, G.:Detection of platelet auto-antibodies by a radioactive antiimmunoglobulin test. Vox Sang., 35:357, 1978.

38) Sugiura, K., Steiner, M., Baldini, M.:Characterization and measurement of normel platelet associated immunoglobulin G by fluorospectrophotometry. Bioch. Biophys. Acta, 631:166, 1980.

39) von dem Borne, A. E. G. Kr., Verheugt, F. W. A., Oosterhof, F., von Riesz, E., De la Riviere, A. B., Engelfriet, C. P.:Asimple immunofluorescence test for the detection of platelet anti-bodies. Brit. J. Haematol., 39:195, 1978.

40) Gudino, M., Miller, W. V.:Application of the enzyme linked immunospeci fic assay (ELISA) for the detection of platelet antibodies. Blood, 57:32, 1981.

41) Leporrier, M., Dighiero, G., Auzemery, M., Binet, J. L:Detection and quantification of platelet bound antibodies with immunoperoxidase. Brit. J. Haematol., 42:605, 1979.

42) Schmidt, G. M., Bross, J., Blume, K. G., Enders, N., Santos, S., Novitski, M., Chiller. R.K.:Detection of platelet-directed immunoglobulin G in sera using the peroxidase anti-peroxidase (PAP) slide technique. Blood, 55:299, 1980.

43) Tate, D. Y., Soreson, R. L., Gerrard, J. M., White, J. G., Krivit, W.:An immunoenzyme histochemical technique for the detection of platelet antibodies from the serum of patients with idiopathic (autoimmune) thrombocytopenic purpura (ITP). Brit. J. Haematol., 37:265, 1977.

44) 厚生省特定疾患特発性造血障害調査研究班昭和55年度研究業績報告書, 215, 1981.

45) Najean, Y., Ardaillou, N., Dresch, C., Bernard, J.:The platelet destruction site in thrombo:cytopenic purpuras. Lab. Invest., 4:206, 1955.

46) Bowman, H. E.:Pettit, V.D., Caldwell, F.T., Smith, E.B.:Morphology of the spleen in idio-pathic thrombocytopenic purpura. Lab. Invest., 4:206, 1955.

47) 安永幸二郎:特発性血小板減少性紫斑病の診断基準について-調査票の成績からの帰納的考察. 厚生省特定疾患「特発性血小板減少性紫斑病」調査研究班, 昭和49年度研究業績報告書, 1975. p. 11.

48) Lusher, J. M., Zuelzer, W. W.:Idiopathic thrombocytopenic purpura in childhood. J. Pediat., 68:971, 1966.
pubmed

49) Choi, S. I., McClure, P. D.:Idiopathic thrombocytopenic purpura in childhood. Canad. Med. Ass. J., 97:562, 1967.
pubmed

50) Robson, H. N., Duthie, JJ. R.:Capillary resistance and adrenocortical activity. Br. Med. J., 2:971, 1950.
pubmed

51) Faloon, W. W., Greene, R. W., Losner, E. L:The hemostatic defect in thrombocytopenia as studies by the use of ACTH and cortisone. Am. J. Med., 13:12, 1952.

52) Walker, J. H., Walker, W.:Idiopathic thrombocytopenic purpura in childhood. Arch. Dis. Child., 36:649, 1961.
pubmed

53) Weisberger, A. S., Suhrland, L. G.:Massive corticosteroid therapy in the management of resistant thrombocytopenic purpura, Am. J. Med. Sci., 236:425, 1958.
pubmed

54) Shulman, N. R., Weinrach, R. S., Libre, E. P., Andrews, H. L:The role of the reticuloendo:thelial system in the pathogenesis of idiopathic thrombocytopenic purpura. Trans. Assoc. Am. Physicians, 78:374, 1965.

55) Carpenter, A. F., Wintrobe, M. M., Fuller, F. A., Haut, A., Cartwright, G. E.:Treatment of idiopathic thrombocytopenic purpura. J. A. M. A., 171:1911, 1959.

56) Nordoy, A., Neset, G.:Splenectomy in hematologic diseases. Acta Med. Scand., 183:117, 1968.
pubmed

57) Charlesworth, D., Torrance, H. B.:Splenectomy in thrombocytopenic purpura. Br. J. Surg., 55:437, 1968.
pubmed

58) Curtis, G. M., Movitz, D.:The surgical significance of the accessory spleen. Ann. Surg., 123:276, 1946.

59) Evans, T. S., Spinner, S., Piccolo, P., Swirsky, R., White, R., Kiesewetter, W.:Recurrent hypersplenism due to accessory spleen. Acta Haematol., 10:350, 1953.

60) Best, W. R., Darling, D. R. A.:Acritical look at the splenectomy-S. L. E. controversy. Med. Clin. North Am., 46:19, 1962.

61) Sussman, L. N.:Azothioprine in refractory idiopathic thrombocytopenic purpura. J. A. M, A., 202:259, 1967.
pubmed

62) Bouroncle, B, A., Doan, C. A.:Treatment of refractory idiopathic thrombocytopenic purpura. J. A, M. A., 207:2049, 1969.
pubmed

63) Hilgartner, M. W., Lanzkowsky, P., Smith, C. H.:The use of azathioprine in refractory idiopathic thrombocytopenic purpura in children. Acta Paediatr. Scand., 59:409, 1970.
pubmed

64) Martin, H., Nowicki, L., Schubert, J. C. F., Schubert, H.:Behandlung des Morbus Werlhof mit actinomycin C. Dtsch. Med. Wochenschr., 92:1061, 1967.

65) Laros, R. K., Penner, J. A.:Thrombocytopenic purpura treated with cyclophosphamide. J. A. M. A., 215:445, 1971.
pubmed

66) Mamont, A. M., Damasio, E. E., Gori, E.:Vinblastine sulphate in idiopathic thrombocytopenic purpura. Lancet, ii:94, 1971.

67) 安永幸二郎:慢性ITPにおける摘脾の反応型と摘脾後療法について・厚生省特定疾患「特発性血小板減少性紫斑病」調査研究班, 昭和49年度研究業績報告書, 1975. p 458.

68) Imbach, P., Barandun, S., Baumgartner, C., Hirt, A., Hofer, F., Wagner, H. P.:High:dose intraveneous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv. Paediat. Acta, 36:81, 1981.
pubmed

69) Imbach, P., Barandun, S., d:Apuzzo, V., Baumgartner, C., Hirt, A., Morell, A., Rossi, E., Schoni, M., Vest, M., Wagner, H. P.:High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet, i:1228, 1981.
pubmed

70) Schmidt, R. E, Budde, U., Schafer, G., Stroehmann, I.:High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura. Lancet, ii:475, 1981.

71) Cohen, R. J., Dennis, L. H., Conrad, M. E.:Anticoagulant therapy in idiopathic thrombocytopenic purpura. Blood, 31:647, 1968.
pubmed

72) Krivit, W., Yunis, E., White, J. G.:Platelet survival studies in Aldrich syndrome. Pediatrics, 37:339, 1966.
pubmed

73) Pearson, H. A., Shulman, N. R., Oski, F. A., Eitzman, D. V.:Platelet survival in Wiskott-Aldrich syndrome. J. Pediatr., 68:754, 1966.
pubmed

74) Grottum, K. A., Hoving, T., Holmsen, H., Abrahamsen, A. F., Jeremic, M., Seip, M.:Wiskott-Aldrich syndrome:Quantitative platelet defects and short platelet survival, Br. J. Haematol., 17:373, 1969.

75) Kuramoto, A., Steiner, M., Baldini, M. G.:Lack of platelet response to stimulation in the Wiskott-Aldrich syndrome. N. Engl. J. Med., 282:475, 1970.
pubmed

76) Blaese, R. M., Strober, W., Brown, R. S., Waldman, T. A.:The Wiskott-Aldrich syndrome. A disorder with a possible defect in antigen processing of recognition. Lancet, i:1056, 1968.

77) Cooper, M. D., Chase, H. P., Lowman, J. T., Krivit, W., Good, R. A.:Wiskott-Aldrich syndrome. An immunologic deficiency disease involving the afferent limb of immunity. Am. J. Med., 44:499, 1968.

78) Fanconi, G.:Familial constitutional panmyelocytopathy, Fanconi:sanemia (F. A.). I. Clinical aspects. Ser. Hematol., 4:233, 1967.

79) Oski, F. A., Naiman, J. L., Allen, D. M., Diamond, L. K.:Leukocytic inclusions-Dohle bodies associated with platelet abnormality (The May-Hegglin anomaly). Blood, 20:657, 1962.
pubmed

80) Beck, E. A., Baumgartner, H. R.:Thrombopathy in May-Hegglin anomaly. Schweiz. Med. Wochenschr., 100:330, 1970.
pubmed

81) Davis, J. W., Wilson, S. J.:Platelet survival in the May-Hegglin anomaly. Br. J. Hematol., 12:61, 1966.

82) Murphy, S., Oski, F. A., Gardner, F. H.:Hereditary thrombocytopenia with an intrinsic platelet defect. N. Engl. J. Med., 281:857, 1969.
pubmed

83) Myllyla, G., Pelkonen, R., Ikkala, E., Apajalahti, J.:Hereditary thrombocytopenia;report of three families. Scand. Scand. J. Haematol., 4:441, 1967.
pubmed

84) Horowitz, H. I., Nachman, R. L:Drug Purpura. Ser. Hematol, 2:287, 1965.

85) Blajchman, M. A., Lowry, R. C., Pettit, J. E., Stradling, P.:Rifampicin-induced immune thrombocytopenia. Br. Med. J., 3:24, 1970.
pubmed

86) Manohitharajah, S. M., Jenkins, WJ., Roberts, P. D., Clarke, R. C.:Methyldopa and associated thrombocytopenia. Br. Med. J., 1:494, 1971.
pubmed

87) Ackroyd, J. F.:The pathogenesis of thrombocytopenic purpura due to hypersensitivity to Sedormid. Clin. Sci., 7:249, 1949.
pubmed

88) Ackroyd, J. F.:The role of complement in sedormid purpura. Clin. Sci., 10:185, 1951.
pubmed

89)Ackroyd, J.F.:Allergic purpura, including purpura due to food, drugs and infections. Am. J. Med., 14:1953.
pubmed

90) Okuma, M:Studies on experimental immune thrombocytopenia. VI. Thrombocytopenia in rabbits induced by sensitization with quinidine. Acta Haematol. Jap., 30:767, 1967.

91) Okuma, M.:Studies on experimental immune thrombocytopenia. V. Serological studies on thrombocytopenia in rabbits induced by quinidine with special reference to the role of quinidine in the immunological reactions. Acta Haematol. Jap., 30:785, 1967.

92) Schulman, N. R.:A mechanism of cell destruction in individuals sensitized to foreign antigens and its implications in auto-immunity. Ann. Intern. Med., 60:506, 1964.

93) Eisner, E. V. Cromwell, E. B.:Hydrochlorothiazide-dependent thrombocytopenia due to IgM antibody. J. A. M. A., 215:480, 1971.

94) 安永幸二郎, 大熊稔:アレルギー性紫斑病. 診療, 20:1412, 1967.

95) Horowitz, H. I., Rappaport, H. I., Young, R. C., Fujimoto, M. M.:Changes in platelet factor 3as a means of demonstrating immune reactions involving platelets:its use as a test for quinidine-induced thrombocytopenia. Transfusion, 5:336, 1965.

96) Wakisaka, G., Yasunaga, K., Nishikawa, T.:Hemorrhagic diathesis in leukemia. Research papers on blood coagulation. Special Committee on Blood Coagulation, Japan Hematological Society, Tokyo, 1960, p. 260.

97) 脇坂行一, 安永幸二郎, 西河直:再生不良性貧血と出血性素因. 日本臨牀, 17:2117, 1959
Medical*Online

98) Willis, W. H.:Thrombocytopenic purpura and carcinoma of stomach:Report of a case with purpura appearing after subtotal gastrectomy. Ann. Intern. Med., 16:782, 1942.

99) Dameshek, W., Reeves, W. H.:Exacerbation of erythematosus following splenectomy in 'idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia. Am. J. Med., 21:560, 1956.
pubmed

100) Eversole, S. L.:Cases of disseminated lupus erythematosus diagnosed as idiopathic thrombocytopaenic purpura. Bull. Johns Hopkins Hosp., 96:210, 1955.
pubmed

101) Rabinowitz, Y., Dameshek, W.:Systemic lupus erythematosus after 'idiopathic' thrombocytopenic purpura:A review. Ann. Intern. Med., 52:1, 1960.
pubmed

102) Karpatkin, S., Siskind, G.M.:In vitro detection of platelet antibody in patients with idiopathic thrombocytopenic purpura and systemic lupus erythematosus. Blood, 33:795, 1969.

103) Aster, R. H.:Pooling of platelets in the spleen:ro (e in the pathogenesis of:hypersplenic:thrombocytopenia. J. Clin. Invest., 45:645, 1966.

104) Penny, R., Rozenberg, M. C., Firkin, B. G.:The splenic platelet pool. Blood, 27:1, 1966.
pubmed

105) Cohen, P., Gardner, F. H., Barnett, C.O.:Reclassification of the thrombocytopenias by the 51Cr-labelling method for measuring Platelet life span. N. Engl. J. Med., 264:1294, 1350, 1961.

106) Najean, Y., Ardaillou, N., Caen, J., Larrieu, M. J., Bernard, J.:Survival of radiochromium labelled platelets in thrombocytopenia. Blood, 22:718, 1963.
pubmed

107) Aster, R. H.:Jandl, J. H.:Platelet sequestration in man. II. Immunological and clinical studies. J. Clin. Invest., 43:856, 1964.
pubmed

108) Jandl, J. H., Aster, R. H.:Increased splenic pooling and the pathogenesis of hypersplenism. Am. J. Med. Sci., 253:383, 1967.
pubmed

109) Welch, R. G.:Thrombocytopenic purpura and chicken-pox. Arch.Dis. Child., 31:38, 1956.

110) Ferguson, A.W.:Rubella as a cause of thrombocytopenic purpura. Pediatrics, 25:400, 1960.
pubmed

111) Ackroyd, J. K.:Three cases of thrombocytopenic purpura occurring after rubella. Quart. J. Med., 42:299, 1949.

112) Newton, Wa., Zuelzer, W.W.:Idiopathic thrombocytopenic purpura in childhood. N. Engl. J. Med., 245:879, 1951.
pubmed

113) Kolars, C. P., Spink, W.W.:Thrombocytopenic purpura as a complication of mumps. J. A. M. A., 168:2213, 1958,

114) Radel, E. G., Schorr, J.B.:Thrombocytopenic purpura with infectious mononucleosis. J. Pediatr., 63:46, 1963.
pubmed

115) Meindersma, T. E., De Vries, S.L:Thrombocytopenic purpura after smallpox vaccination. Br. Med. J., 1:226, 1962.

116) Krevans, J. R., Jackson, D.P.:Hemorrhagic disorder foltowing massive whole blood transfusion. J, A. M. A., 159:171, 1955.

117) Jackson, D. P., Krevans, Jr., Conley, C. L.:Mechanism of the thrombocytopenia that follows multiple whole blood transfusions. Trans. Ass. Am. Physicians, 69:155, 1956.

118) Zucker, M. B., Siegel, M., Clifton, E. E., Bellvile, J. W., Howland, W. S., Grossi, C. E.:Gene. realized excessive oozing in patients undergoing major surgery and receiving multiple blood transfusions. J. Lab. Clin. Med., 50:849, 1957.

119) Schulman, N. R., Aster, R. H., Leitner, A., Hiller, M. C.:Immuno-reactions involving platelets. V. Post-transfusion purpura due to a complement-fixing antibody against a genetically controlled platelet antigen. J. Clin. Invest., 40:1597, 196L

120) Morrison, F. S., Mollison, P. L.:Post-transfusion purpura. N. Engl. J. Med., 275:243, 1966.
pubmed

121) Nicholls, R. J., Davies, P., Kenwright, M. G.:Thrombocytopenic purpura after blood transfusion. Br. Med. J., 2:581, 1970.
pubmed

122) Kasabach, H. H., Merritt, K. K.:Capillary hemangioma with extensive purpura. Am. J. Dis. Child., 59:1063, 1940.

123) Hill, G. J., Longino, L. A.:Giant hemangioma with thrombocytopenia. Surg. Gynecol. Obstet., 114:304, 1962.
pubmed

124) Shin, W. K. T.:Hemangiomas of infancy complicated by thrombocytopenia. Am. J. Surg., 116:896, 1968.

125) Sutherland, D. A., Clark, H.:Hemangioma associated with thrombocytopenia. Am. J. Med., 33:150, 1962.
pubmed

126) Propp, R. P., Scharfman, W. B.:Hemangioma-thrombocytopenia syndrome associated with mic. roangiopathic hemolytic anemia. Blood, 28:623, 1966.

127) Schneider, H. J., Lascari, A. D.:Consumption coagulopathy in an infant with Kasabach-Merritt syndrome. Helv. Paediatr. Acta, 23:674, 1968.

128) Inceman, S., Tangun, Y.:Chronic defibrination syndrome due to a giant hemangioma as:sociated with microangiopathic hemolytic anemia. Am. J. Med., 46:997, 1969.

129) Pyesmany, A., Ekert, H., Williams, K., Hittle, R.:Intravascular coagulation secondary to cavernous hemangioma in infancy:response to radiotherapy Can. Med. Assoc. J., 100:1053, 1969.
pubmed

130) Podriguez-Erdmann, F., Bulton, L., Murray, J. E., Moloney. W. C.:Kasabach-Merritt syndrome. Coagulo-analytic observations. Am. J. Med. Sci., 261:9, 1971.

131) Smith, M. D., Smith, D. A., Flectcher, M.:Haemorrhage associated with thrombocytopenia in megaloblastic anemia. Br. Med. J., 1:982, 1962.

132) Kotilainen, M.:Platelet kinetics in normal subjects and in haematological disorders. Scand. J. Haematol., Suppl. 5, 1969.
pubmed

133) Kameshek, W., Valentine, E.H.:The sternal marrow in pernicious anemia. Arch. Path., 23:159, 1937.

134) Epstein, R.D.:Cells of the megakaryocyte series in pernicious anemia:In particular the effect of specific therapy. Am. J. Pathol, 25:239, 1949.
pubmed

135) Queisser, U., Queisser, W., Spiertz, B.:Polyploidization of megakaryocytes in normal humans, in patients with idiopathic thrombocytopenia and with pernicious anaemia. Br. J. Haematol., 20:489, 1971.
pubmed

136) Gross, S, Keefer, V., Newman, A.J.:Platelets in iron deficiency response to therapy. Pediatrics, 34:315, 1964.
pubmed

137) Moschcowitz, E.:An acute febrile pleiochromic anemia with hyaline thrombosis of terrninal and capillaries;an undescribed disease. Arch. Intern. Med., 36:89, 1925.

138) Singer, K., Bornstein, F.P., Wile, S.A.:Thrombotic thrombocytopenic purpura, Hemorrhagic diatheses with generalized platelet thromboses. Blood, 2:542, 1947.
pubmed

139) Orbison, J.L.:Morphology of thrombotic thrombocytopenic purpura with demonstration of aneurysms. Am. J. Pathol., 28:129, 1952.
pubmed

140) Feldman, J. D., Mardiney, M. R., Unanue, E. R., Cutting, H.:The vascular pathology of thrombotic thrombocytopenic purpura. An immunohistochemical and ultrastructual study. Lab. Invest., 15:927, 1966.

141) Amorosi, E. L., Ultmann, J. E.:Thrombotic thrombocytopenic purpura. Report of 16 cases and review of the literature. Medicine, 45:139, 1966,

142) Kwaan, H. C., Gallo, G., Potter, E., Cutting, H., Stanzler, R.:The nature of the vascular lesion in thrombotic thrombocytopenic purpura. Ann. Intern. Med., 68:1169, 1968.

143) Kwaan, H. C.:Dynamics of Thrombus Formation and Dissolution. (Johnson, S. A. and Guest, M. M. eds.), Philadel. & Toronto:J. B. Lippincott, 1969. p. 340.

144) Brain, M. C.:Hemolytic-uraemic syndrome. Lancet, ii:1394, 1968.

145) Rubenberg, M. L., Regoeczi, E., Bul|, B. S., Dacie, J. V., Brain, M. C.:Microangiopathic hemoliytc anemia. The experimental production of hemolysis and red cell fragmentation by defibrination in vivo. Brit. J. Haematol., 14:627, 1968.

146) Singer, K.:Thrombotic thrombocytopenic purpura. Adv. Intern. Med., 6:195, 1954.
pubmed

147) Cahalane, S. F., Horn, Rc.:Thrombotic thrombocytopenic purpura of long duration. Am. J. Med., 27:333, 1959.
pubmed

148) Carter, J. R.:Thrombotic thrombocytopenic purpura. The Platelet (Brinkhous, K. M., Schermer, R. W., Mostofi, F. K. eds.), Baltimore:Williams and Wilkins, 1971. p. 285.

149) Lerner, R. G., Papaport, S. I., Meltzer, J.:Thrombotic thrombocytopenic purpura, Seriacl clotting studies, relation to the generalized Shwarzman reaction, and remission after adrenal ateroid and dextran therapy. Ann. Intern. Med., 66:1180, 1967.

150) Barnhart, M. I., McCutchon, S. A., Riddle, J. M., Ohorodnik, J. M.:Thrombotic thrombocytopenic purpura as model of accelated protein synthesis. Thromb. Diath. Haemorrh., 12:211, 1964.

151) Bakemeier, R. F.:Immunological Diseases. Boston:Little Brown, 1965. p. 876.

152) Adelson, E., Heitzman, E. J., Fennessey, J. F.:Thrombohemolytic thrombocytopenic purpura. Arch. Intern. Med., 94:43, 1954.

153) Brittingh am, T. E., III Chaplin, H., Jr.:Attempted passive transfer of thrombotic thrombocytopenic purpura. Blood, 12:480, 1957.

154) Laszlo, M. H., Alvarez, A., Feldman, F.:The association of thrombotic thrombocytopenic purpura and disseminated lups erythematosus Report of a case Ann Inter n Med., 42:1308, 1955.

155) Siegel, B. M., Fiedman, I. A., Kessler, S., Schwarz, S.O.:Thrombohemolytic thrombocytopenic purpura and lupus erythematosus. Ann. Intern. Med., 47:1022, 1957.

156) Distenfeld, A.. Oppenheim, E.:The treatment of acute thrombotic thrombocytopenic purpura with corticosteroids and splenectomy. Report of three cases. Ann. Intern. Med., 65:245, 1966.

157) Hill, J. B., Cooper, W. M.:Thrombotic thrombocytopenic purpura Treatment with cortico steroids and splenectomy. Arch. Intern. Med., 122:353, 1968.

158) Hill, J. B., Loeb, E.:Massive hormonal therapy and splenectomy in acute thrombotic thrombo cytopenic purpura. J. A. M. A., 173:778, 1960.

159) Moorhead, J. F.:Thrombotic thrombocytopenic purpura Recovery after splenectomy. Arch. Intern. Med., 117:284, 1966.
pubmed

160) Levin, H., Al frey, C. P.:134) より引用

161) Richardson, J. H., Smith, B. T.:Thrombotic thrombocytopenic purpura. Survival in pregnancy with heparin sodium therapy. J. A. M. A., 203:518, 1968.
pubmed

162) Gasser, C., Gautier, E., Steck, A., Sibenma, R. E., Oechslin, R.:Hamolytischuramische Syn:drome:Bilaterale Nierenrindennekrosen bei akuten erworbenen Hamoly tischen Anamien. Schweiz. Med. Wochenschr., 85:905, 1955.

163) Vitsky, B. H., Suzuki, Y., Strauss, L., Churg, J.:The hemolyticuremic syndrome:A study of renal pathologic alterations. Am. J. Pathol., 57:905, 1969.

164) Brain, M. C.:The haemolytic-uraemic syndrome. Ser. Hematol., 6:162, 1969.

165) Robson, J. S., Martin, A. M., Ruckley, A., Macdonald, M. K.:Irreversible postpartum renal failure. A new syndrome. Quart. J. Med., 37:423, 1968.
pubmed

166) Clarkson, A. R., Meadows, R., Lawrence, J. R.:Post-partum renal failure. The generalized Shwartzman reaction. Three further cases and a review. Austral. Ann. Med., 18:209, 1969.

167) Katz, J., Lurie, A., Kaplan, B. S., Krawitz, S., Metz, J.:Coagulation findings in the hemolytic syndrome of infancy:Simitarity to hyperacute renal allograft rejection. J. Pediatr., 78:426, 1971.
pubmed

168) Kaplan, B. S., Katz, J., Krawitz, S., Lurie, A.:An analysis of the results of therapy in 67 cases of the hemolytic-uremic syndrome. J. Pediatr., 78:420, 1971.
pubmed

169) Ponticelli, C., Imbasciati, G., Graziani, G.:Haemolytic-uremic syndrome and heparin therapy. Lancet, i:246, 1970.

170) Hardisty, R. M., Wolf, H. H.:Hemorrhagic thrombocythaemia:aclinical and laboratory study. Br, J. Haematol., 1:390, 1955.

171) Spaet, T. H., Bauer, S., Melamed, S.:Hemorrhagic thrombocythemia. A blood coagulation disorder. Arch. Intern. Med., 98:377, 1956.
pubmed

172) Hyun, B. H., Dawson, E. A., Custer, R. P.:Evaluation of thrombocythemia by the thromboplastin generation test. Am. J. Pathol., 29:539, 1958.

173) Gunz, F. W.:Hemorrhagic thrombocythemia. Blood, 15:706, 1960.
pubmed

174) Ozer, F. L., Truax, W. E., Miesch, D. C., Levin, W. C,:Primary hemorrhagic thrombocythemia. Am. J. Med., 28:807, 1960.

175) Webb, A. T., Myer, F. L., Lonser, E. R,:Hemorrhagic thrombocythemia. Arch. Intern. Med., 111:280, 1963.

176) McClure, P. D., Ingram, G. I. C.., Slacey, R, S., Glass, U. H., Matchett, M. O.:Platelet function tests in thrombocythemia and thrombocytosis. Brit. J. Haematol., 12:478, 1966

177) Cronberg, S., Nilsson Inga Marie, Gydell, K.:Hemorrhagic thrombocythemia due to defective platelet adhesiveness. Scand. J. Haematol., 2:208, 1965,

178) Spaet, T. H., Leinicks, I., Gaynor, E., Goodstein, M. L.:Defective platelets in essential thrombocythemia. Arch. Intern. Med., 124:135, 1969.

179) 安永幸二郎, 山口延男, 橋本武, 石田尚, 外林秀紀:原発性出血性血小板血病の1例-血小板血病における出血発現の機序についての考察. 第33回日血総会, 197L

P.57 掲載の参考文献

1) Hardisty, R. M.:Disorders of platelet function. Br. Med. Bull., 33:207, 1977.
pubmed

2) Glanzmann, E.:Hereditare haemorrhagische Thrombasthenie Ein Bin Beitrag zur Pathologie der Blutpltittchen, Jahrb. Kindh., 88:113, 1918.

3) Zucker, M. B., Pert, J. A. and Hilgartner, M. W.:Platelet function in a patient with throm basthenia. Blood, 28:524, 1966.

4) Caen, J. and Cousin, C.:Letrouble d:adhesivste "in vivo" des poaquettes dans la maladie de Willebrand et lesthrombastenies de Glanzmann. Nouv. Rev. Franc. Hemat., 2:685, 1962.

5) Caen, J. P., Castaldi, P. A., Leclerc, J. C., Inceman, S., Larrieu, M. J., Probst, M and Bernard, J.:Congenital bleeding disorders with long bleeding time and normal platelet count. Amer. J. Med., 41:4, 1966.

6) Zucker, M.:Platelet adhesion, release and aggregation. Thromb. Diath. Haemorrh., Suppl. 13:301, 1964.

7) Hardisty, R. M., Dormansky, K, M. and Hutton, R. A.:Thrombasthenia. Brit. J. Haemat., 10:371, 1964.

8) Kasar-Glanzmann, R. and LUscher, E. F.:The mechanism of platelet aggregation in relation to hemostasis. Thromb. Diath. Haemorrh., 7:480, 1962.

9) Nachman, R. L. & Ferris, B.:Studies on the proteins of human platelet membranes. J. Biol. Chem., 247:4468, 1972.
pubmed

10) Nurden, A. T. & Caen, J. P.:An abnormal platelet glycoprotein pattern in three cases of Gtanzmann:s thrombasthenia. Br. J. Haemat., 28:253, 1974.

11) Phillips, D. R., Jenkins, C. S. P., LUscher, E. F. & Larrieu, M. J.:Molecular differences of exposed surface proteins on thrombasthenic platelet plasma membranes. Natur. London, 257:599, 1975.

12) Phillips, D. R. & Poth, A. P.:Platelet membrane defects in Glanzmann:s thrombasthenia. Evidence for decreased amounts of two major glycoproteins. J. Clin. Invest., 60:535, 1977.

13) Caen, J. P., Nurden, A. T. and Kunicki, T. J.:Inherited abnormalities of platelet glycoproteins. Phil. Trans. R. Soc. Lond., B 294:281, 1981.

14) Hagen, I., Nurden, A., Bjerrum, O. J., Solum, N. O. & Caen, J.:Immunochemical evidence for protein abnormalities in platelet from patients with Glanzmann:s thrombasthenia and Bernard Soulier syndrome. J. Clin. Invest., 65:722, 1980.
pubmed

15) Mustard, J. F., Regoeczi, E., Perry, D. M.:Fibrinogen and ADP-induced platelet aggregation. Blood, 52:453, 1978.

16) Bennett, J. S., Vilair, G. V.:Exposure of platelet fibrinogen receptors by ADP and epine phrine. J. Clin. Invest., 64:1393, 1979.

17) Mustard, J. F., Kinlough-Rathbone, R, L., Packham, M. A.:Comparison of fibrinogen association with normal and thrombasthenic platelets on exposure to ADP or chymotrypsin. Blood, 54:987, 1979.
pubmed

18) Peerschke, E. I., Zucker, M. B., Grant, R. A.:Correlation between fibrinogen binding to human platelets and platelet aggregability. Blood, 55:841, 1980.
pubmed

19) Coller, B. S.:Interaction of normal, thrombasthenia, and Bernard-Soulier platelet with immobilized fibrinogen:Defective platelet-fibrinogen interaction in thrombasthenia. Blood, 55:169, 1980.
pubmed

20) Grant, R. A., Peerschke, E. I., Zucker, M. B.:Altered surface properties of human blood platelets associated with the loss of aggregability. J. Cell Biol., 83:64, 1979.

21) Degos, L., Dautigny, A., Brouet, J. C.:A molecular defect in thrombasthenic platelets. J. Clin. Invest., 56:235, 1975.

22) Levy-Toledano, S., Tobelem, G., Legrand, C.:An aquired IgG antibody occurring in a throm basthenic patient:It effect on normal human platelet function. Blood, 51:1065, 1978.

23) Gerrard, J. M., Schollmeyer, J. V., Phillips, D. R.:a-actinin deficiency in thrombasthenia. Am. J. Pathol., 94:509, 1979.
pubmed

24) Zucker, M. B., Pert, J., Hilgartner, M W.:Platelet function in a patient with thrombastenia. Blood, 28:524, 1966.

25) Weiss, H. J., Kochwa, S.:Studies of platelet function and proteins in 13 patients with Glanzmann's thrombasthenia. J. Lab. Clin. Med., 71:153, 1968.

26) Larrieu, M. J., Caen, J. P., Lelong, J. C. and Bernard, J.:Maladie de Glanzmann. Etude Clinique, biologique et pathogenique a propos de cing observa tions. Nouv. Rev. Franc. Hemat., 1:662, 1961.

27) Inceman, S., Tangun, A. and Aran, M.:Essential athrombia. Thromb. Diath. Haemorrh., 8:502, 1962.

28) Ulutin, O. N.:Qualitative platelet disorders:Classification and pathogenesis. Ann N.Y. Acad. Sci., 201:174, 1972.
pubmed

29) 安永幸二郎:Essential athrombia は独立の entity か. 血液と脈管, 3:211, 1972.

30) 安藤泰彦, 渡辺清明, 他:血小板無力症と本態性アトロンビアーとくに血小板膜の異常について. 日血会誌, 41:966, 1978.

31) von Willebrand, E. F. and Jurgens, R.:Uber eine neue Bluterkrankheit, die konstituelle Thrombopathie. Klin. Wschr., 12:444, 1933.

32) Alexander, B., Goldstein, R. l Dual hemostatic defect in pseudohemophilia. J. Clin. Invest., 32:551, 1953,

33) Howard, M. A., Firkin, B. G.:Ristocetin-a new tool in the investigation of platelet aggregation. Thromb. Diathes. hemorrh., 26:362, 1971.

34) Tschopp, T., Weiss, H. J., Baumgartner, H. R.:Decreased adhesion of platelets to subendothelium in von Willebrand's disease. J. Lab. Clin. Med., 83:296, 1974.
pubmed

35) Weiss, H. J., Baumgartner, H. R., Tschopp, T. B.:Correction by factor W of the impaired platelet adhesion to subendotherium in von Willebrand's disease. Blood, 51:267, 1978.

36) Bernard, J., Soulier, J. P.:Sur une nouvelle variete de dystrophie thrombocytaire hemorragipare congenitale. Sem. Hop. Paris, 24:3217, 1948.

37) Grottum, K. A., Solum, N. O.:Congenital thrombocytopenia with giant platelet:Adefect in the platelet membrane. Brit. J. Haematol, 16:277, 1969.

38) Caen, J. P., Nurden, A. T., Jeanneau, C., Michel, H., Tobelem, G., Levy-Toledano, S., Sultan, Y., Valensi, F. & Bernard, J.:Bernard-Soulier syndrome:anew platelet glycoprotein abnormality. Its relationship with platelet adhesion to subendothelium and with the factor VIII von Willebrand protein. J. Lab. Clin. Med., 87:586, 1976.

39) Legrand, Y., Fauvel, F., Gutman, N.. Muh, J. P., Tobelem, G., Souchon, H., Karniguian, A. & Caen, J. P.:Microfibris (MF) platelet interaction:requirement of von Willebrand factor. Thromb. Res., 19:737, 1980.

40) Nurden, A. T. & Caen, J. P.:The different glycoprotein abnormalities in thrombasthenic and Bernard-Soulier platelets. Semin. Hemat., 16:234, 1979.
pubmed

41) Jamieson, G. A. & Okumura, T.:Reduced therombin binding and aggregation in Bernard-Soulier platelets. J. Clin. Invest., 61:861, 1978.
pubmed

42) Nurden, A. T. & Caen, J. P.:Specific roles for platelet surface glycoproteins in platetet function. Nature, Lond., 255:720, 1975.

43) Hagen, I., Nurden, A., Bjerrum, O. J., Solum, N. O. & Caen, J. P.:Immunochemical evidence for protein abnormalities in platelets from patients with Glanzmann:s thrombasthenia and Bernard-Soulier syndrome. J. Clin. Invest., 65:722, 1980.

44) Solum, N. O., Hagen, I. & Sletback, T.:Further evidence for glycocalicin being derived from a larger amphiphilic platelet membrane glycoprotein. Thromb. Res., 18:773, 1980.

45) Degos, L., Tobelem, G., Lethielieux, P.:A molecular defect in platelets from patients with Bernard-Soulier syndrome. Blood, 50:899, 1977.

46) Zucker, M. B., Kim, S. J., McPherson, J.:Binding of factor VIII to platelets in the presence of ristocetin. Br. J. Haematol., 35:535, 1977.
pubmed

47) Bithell, T. C., Parekh, S. J. and Strong, R. R.:Platelet function studies in the Bernard-Soulier syndrome. Ann. N. Y. Acad. Sci., 201:145, 1972.
pubmed

48) 山田兼雄, 鈴木功一, 虎谷或子, 真貝晃, 目黒崇, 山本三保子, 渡辺清明:Bernard-Soulier syndrome (Macrothrombocytic thrombopathia) の血小板磯能に関する検討. 臨床血液, 15:915, 1974.

49) Howard, M. A., Hutton, R. A., Hardisty, R. M.:Hereditary giant platelet syndrome:A disorder of a new aspect of platelet function. Br. Med. J., 4:586, 1973.

50) Hardisty, R. M. and Hutton, R. A.:Bleeding tendency associated with "new" abnormality in platelet behaviour. Lancet, i:983, 1967.
pubmed

51) Weiss, H. J.:Platelet aggregation, adhesion and adenosine diphosphate release in thrombopathia (platelet factor 3 deficiency). Amer. J. Med., 43:570, 1967.
pubmed

52) White, J. G.:Ultrastructural studies of the gray platelet syndrome. Am. J. Pathol., 95:445, 1979.
pubmed

53) Weiss, H. J., Amus, R. P.:Ultrastructural findings in storage pool disease and aspirin like defects of platelets. Amer. J. Path., 71:447, 1973.

54) Weiss, H. J., Chervenick, P. A., Zalusky, R. and Factor, A.:A familial defect in platelet function associated with impaired release of adenosine diphosphate. New Eng. J. Med., 281:1264, 1969.

55) Hemmeler, G.:Thrombopathie familiale. Schweiz. Med. Wsch., 88:1018, 1958.

56) Libanska, J., Falcas, L, Gautier, A., Ammon, J., Spahr, A., Vainer, H., Caen, J.:Thrombo-cytopenie thrombocytopathique hypogranulaire hereditaire. Nouvelle Revue francaise d'Hematologie, 15:165, 1975.

57) Raccuglia, G.:Gray platelet sydrome. A variety of qualitative platelet disorder. Am. J. Med., 51:818, 1971.

58) Caen, J. P., Levy-Toledano, S., Dupuy, E., Fauvel, F.:Congenital platelet granule deficiency (Gray syndrome):a new model for biochemical and functional human platelet organelles relationship. Blood, 54:236, 1979.

59) Gerrard, J. M., Phillips, D. R., Rao, G. H. R., Plow, E. F., Walz, D. W., Ross, R., Harker, L. A., White, J. G.:Biochemical studies of two patients with the gray platelet syndrome. Selective deficiency of platelet alpha granules. J. Clin. Invest., 66:102, 1980.

60) Hermansky, F., Pudlak, P.:Albinism associated with hemorrhagic diathesis and unusual pigmented reticular cells in the bone marrow:Report of two cases with histochemical studies. Blood, 14:162, 1959.
pubmed

61) Grottum, K. A., Hovig, T., Holmsen, H.:Wiskott-Aldrich syndrome:Qualitative platelet defects and short platelet survival. Br. J. Haematol., 17:373, 1969.
pubmed

62) Shapiro, R. S., Gerrard, J. M., Perry, G. S. m, White, J. G., Krivit, W., Kersey, J. H.:Wiskott-Aldrich syndrome:detection of the carrier state by metabolic stress of platelets. Lancet, i:121, 1978.

63) Buchanan, G. R. & Handin, R. I.:Platelet function in the Chediak:Higashj syndrome. Blood, 47:941, 1976.
pubmed

64) Smith, J. B., Ingerman, C., Koesis, J J. and Silver, M. J:Formation of prostaglandins during the aggregation of human blood platelets. J. Clin. Invest., 52:965, 1973.

65) Phillips, D. R., Agin, P. P.:Platelet plasma membrane glycoproteins:Evidence for the presence of nonequivalent disulfiede bonds using nonreduced-reduced, two dimensional gel electrophoresis, J. Biol. Chem., 252:2121, 1977.
pubmed

66) Hamberg, M., Svensson, J. and Samuelsson, B.:Thromboxanes:Anew group of biologically active compounds derived from prostaglandin endoperoxides. Proceedings of the National Academy cf Sciences of the United States of America, 72:2994, 1975.

67) Chesney, C. M., Barker, A. S., Carvalho, A. C.:Adenylate cyclase and phosphodiesterase activity in the platelet release abnormality. Thromb. Haemost., 38:971, 1977.

68) Malmsten, C., Hamberg, M., Svensson, J.:Physiclogical role of an endoperoxide in human platelets:Hemostatic defect due to platelet cyclo-oxygenase deficiency. Proc. Nat. Acad. Sci. USA, 72:1446, 1975.
pubmed

69) Nyman, D., Eriksson, A. W. Lehmann, W. and Blomback, M.:Inherited defective platelet aggregation with arachidonate as the main expression of a defective metabolism cf arachidonic acid. Thromb. Res., 14:739, 1979.

70) Lagarde, M., Byron, P. A., Vargafting, B. and Dechauanne, M.:Impairment of platelet thromboxane A2 generation and of the platelet release reaction in twc patients with congenital deficiency of platelet cycloc, xygenase. Brit. J. Haemat., 38:251, 1978.

71) Weiss, H. J.:Abnormality in platelet function due to defects in the release reacticn. Ann. NY Acad. Sci., 201:161, 1972.
pubmed

72) Weiss, H. J., Lages, B. A.:Possible congenital defect in platelet thromboxane synthetase Lancet, i:760, 1977.
pubmed

73) Mestel, F., Oetliker, O., Beck, E.:Severe bleeding associated with defective thromboxane synthetase. Lancet, i:157, 1980.
pubmed

74) Deykin, D., Rittenhouse-Simmons, S., Russell, F. A.:Impaired Ca2+mobilization:A possible cause of platelet dysfunction. Clin. Res., 21:503 A, 1978.

75) Czapek, E. E., Deykin, D., Salzman, E. W.:Platelet dysfunction in glycogen storage disease type 1. Blood, 41:235, 1973.
pubmed

76) Corby, D. G., Putnam, C. W., Green, H. L:Impaired platelet function in glucose-6-phosphatase deficiency. J. Pediatr., 85:71, 1974.

77) Hutton, R. A., Machanab, A. J. and Rivers, R. P. A.:Defect of platelet functicn associated with chronic hypoglycaemia. Archives of Disease Childhood, 51:49, 1976.

78) Castaldi, P. A., Rozenberg, M. C., Stewart, J. H.:The bleeding disorder of uremia. Lancet, ii:66, 1966.

79) Salzman, E. W., Neri, L. J.:Adhesiveness of blood platelets in uremia Thrombos. Diath. Haemorrh., 15:84, 1966.

80) Horowitz, H. I., Cohen, B. D., Martinez, P., Papayoanou. M. F.:Defective ADP:induced platelet factor 3 activation in uremia. Blood, 30:331, 1967.
pubmed

81) Rabiner, S. F., Hrodek, O.:Platelet factor 3 in normal subjects and patients with renal failure. J. Clin. Invest., 47:901, 1968.
pubmed

82) Bollard, H. S., Marcus, A, J.:Primary and secondary Platelet aggregation in uremia. Scand. J. Haematol., 9:198, 1972.

83) Horowitz, H.I., Stein. L. M, Cohen, B.D., White, J.G.:Further studies on the platelet inhibitory effect of guanidinosuccinic acid:its role in uremic bleeding. Am. J. Med., 49:336, 1970.

84) Rabiner, S. E, Molinas, F.:The role of phenol and phenolic acids on the thrombocytopathy and defective platelet aggregation of patients with renal failure. Am. J. Med., 49:346, 1970.

85) Davis, J. W., McField, J. R., Phillips, P. L., Graham, B. A.:Effects of exogenous urea, creatinine, and guanidinosuccinic acid on human platelet aggregation in vitro. Blood, 39:388, 1972.

86) Remuzzi, G., Marchesi, D., Livio, M., Cavenaghi, A. E., Mecca, G., Donati, M.B., de Gaetano, G.:Altered platelet and vascular prostaglandin generation in patients with renal failure and prolonged bleeding times. Thromb. Res., 13:1007, 1978,
pubmed

87) Niewiarowski, S., Guzzo, J., Rao, A. K., Berman, I., James, P.:Increased levels of low affinity platelet factor 4 in plasma and urine of patients with chronic renal failure. Thromb. Haemostas., 42:416, 1979.

88) Green, D., Santhanam, S., Krumolovsky, F. A., Del Greco, F.:β-thromboglobulin in patients with chronic renal failure:Effect of haemodialysis. Thromb. Haemostas., 42:416, 1979.

89) Zucker, S., Mielke, C. H.:Clasification of thrombocytosis based on platelet function tests. Correlation with hemorrhagic and thrombotic complecations. J. Lab. Clin. Med., 80:385, 1972.

90) Kaywin, P., McDonough, M., Insel, P. A., Shatti, S. J.:Platelet function in essential thrombo-cythemia. Decreased epinephrine responsiveness associated with a deficiency of plateletα-adrenergic receptors. N. Engl. J. Med., 299:505, 1978.

91) Keenan, J. P., Wharton, J. Shepherd, A. J. N., Bellingham, A. J.:Defective lipid peroxidation in myeloproliferative disorders:Apossible defect of prostaglandin synthesis. Br. J. Haematol., 35:275, 1977.

92) Gerrard, J. M., Stoddard, S. F., Shapiro, R. S., Coccia, P. F., Ramsay, N. K. C., Nesbit, M. E., Rao, G. H. R., Krivit, W., White, J. G.:Platelet storage pool deficiency and prostaglandin synthesis in chronic granulocytic leukaemia. Br. J. Haematol, 40:597, 1978.

93) Bolin, R. B., Okumura, T., Jamieson, G. A.:Changes in distribution of platelet membrane glycoproteins in patients with myeloproliferative disorders. Am. J. Haematol, 3:63, 1977.

94) Okuma, M., Uchino, H.:Altered arachidonate metabolism by platelets in patients with myeloproliferative disorders. Blood, 54:1258, 1979.
pubmed

95) Wu, K. K.:Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Ann. Intern. Med., 88:7, 1978.
pubmed

96) Cooper, B., Ahem, D.:Characterization of the platelet prostaglandin D2 receptor. Lose of pro:staglandin D2 reseptol:s in platelets of patients with myeloproliferative disorders. J. Clin. Invest., 64:586, 1979.

97) Cowan, D. H., Graham, R. C., Bounach, D.:The platelet defect in leukemia, platelet ultra-structure, adenine nucleotide metabolism, and the release reaction. J. Clin. Invest., 56:188, 1975.

98) Russell, N. H., Keenan, J. P., Bellingham, A. J.:Thrombocytopathy in preleukaemia:association with a defect of thromboxane A2 activity. Br. J. Haematol, 41:417, 1979.
pubmed

99) Lackner, H.:Haemostatic abnormalities associated with dysproteinemia. Semin. Haematol, IO:125, 1973.

100) Hrodek, O.:L:agregation des plaquettes chez le nouveau-ne Nouvelle Revue francaise. d'Hematologie, 9:569, 1969.

102) Corby, D. G., Zucker, T. F.:Newborn platelet dysfunction:A storage pool and release defect. Thrombos. Haemostas., 36:200, 1976.

103) Bleyer, W. A., Breckenridge, R. T.:Studies on the detection of adverse drug reactions in the newborn. 1. The effects of prenatal aspirin on newborn hemostasis. JAMA, 213:2049, 1970.

104) Zahavi, J., Marder, V. J,:Aquired`storage pool disease:of platelets associated with circulating antiplatelets antibodies. Am. J. Med., 56:883, 1974.

105) Karpatkin, S., Lackner, H. L.:Association of antiplatelet antibody with functional platelet disorders. Autoimmune thrombocytopenic purpura, systemic lupus erythematosus and thrombopathia. Am. J. Med., 59:599, 1975.
pubmed

106) Pareti, F. I., Capitano, A., Mannucci, P. M.:Acquired storage pool disease in platelets during disseminated intravascular coagulation. Blood, 48:511, 1976.

107) Wilson, P. A., McNicol, G. P., Douglas, A. S.:Platelet abnormality in human scurvy. Lancet, i:975, 1967.

108) Clancy, R., Jenkins, E., Firkin, B.:Platelet defect of infectious mononucleosis. Brit. Med. J., 4:646, 1971.
pubmed

109) Levine, P. H.:A qualitative platelet defect in severe vitamin Bi2 deficiency:Response, hyper-response and thrombosis after vitamin B12 therapy. Ann. Intern. Med., 78:533, 1973.

110) Roth, G. J., Stanford, N., Majerus, P. W.:Acetylation of prostaglandine synthetase by aspirin. Proc. Natl. Acad. Sci. USA., 72:3073, 1975.

111) Evans, G., Packham, M. A., Nishizawa, E. E., Mustard, J. F., Muphy, E. A.:The effect of acetylsalicylic acid on platelet function. J. Exp. Med., 128:877, 1968.

112) Cazenave, J. P., Packham, M. A., Guccion, M. A., Mustard, J. F.:Inhibition of platelet adherence to damaged surface of rabbit aorta. J. Lab. Clin. Med., 86:551, 1975.

113) Weiss, H. J:The effect of clinical dextran on platelet aggregation, adhesion and ADP release in man:in vivo and in vitro studies. J. Lab. Clin. Med., 69:37, 1967 b.

114) McClure, P., Casserly, J., Monsier, Ch., Crozier, D.:Carbenicillin-induced bleeding disorder. Lancet, ii:1307, 1970.

115) Cazenave, J. P., Guccion, M. A., Packham, M. A., Mustard, J. F.:Effects of Cepharothin and Penicillin G on platelet function in vitro. Br. J. Haematol., 35:135, 1977.

116) Malpass, T. W., Harker, L. A.:Acquired disorders of platelet function. Semin. Hematol., 17:242, 1980.
pubmed

lOl) Ts:ao, C., Green, D., Schultz, K.:Function and ultrastructure of platelets of neonates:enhanced ristocetin aggregation of neonatal platelets. Br. J. Haematol., 32:225, 1976.

P.85 掲載の参考文献

1) Ratnoff, O. D. and Colopy, J. E.:A familial hemorrhagic trait associated with a deficiency of aclot. promoting fraction of plasma. J. Clin. Med., 34:602, 1955.

2) Ratnoff, O. D.:Aquarter century with Mr. Hageman. Thrombos. Haemost., 43:95, 1980.

3) Tans, G. and Griffin, J. H.:Properties of sulfatides in factor-XII. dependent contact activation. Blood, 59:69, 1982.
pubmed

4) Saito, H., Scott, J. G., Movat, H. Z. and Scialla, S. J.:Molecular heterogeneity of Hageman trait (factor XII deficiency). J. Lab. Clin. Med., 94:256, 1979.
pubmed

5) Saito, H. and Scialla, S. J.:Isolation and properties of an abnormal Hageman factor (factor XII) molecule in a cross-reacting material-positive Hageman trait plasma. J. Clin. Invest., 68:1028, 1981.

6) 柴田義純, 井出望, 池田洋一, 板倉利達, 松崎舜二, 高野尚之, 藤野旭, 大島一洋, 今川大仁, 小浜貴良, 山中學, 三好和夫:Hageman factor欠乏症の1例. 本邦における第1例. 日血誌, 28:555, 1965.

7) Egeberg, O.:Factor XII defect and hemorrhage. Evidence fora new type of hereditary hemostatic disorder. Thrombos. Diathes. haemorrh., 23:432, 1970.

8) Walsh, P. N.:The effects of collagen and kaolin on the intrinsic coagulant activity of plate. lets. Evidence for an alternative pathway in intrinsic coagulation not requring factor Xn. Brit. J. Haematol., 22:393, 1972.

9) Walsh, P. N. and Grifrin, J. H.:Contributions of human platelets to the proteolytic activation of blood coagulation factors Xn and XI. Blood, 57:106, 1981.

10) Ratnoff, O. D., Busse, R. J, and Sheon, R. P.:The demise of John Hageman. New Engl. J. Med., 279:760, 1968.

11)Aznar,J.and Pavon, A.F.:Thromboembolic accidents in patients with congenital deficiency

12) Rosenthal R. L., Dreskin, O. H. and Rosenthal, N.:New hemophilia. like disease caused by deficiency of a third plasma thromboplastic factor. Proc. Soc. Exp. Biol. Med., 82:171, 1953.

13) Bouma, B. N. and Griffn, J. H.:Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. J. Biol. Chem., 252:6432, 1977.

14) Jacobs, A., Mannhalter, C., Margalit, R. and Schiffman, S.:Contact activation of factor XI Brit. J. Haemat., 49:77,1981
pubmed

15) Rimon, A., Schiffman, S., Feinstein, D. I. and Rapaport, S.:Factor XI activity and factor XI antigen in homozygous and heterozygous factor XI deficiency. Blood, 48:165, 1976.
pubmed

16) Saito, H. and Goldsmith, G. H.:Plasma thromboplastin antecedent (PTA, factor XI):A specific and sensitive radioimmunoassay. Blood, 50:377, 1977.
pubmed

17) Muir, W. A. amd Ratnoff, O. D.:The prevalence of plama thromboplastin antecedent (PTA, factor XI) deficiency. Blood, 44:569, 1974.

18) 松岡松三, 萩原洋三, 小野儀太郎, 峯村直, 松岡恒美, 丸山勝夫:Plasma thromboplastin antecedent ( PTA) 欠乏症の2例. 日本臨床, 18:926, 1960.

19) Nossel, H. L., Niemetz, J. and Sawitsky, A.:Blood PTA (factor XI) 1evels following plasma infusion. Proc. Soc. Exp. Biol. Med., 115:896, 1964.

20) Rosenthal, R. L. and Sloan, E.:PTA (factor XI) levels and coagulation studies after plasma infusions in PTA-deficient patients. J. Lab, Clin. Med., 66:709, 1965.
pubmed

21) Hathaway, W. E., Belhasen, LP. and Hathaway, H. S.:Evidence for a new plasma thromboplastin factor. 1. Case report, coagulation studies and physicochemical properties. Blood, 16:521, 1965.

22) Wuepper, K. D.:Prekallikrein deficiency in man. J. Exp. Med., 138:1345, 1973.

23) Kaplan, A. P.:Initiation of the intrinsic coagulation and fibrinolytic pathways of man:The role of surfaces, Hageman factor, prekallikrein, high molecular weight kininogens and factor XI. Prog, Hemostas Thromb., 4:127, 1978.

24) Saito, H., Goodnough, L. T., Soria, J., Soria, C., Aznar, J. and Espana, F.:Heterogeneity of human prekallikrein deficiency (Fletcher trait). Evidence that five of 18 cases are positive for cross-reacting material. New Engl. J. Med., 305:910, 1981.
pubmed

25) 重清俊雄, 藤野修, 荒河忠治, 猪本享司, 川内茂徳, 白神碑, 三好和夫:Fletcher因子欠乏症. 1家系中に認められた2例の homozygote と10 例のheterozygote. 日血誌 (抄録), 44:512, 1981

26) Saito, H., Ratnoff, O. D., Waldmann, R. and Abraham, J. P.:Fitzgerald trait. Deficiency of a hitherto unrecognized agent, Fitzgerald factor, participating in surface mediated reactions of clotting, fibrinolysis, generation of kinins, and the property of diluted plasma enhancing vascular premeability (PF/Dil.). J. Clin. Invest., 55:1082, 1975,

27) Lacombe, M-J., Varet, B. and Levy, J-P.:Ahitherto undescribed plasma factor acting at the contact phase of blood coagulation (Flaujeac factor):Case report and coagulation studies. Blood, 46:761, 1975.

28) Colman, R. W., Bagdasarian, A., Talamo, R. C., Scott, C. F., Seavey, M., Guimaraes, J. A., Pierce, J. V., Kaplan, A. P. and Weinstein, L.:Williams trait, human kininogen deficiency with diminished level of plasminogen proactivator and prekallikrein associated with abnormalities of the Hagemanfa ctor・dependent pathway. J. Clin. Invest., 56:1650, 1975.

29) Lutcher, C. L.:Reid trait:A new expression of high molecular weight kininogen (HMWkininogen) deficiency. Clin. Res., 34 (Abstract):47A, 1976.

30) Hayashi, H., Koya, H., Kuroda, M., Kitazima, K., Kimura, I., Katori, M. and Oh-ishi, S.:The first cases of Fitzgerald factor deficiency in the orient:Three cases in one family. Acta haemat., 63:107, 1980.

31) 中村克己, 飯島憲司, 福田千佐子, 門脇秀夫, 生駒尚秋, 大石幸子, 内田泰弘, 鹿取信:Tachibana Trait:Fitzgerald因子 (高分子キニノゲン) 欠損症-本邦第2家系目. 日血誌 (抄録), 44:317, 1981.

32) Brinkhous, K. M.:A short history of hemophilia, with some comments on the word "Hemophilia". Handbook of Hemophilia. Part 1. (Brinkhous, K. M. and Hemker, H. C. eds.), Amsterdam:Excerpta Medica, New York:American Elsevier Publishing Company, Inc., 1975. p. 3-20.

33) 福井弘:血液凝固. 病態の生化学4. 血液, 中外医学社, P. 294～400.

34) Palvovsky, A.:Contribution to the pathogenesis of hemophilia. Blood, 2:185, 1947.

35) Koller, F., Krusi, G. and Luchsinger, P.:Ueber eine besondere Form htimorrhagischer Diatuese. Schweiz. med. Wochenschr., 80:1101, 1950.

36) Aggeler, P. M., White, S. G., Glendening, M. S., Page, E. W., Leake, TB. and Bates, CT.:Plasma thromboplastin component (PTC) deficiency:Anew disease resembling haemophilia. Proc. Soc. exp, Biol. Med., 79:692, 1952.

37) Biggs, R., Douglas, A. S., Macfarlane, R. G., Davie, J. V., Pitney, W. R., Merskey, C. and O:Brien, J. R.:Christmas disease:A condition previously mistaken for haemophilia. Brit. med. J., 2:1378, 1952.

38) Cramer, R., FIUckiger, P., Gasser, C., Koller, F., Loeliger, E. A. and Matter, M.:Hemophilia B. Two cases of hereditary hemophilia due to a deficiency of a new clotting factor (Christmas factor). Acta haematol., 10:65, 1953.

39) Soulier, J. P. and Larrieu, J. M.:Differentiation of hemophilia into two groups. A study of thirty-three cases. New Engl. J. Med., 249:547, 1953.

40) Nachman, R. L.:von Willebrand's disease-A clinical and molecular enigma. 第4回日本血栓止血学会, 特別講演. 大阪, 1981年12月4日

41) 弘田長:出血病患者の実験. 東京医学会雑誌, 3:357, 1889.

42) 山下弁治郎:血友病の一例. 成医会月報, 247:30, 1902.

43) 館野昌辰:本邦に於ける血友病日血誌, 6:427, 1942.

44) 吉田邦男, 梅垣健三, 福井弘, 中島清治:Plasma thromboplastin component (PTC) 欠乏による出血性素質. 日血誌, 19:511, 1956.

45) 吉田邦男:血友病の疫学, 血友病 (吉田邦男, 安部英, 福武勝博, 神前五郎監修), 全国ヘモフィリア友の会, 1981・P・19-57

46) McKee, P. A., Anderson, J. C. and Switzer, M. E.:Molecular structural studies of human factor VII. Ann. N. Y. Acad. Sci., 240:8, 1975.

47) Hoyer, L. W. and Rick, M. E.:Implications of immunologic methods for measuring antihemophilic factor (factor VIII). Ann. N. Y. Acad. Sci., 240:97, 1975.
pubmed

48) Fukui, H., Mikami, S., Okuda, T., Murashima, N., Takase, T. and Yoshioka, A.:Studies of von Willebrand factor:effects of different kinds of carbohydrate oxidases, SHinhibitors and some other chemical reagents. Brit. J. Haemat., 32:59, 1977.

49) Perret, B. A., Furlan, M. and Beck, E. A.:Studies of factor VIII-related protein. II. Estimation of molecular size differences between factor VIII oligomers. Biochim. Biophys. Acta, 578:164, 1979.
pubmed

50) Hoyer, LW. and Shainoff, J. R.:Factor VIII-related protein circulates in normal human plasma as high molecular weight multimers. Blood, 55:1956, 1980.

51) Hoyer, L. W. and Breckenridge, R. T.:Immunologic studies of antihemophilic factor (AHF, factor VIII):cross-reacting material in a genetic variant of hemophilia A. Blood, 32:962, 1968.

52) Denson, N. W. E., Biggs, R., Haddon, M. E., Borrett, R. and Cobb, K.:Two types of hemophilia (A+and A-):a study of 48 cases. Brit. J. Haemat., 17:163, 1969.

53) Peake, I. R., Bloom, A. L., Giddings, J. C. and Ludlam, C. A.:An immunoradiometric assay for procoagulant factor VVIII antigen:Results in haemophilia, von Willebrand's disease and fetal plasma and serum. Brit. J. Haemat., 42:269, 1979.

54) Reisner, H. M., Barrow, E. S. and Graham, J. B.:Radioimmunoassay for coagulant factor VIII-related antigen (VIII:CAg). Thromb. Res., 14:235, 1979.

55) Holmberg, L, Borge, L, Ljung, R. and Nilsson, I. M.:Measurement of antihaemophilic factor A antigen (VIII:CAg) with a solid phase immunoradiometric method based on homologous non-haemophilic antibodies. Scand. J. Haematol., 23:17, 1979.
pubmed

56) Rotblat, F. and Tuddenham, E, GD.:Immunologic studies of factor VIII coagulant activity (VII:C) 1. Assays based on a haemophilic and an acquired antibody to VIII:C. Thromb. Res., 21:431, 1981.

57) Zimmerman, T. S., Ratnoff, O. D. and Littell, A. S.:Detection of carriers of classic hemophilia using an immunologic assay for antihemophilic factor (Factor VIII). J. Clin. Invest., 50:255, 6971.

58) Lyon, M. F.:Chromosomal and subchromosomal inactivation. Ann. Rev. Genet., 2:31, 1968.

59) 徳田晴厚:血友病A保因者の検出, 保因者血漿中の第VIII因子活性, 第VIII因子抑制物質中和能, 抗ヒト第VIII 因子抗体中和能. 第VIII因子関連抗原及びvon Willebrand因子活性. 奈良医学雑誌, 29:47, 1978.

60) Ikkala, E.:Haemophilia:Astudy of its laboratory, clinical, genetic and social aspects based on known haemophiliacs in Finland. Helsinki, 1960. p. 99-101.

61) 福井弘:凝固第1相の阻止物質. 日血誌, 36:458, 1973.

62) Kasper, C. K., Aledort, L. M., Counts, R. B., Edson, J. R., Fratantoni, J., Green, D., Hampton, J. W., Hilgwartner, M. W., Lazerson, J., Levine, P. H., McMillcon, C. W., Pool, J. G., Shapiro, S, S., Shulman, N. R. and Van Eys, J.:A more uniform measurement of factor W inhibitors. Thrombos. Diathes. haemorrh., 34:869, 1975.

63) Fekete, L. F., Holst, S. L., Peetoom, F. and Deveber, L. L.:" Auto" factor IX (concentrate:A new therapeutic approach to the treatment of hemophilia A patients with inhibitors. 14th International Congress of Hematology, 1972, San Paolo, Brazil. (abstr. 295).

64) Fukui, H., Fujimura, Y., Takahashi, Y., Mikami, S. and Yoshioka, A.:Laboratory evidence of DIC under FEIBA treatment of a hemophilic patient with intracranial bleeding and high titre factor Vnl inhibitor. Thromb. Res., 22:177, 1981.

65) Fantle, P., Sawers, RJ. and Marr, A. G.:Investigation of a hemorrhagic disease due to betaprothromboplastin deficiency complicated by a specific inhibitor of thromboplastin formation. Aust. Ann. Med., 5:163, 1956.

66) Roberts, H. R., Gross, G. P., Webster, W. P., Dejanov, I.I. and Penick, G. D.:Acquired inhibitors of plasma factor IX ;astudy of their induction, properties and neutralization. Am. J. Med, Sci., 251:43, 1966.

67) Roberts, H. R., Grizzle, J. E., Mclester, W. D. and Penick, G. D.:Genetic variants of hemophilia B:detection by means of a specific PTC inhibitor. J. Clin. Invest., 47:360, 1968.
pubmed

68) Hougie, C. and Twomey, J. J.:Haemophilia BM;a new type of factor IX (deficiency. Lancet, i:698, 1967.
pubmed

69) Denson, K. W. E., Biggs, R, and Mannucci, P. M.:An investigation of three patients with Christmas disease due to an abnormal type of factor IX . J. Clin. Path., 21:160, 1968.

70) Brown, PE., Hougie, C. and Roberts, H. R.:The genetic heterogeneity of hemophilia B. New Engl. J. Med., 283:61, 1970.

71) Veltkamp, J. J., Meilof, J., Remmelts, H. G., van der Vlerk, D. and Loeliger, E. A.:Another genetic variant of haemophilia B:haemophilia B Leyden. Scand. J. Haemat., 7:82, 1970.
pubmed

72) 藤村吉洋, 高瀬俊夫, 阪井利幸, 嶋緑倫, 福井弘:血友病B患者における第IX因子抗原の免疫学的研究. 日血誌, 45:952, 1982.

73) Thompson, A. R.:Factor IX (antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B. J. Clin. Invest., 59:900, 1977.
pubmed

74) Yang, H. C.:Immunologic studies of factor IX (Christmas factor) II Immunoradiometric assay of factor IX antigen. Brit. J. Haematol., 39:215, 1978.

75) DiScipio, R. G., Kurachi, K. and Davie, E. W.:Activation of human factor IX (Christmas factor). J. Clin. Invest., 62:1528, 1978.

76) Bertina, R. M. and Veltkamp, JJ.:Detection, purification and comparison of factor IX like molecules. Thrombos. Haemost., 38:217, 1977 (Abstract).

77) Bertina, R. M.:Genetic variants of factor IX Haemophilia (Seligsohn, U., Rimon, A. and Horoszowski, H. eds.), New York:Alan, R., Liss, Inc. 1981. p. 19-27.

78) osterud, B., Kasper, C. K. and Prodanos, C.:Factor IX (variants of hemophilia B. The effects of activated factor XI and the reaction product of factor VII and tissue factor on the abnormal factor IX molecules. Thromb. Res., 15:235, 1979.
pubmed

79) Osterud, B., Kasper, C. K., Lavine, K. K., Prodanos, C. and Rapaport, S. I.:Purification and properties of an abnormal blood Coagulation factor IX (Factor IX Bm /Kinetics of its inhibitr of factor X activation by factor VIIand bovine tissue factor. Thrombos. Haemost., 45:55, 1681.

80) Kasper, C. K., Osterud, B., Minami, J. Y., Shonick, W. and Rapaport, S. I.:Hemophilia B, characterization of genetic variants and detection of carriers. Blood, 50:351, 1977.
pubmed

81) Chung, K. S., Madar, D. A., Goldsmith, J. C., Kingdon, H. S. and Roberts, H. R.:Purification and characterizatioll of an abnormal factor IX (Christmas factor) molecule. Factor IX Chapel Hill. J. Clin. Invest., 62:1078, 1978.

82) Chung, K. S., Madar, D. A., Reisner, H. M., Goldsmith, J. G. and Roberts, H. R.:Purification and characterization of an abnormal factor IX Alabama IX (Ala.). (Abstract) XVII Congress on the International Society of Hematology, Paris, 1978. p, 859.

83) Bertina, R. M, and Veltkamp, J. J.:The abnormal factor IX of hemophilia B+. variants. Thrombos. Haemost., 40:335, 1978.

84) Bertina, R. M. and Veltkamp, J. J.:Agenetic variant of factor IX with decreased capacity for Ca2+ binding. Brit. J. Haematol., 42:623, 1979.

85) Yang, H. C.:Purification and immunological studies of factor IX-Worcester. Blood, 50 (Suppl. 1):289, 1977.

86) Graham, JB.:Genetic problems:Hemophilia and allied disease. Hemophilia and Hemophiloid Disease (Brinkhous, K. M., eds.), Chapel Hill:The University of North Carolina Press, 1957. p. 137-159.

87) Vehav, G. A. and Davie, E. W.:Preparation and properties of bovine factor VIII (Antihemophilic factor). Biochemistry, 19:401, 1980.

88) Kisiel, W., Canfield, W. M., Ericsson, L. H. and Davie, E. W.:Anticoagulant properties of bovine plasma protein C following activation by thrombin. Biochemistry, 16:5824, 1977.
pubmed

89) Merskey, C.:The occurrence of hemophilia in the human female. Quart. J. Med., 79:299, 1951.
pubmed

90) Morita, H.:The occurrence of homozygous hemophilia in the female. Acta Haemat., 45:112, 1971.
pubmed

91) Yoshiya, H., Kamisue, M., Adachi, T. and Fukui, H.:Hemophilia in a woman with female sex chromosome. J. Nara Med. Ass., 20:559, 1969.

92) Barrow, E. M. and Graham, J. B.:Blood coagulation factor VIII (antihemophilic factor):with comments on von Willebrand's disease and Christmas disease. Phy. Rev., 54:23, 1974.

93) 片桐真二, 三上貞昭, 吉岡章, 金田美喜夫, 福井弘:女性血友病Bの1例. 臨床血液, 14:415, 1973.

94) von Willebrand, E. A.:Hereditare pseudohemofili. Finska Lak, Sallsk. Handl., 68:87, 1926.

95) Jurgens, R.:Die erblichen Thrombopathien. Ergebn. inn. Med., 53:795, 1937.

96) Alexander, B. and Goldstein, R.:Dual hemostatic defect in pseudohemophilia. J. Clin. Invest., 32:551, 1953.

97) Larrieu, MJ. and Soulier, J. P.:Deficit en facteur antihemophilique A chez une fille, assocle, a un trouble du saignement. Rev. Hemat., 8:361, 1953.

98) Quick, AJ. and Hussey, C. V.:Hemophilic condition in the female. J. Lab. Clin. Med., 42:929, 1953.

99) Nilsson, I. M., Blomback, M., Jorpes, E., Blomback, B. and Johansson, S. A.:von Willebrand's disease and its correction with human plasma fraction I-0. Acta med. scand., 159:179, 1957.
pubmed

100) 福井弘, 馬島保, 田川徳治:出血時間延長を伴うAHF欠乏症の女児2症例. 日血誌, 21:608, 1958.

101) Zucker, M. B.:In vitro abnormality of the blood in von Willebrand's disease correctable by normal plasma. Nature, 197:60, 1963.

102) Salzman, E. W.:Measurement of platelet adhesiveness. A simple in vitro technique demonstrating an abnormality in von Willebrand's disease. J. Lab. Clin. Med., 62:724, 1963.
pubmed

103) Zimmerman, T. S., Ratnoff, O. D. and Powell, A. E.:Immunologic differenciation of classic hemophilia (factor VIII deficiency) and von Willebrand's disease. J. Clin. Invest., 50:244, 1971.

104) Howard, M. A. and Firkin, B. G.:Ristocetin-a new tool in the investigation of platelet aggregation. Thrombos. Diathes. haemorrh., 26:362, 1971.

105) Tschopp, T. P., Weiss, H. J. and Baumgartner, H. R.:Decreased adhesion of platelets to subendothelium in von Willebrand's disease. J, Lab. Clin. Med., 83:296, 1974.

106) Allan, J. P., Cooper, H. A., Wagner, R. H. and Brinkhous, K. M.:Platelet fixed with paraform:aldehyde:Anew reagent for assay of von Willebrand factor and platelet aggregating factor. J. Lab. Clin. Med., 85:318, 1975.

107) Veltkamp, J. J. and van Tilburg, N. H.:Detection of heterozygotes for recessive von Willebr. and:s disease by the assay of antihemophilic antigen. New Engl. J. Med., 289:882, 1973.

108) Stableforth, P., Hughes, J., Wilson, E. and Dormandy, K. M.:The von Willebrand syndrome. Brit. J. Haematol., 29:605, 1975.

109) Sultan, Y., Simeon, J. and Caen, J. P.:Detection of heterozygotes in both parents of homozygous patients with von Willebrand's disease. J. Clin. Path., 28:309, 1975.
pubmed

110) Fukui, H., Yoshioka, A., Mikami, S., Takase, T., Fujimura, Y., Takahashi, Y., Nishino, M. and Iwagaki, K.:Pathophysiology of von Willebrand's disease:Qualitative and quantitative analysis of von Willebrand protein. Acta Haem:Jap., 41:839, 1979.

111) Ruggeri, Z. M., Mannucci, P. M., Jeffcoate, S. L. and Ingram, G. I. C.:Immunoradiometric assay of factor VIII related antigen, with observations in 32 patients with von Willebrand, s disease. Brit. J. Haematol., 33:221, 1976.

112) 高橋幸博:血小板第VIII因子関連抗原に関する研究. 第2報:血小板第VIII因子関連抗原量及び交叉免疫電気泳動像の検討. 奈医誌. 30:288, 1979.

113) Holmberg, L. and Nilsson, I. M.:Genetic variants of von Willebrand's disease. Brit. Med. J. iii:317, 1972.

114) Kernoff, P. B. A., Gruson, R. and Rizza, C. R.:Avariant of factor VIII related antigen. Brit. J. Haematol., 26:435, 1974.

115) Peake, I. R., Bloom, A. L. and Giddings, J. C.:Inherited variants of factor VIII related protein in von Willebrand's disease. New Engl. J. Med., 291:113, 1974.
pubmed

116) van Mourik, J. A. and Bolhuis, P. A.:Dispersity of human factor VIII-von Willebrand factor. Thromb. Res., 13:15, 1978.
pubmed

117) Fass, D. N., Knutson, G. J. and Bowie, EJ. W.:Porcine Willebrand factor:A population of multimers. J. Lab. Clin. Med., 91:307, 1978.

118) Perret, B. A., Furlan, M. and Beck, E. A.:Studies on factor VIII. related protein. H. Estimation of molecular size differences between factor W oligomers. Biochim. Biophys. Acta, 578:164, 1979.

119) Mikami, S., Takahashi, Y., Nishino, M., Okubo, Y, and Fukui, H.:Heterogeneity of molecular size of factor VIII/von Willebrand factor in von Willebrand's disease. Thrombos. Haemost., 45:272, 1981.

120) 三上定昭, 西野正人, 安居資司, 大久保芳明, 嶋裕子, 福井弘:von Willebrand患者および両親の第VIII因子/von Willebrand因子蛋白の分子サイズに関する検討. 臨床血液, 23:1198, 1982.

121) Peake, I. R. and Bloom, A. L.:The use of an immunoradiometric assay for factor VIII-related antigen in the study of atypical von Willebrand's disease. Thromb. Res., 10:27, 1977.

122) Sodez, J. M., Paulson, J. C., Pizzo, S. V. and McKee, P. A.:Carbohydrate on human factor VIII / von Willebrand factor. Impairment of function by removal of special galactose residues. J. Biol. Chem., 253:7202, 1978.

123) Rosenfeld, L. and Kirby, E. P.:The effects of neuraminidase treatment on the biological activities of factor VIII. Thromb. Res., 15:255, 1979.
pubmed

124) Gralnick, H. R. and Coller, B. S.:Carbohydrate deficiency of the factor VIII/von Willebrand factor protein in von Willebrand's disease variants. Science, 192:56, 1976.
pubmed

125) Howard, M. A., Hendrix, L. and Firkin, B. G.:Further studies on the factor VIIIof a patient with variant form of von Willebrand's disease. Thromb. Res., 14:609, 1979.
pubmed

126) 西野正人, 三上定昭, 高橋幸博, 大久保芳明, 嶋緑倫, 吉岡章, 福井弘:第VIII因子濃縮製剤中の第VIII因子/von Willebrand因子の不均一性について. 第2報第VIII因子関連抗原のlarge pore poly:acrylamide gelcrossed immunoeletcrophoresis及びSDS polyacrylamide gel-crossed immunoel ectrophoresis. 奈医誌, 32:208, 1981.

of factor XII. Thrombos. Diathes.haemorrh.,31:525,1974.

P.109 掲載の参考文献

1) Biggs, R., ed.:Human Blood Coagulation, Haemostasis and Thrombosis. Oxford:Blackwell S. P., 1972. p. 75.

2) Quick, A. J., Stanley-Brown, M., Bancroft, F. W.:A study of the coagulation defect in hemophilia and in jaundice. Am. J. Med. Sci., 190:501, 1935.

3) Quick, A. J.:On the constitution of prothrombin. Am. J. Physiol., 140:212, 1943.

4) Owen, C. A., Bollman, J. L.:Prothrombin conversion foctor of dicoumarol plasma. Proc. Soc. Erp. Biol. Med., 67:231, 1948.

5) Telfer, T. P., Denson, W., Wright, D. R.:A new coagulation defect. Brit. J. Haemat., 2:308, 1956.

6) Quick, A. J.:Congenital hypoprothrombinaemia and pseudohypoprothrombinaemia. Lancet, 28:379, 1947.

7) Quick, A. J., Pisciotta, A. V., Hussey, C. V.:Congenital hypoprothrombinemic states. Arch. Int. Med., 95:2, 1955.

8) Quick, A. J.:Hemorrhagic diseases, 2nd ed. Philadelphia:Lea & Febiger, 1966. p. 60.

9) 山中學:血液凝固の最近の知見-分子病としての凝固異常-. 臨床生理. 1:535, 1971.

10) Rhoads, J. E., Fitz-Hugh, T.:Idiopathic hypoprothrombinemia-an apparently unrecorded condition. Am. J. Med. Sci., 2021662, 1941.

11) Girolami, A., Sticchi, A., Lazzarin, M., Scarpa, R.:Congenital hypoprothrombinemia. case report. Acta haemat., 44:164, 1970.
pubmed

12) Baudo, F., De Cataldo, F., Josso, F., Silvello, L.:Hereditary hypoprothrombinaemia, Acta haemat., 47:243, 1972.
pubmed

13) Josso, F., De Sanchez, M., Lavergne, J. M., Menache, D., Soulier, J. P.:Congenital abnormality of the prothrombin molecule (factor II) in four siblings:prothrombin Barcelona. Blood, 38:9, 1971.

14) Girolami, A., Lazzarin, M., Brunetli, A., Scarpa, R., Molars, G.:Congenital hypoprothrombinemia. A case report. Haemat. lat., 12:77, 1969. Acta haemat., 44:174, 1970より引用

15) Girolami, A., Lazzarin, M., Scarpa, R., Brunetti, A.:Congenital hypoprothrombinemia. A case report with some considerations on the behavior of the T. G. T. in this condition. Coagulation, 3:45, 1970.

16) Kattlove, H. E., Shapiro, S. S., Spivack, M.:Hereditary prothrombin deficiency. New Eng. J. Med, 282:57, 1970.
pubmed

17) Shapiro, S. S., Martinez, J., Holburn, R. R.:Congenital dysprothrombinemia:an inherited structual disorder of human prothrombin. J. Lab. Clin. Med., 48:2251, 1969.

18) Quick, A. J., Husshy, C. V.:Hereditary hypoprothrombinaemias. Lancet, i:173, 1962.

19) Biggs, R., Douglas, A. S.:The measurement of prothrombin in plasma. J. clin. Path., 6:15, 1953.
pubmed

20) Karpatkin, S., Ingram, G. I. C., Graham, J. B.:Severe isolated prothrombin deficiency:an aquired state with complete recovery. Thromb. Diath. Haemorrh., 8:221, 1962.

21) Pool, J. G., Desai, R., Kropatkin, M.:Congenital hypoprothrombinemia in a negro boy. Thro mb. Diath. Haemorrh., 8:235, 1962.

22) B (rrchgrevink, C. F., Egeberg, O., Pool, J. G., Skulason, T., Stormorken, H., Waaler, B.:Astudy of a case of congenital hypoprothrombinaemia. Brit. J. Haemat., 5:294, 1959.

23) Stefanini, M., Dameshek, W.:The Hemorrhagic Disorders. 2nd ed. NY:Grune & Stratton, 1962. p. 289.

24) Josso, P. F., Prou-Wartelle, O., Soulier, J. P.:Etude d'un cas d'hypoprothrombinemie congenitale. N. R. F. Hemat., 2:647, 1962.

25) Van Creveld, S.:Congenital idiopathic hypoprothrombinemia. Acta Paediat (Uppsala), Suppl. 100, p. 245文献22) より引用

26) De Bastos, O., Reno, R. S., Correa, O. T.:A study of three cases of familial congenital hypoprothrombinaemia ( Factor n deficiency). Thromb. Diath. Haemorrh., 11:497, 1964.

27) Owren, P. A.:Parahemophilia;Haemorrhagic diathesis due to absence of a previously unknown clotting factor. Lancet, i:446, 1947.
pubmed

28) Alexander, B., et al.:Synonymy of the nonprothrombin plasma factors involved in the conversion of prothrombin to thrombin. Trans. Fifth Conference on Blood Clotting and allied Problems (Flynn, J. E., Ed.). New York:Josiah Macy, Jr. Foundation, 1952. P. 329.

29) Seeler, R. A.:Parahemophilia factor V deficiency. Med. Clin. North Am., 56:119, 1972.
pubmed

30) Girolami, A., Venturelli, R., Righini, F., Scarpa, R.:Parahemophilia, a case report. Acta Haemat., 6:242, 1971.

31) 吉田邦男:血友病・類縁疾患. 日本臨床, 32 (増):1833, 1974.

32) Brink, A. J., Kingsley, C. S.:Afamilial disorder of blood coagulation due to deficiency of the labile factor. Quart. J. Med., 21:19, 1952.

33) 佐竹清人, 高沢登四男, 盤若博司, 八幡浩二, 綿貫実:軽症型特発性第V因子欠乏症 (パラ血友病) の1例. 内科, 14:530, 1964.

34) 水晶輝夫, 塚田恒安, 戸井田一義, 立川実, 松岡松三:軽症第V因子欠乏症の1家系. 臨床血液, 10:163 (抄), 1969.

35) 島田惇, 斉藤英彦, 勝見乙平:先天性第V, 第VIII因子合併欠乏症の1例. 日本臨床. 23:159, 1965.

36) Saito, H., Shioya, M., Koie, K., Kamia, T., Katsumi, O.:Congenital combined deficiency of factor V and factor VIII, A case report and the effect of transfusion of normal plasma, and hemophilic blood, Thromb. Diath. Haemorrh., 22:316, 1969.

37) Smit Sibinga, C. T., Gokemeyer, J. D. M., Kate, L. P., Bos-van Zwol, F.:Combined deficiency of factor V and factor Wn:report of a family and genetic analysis. Brit. J. Haemat., 23:467, 1972.

38) 神谷忠, 石黒順造, 鯉江捷夫, 佐光富士男, 浅井紀一:先天性第V, 第VIII因子合併欠乏症の1家系. 臨床血液, 13:634 (抄), 1972.

39) 遠藤安行, 柴田昭, 三浦亮, 秋浜哲雄, 斉藤保子, 山口昭彦, 福田光之, 新藤徹郎, 樋口誠一, 伊藤政志:先天性第V因子欠乏症の2例. 臨床血液, 15:1028, 1974.

40) Borchgrevink, C. F., Owren, P. A.:Surgery in a patient with factor V (proaccelerin) deficiency. Acta Med. Scand., 170:743, 1961.

41) Seeler, R. F., Shwlaki, M. Z.:Platelet function studies in factor V deficiency. Acta Haemat., 48:176, 1972.

42) 森田久男, 加々美光安, 三好美春:Owren病の1例. 臨床血液, 1:55, 1960.

43) 丹呉幹彦, 氏家昭, 石川喜年, 安河内太郎:同胞にみられた先天性第V因子欠乏症 (パラ血友症) の 2例. 日内会誌, 54:112, 1965.

44) 半沢敦正, 水川市郎, 久山栄一, 丹治為世:先天性第V因子欠乏症の-家系. 臨床血液, 8:389, 1967.

45) 井土熊野, 松本常男, 大西英利, 林友信, 小林統祥, 楠瀬桂, 宮内永樹, 山田外春, 上島亮:同胞3名に出現した先天性第V因子欠乏症. 三重医学, 14:101, 1970.

46) 松村忠樹, 高橋正彦, 河野修造, 米田紘一, 橋本仙一郎, 寺岡敦子, 仲本恭子:先天性第V因子欠乏症の1例. 日血会誌33:273, 1970.

47) Owen, C. A., Jr.:The diagnosis of bleeding disorders, 1st ed. Boston:Little Brown & Comp., 1969. p. 187.

48) De Vries, A., Alexander, B., Goldstein, R.:A factor in serum which accelerates the conversion of prothrombin to thrombin I. Its determination and some physiologic and biochemical properties. Blood, 4:247, 1949.

49) Koller, F., Loeliger, A., Duckert, F.:Experiments on a new clotting factor (factor VII). Acta Haemat., 6:1, 1951.
pubmed

50) Alexander, B., Goldstein, R., Landwehr, G., Cook, C. G.:Congenital SPCA deficiency:ahitherto unrecognized coagulation defect with hemorrhage rectified by serum and serum fractions. J. Clin. Invest., 30:596, 1951.

51) Struwe, F. E., Vahleakamp, H.:Beitrag zum Krankheitsbild des kongenitalen Faktor-VII-Mangels. Wien. Klin. Wschrt., 80:147, 1968.

52) 林久智, 佐々木雅英, 吉岡薄夫, 新谷憲治, 半沢敦正, 喜多嶋康一:先天性第VII因子欠乏症の1例. 臨床血液, 15:1042, 1974.

53) Prydz, H.:Studies on proconvertin (factor VII), VI, the production in rabbits of an antiserum against factor VII. Scandinav. J. Clin. Lab. Invest., 17:66, 1965.

54) Goodnight, S. H., Feinstein, D. I., Osterud, B., Rapaport, S. I.:Factor VII antibody-neutralizing material in hereditary and acquired factor VII deficiency. Blood, 38:1, 1971.
pubmed

55) Owen, C. A., Amundsen, M. A., Thompson, J. H., Spittell, J. A., Bowie, E. J. W., Stilwell, G. G., Hewlett, J. S., Mills, S. D., Sauer, W. G., Gage, R. P.:Congenital deficiency of factor VII (hypoconvertinemia). Am. J. Med., 37:71, 1964.

56) Hall, C. A., Rapaport, S. I., Ames, S. B.:A clinical and family study of hereditary proconvertin (factor VII) deficiency. Am. J. Med., 37:172, 1964.
pubmed

57) Strauss, H. S.:Surgery in patients with congenital factor VII deficiency (congenital hypoproconvertinemia). Blood, 25:325, 1965.
pubmed

58) Marder, V. J., Shulman, N. S.:Clinical aspects of congenital factor VII deficiency. Am. J. Med., 37:182, 1964.

59) Girolami, A., Cattarozzi, G., Meagarvda, G., Lazzarin, M.:Congenital factor VII deficiency, A case report. Blut, 27:236, 1973.

60) Hoag, H. S., Aggeler, P. M., Farrell, A. H.:Disapperance rate of concentrated proconvertin extracts in congenital and acquired hypoproconvertinemia. J. Clin. Invest., 39:554, 1960.

61) 村上元孝, 松田保, 恩地一彰, 万見新太郎, 梅田俊彦, 西野哲夫, 平丸三樹, 高瀬雅子, 横山鉄夫:先天性第VII因子欠乏症の2家系. 臨床血液, 11:388, 1970.

62) Heikinheimo, R., Reinikaineu, M.:Congenital factor VII deficiency, two cases in children of cousins. Thromb. Diath. Haemorrh., 21:246, 1969.

63) Godal, H. C., Madsen, K., Nissen-Mayer, R.:Thrombo-embolism in patients with total proconvertin (factor VII) deficiency. Acta Med. Scand., 171:325, 1962.

64) 勝沼英宇, 安田宏, 川西正広, 福武勝博, 浮田実:先天性第VIII因子欠乏症の1例. 臨床血液, 4:260, 1963.

65) 小田正幸, 荻原洋三, 松岡恒美, 高山博臣, 越知富夫, 中山良子, 久野秀男:先天性第VIII因子欠乏症の 1例. 最新医学, 22:537, 1967.

66) 佐藤琢司, 佐久間均一:同胞3名にみられた先天性第VII因子欠乏症並びにその家族検査成績. 日本小児科学雑誌, 68:1224 (抄), 1964.

67) 古波倉正照, 浅井紀一, 勝見乙平:先天性第Vn因子欠乏症の1例. 日血会誌, 31:578 (抄), 1968.

68) 白川充, 浅山良吉, 兵藤貞夫:第VII因子欠乏症と第X因子欠乏症の各1例. 日血会誌, 32:1032 (抄), 1969. および共済医報, 18:205～209, 1969.

69) 勝沼英宇, 清水航一, 海老原隆郎, 高崎優, 和田斉:先天性第VII因子欠乏症患者のPPSB輸注効果. 臨床血液, 15:128 (抄), 1974.

70) Duckert, F., Fluckiger, P., Isenschmid, H., Matter, M., Vogel-Meng, J., Koller, F.:A modification of the thromboplastin generation test. Acta Haemat., 12:197, 1954.

71) Hougie, C., Barrow, E. M., Graham, J. B.:Stuart clotting defect. I. segregation of a hereditary hemorrhagic state from the heterogenous group heretofore called "stable factor" (SPCA, proconvertin, factor VII) deficiency. J. Clin. Invest., 36:485, 1957.
pubmed

72) Denson, K. W.:Electrophoretic studies of the Prower factor:a blood coagulation factor which differs from factor VII. Brit. J. Haemat., 4:313, 1958.
pubmed

73) Denson, K. W. E., Lurie, A., Cataldo, F. D., Mannucci, P. M.:The factor-X defect:recognition of abnormal forms of factor X. Brit. J. Haemat., 18:317, 1970.

74) Girolami, A., Molaro, G., Lazzarin, M., Scarpa, R., Brunetti, A.:'new' congenital haemyrrhagic condition due to the presence of an abnormal factor X (factor X Friuli):study of a large kindred. Brit. J. Haemat., 19:179, 1970.

75) Girolami, A., Carli, A., Falomo, R., Marco, L.D.:Factor X Friuli coagulation disorder. Blut, 27:151, 1973.

76) Girolami, A., Coser, P., Brunetti, A., Prinoth, O.:Classical factor X deficiency. Acta Haemat., 53:118, 1975.
pubmed

77) 安永幸二郎, 岡本美恵子, 脇坂行一:先天性第X因子欠乏症の1例. 日血会誌, 27:377 (抄), 1964,

78) 森和夫, 平塚巖, 細谷雄太, 中野昇, 北村竜男, 浜島昭雄:先天性第va, 第X因子合併欠乏症の一家系. 臨床血液, 12:108 (抄), 1971.

79) 森和夫, 平塚巖, 中野昇, 北村竜男, 内藤恒吉:先天性第X因子欠乏症の1例. 臨床血液, 13:635 (抄), 1972.

80) 岡本美恵子, 中山弘, 立川卓男, 脇坂行一, 安永幸二郎:先天性第X因子欠乏症患者における輸注第 X因子の消長並びに家系調査. 日血会誌, 30:721 (抄), 1967.

81) 安永幸二郎:先天性第X因子欠乏症. 代謝, 8 (臨増):1124, 1971.

82) Girolami, A., Lazzarin, M., Scarpa, R., Brunetti, A.:Further studies on the abnormal factor X (factor X Friuli) coagulation disorder:a report of another family. Blood, 37:534, 1971.
pubmed

83) Graham, J. B., Barrow, E. M., Hougie, C.:Stuart clotting deffect. II. genetic aspects of a 'new' hemorrhagic state. J. Clin. Invest., 36:497, 1957.

84) Lechler, E. L., Webster, W. P., Roberts, H. R.:The inheritance of Stuart disease:investigation of a family with factor X defficiency. Am. J. Med. Sci., 249:291, 1965.

85) Girolami, A., Brunetti, A., Bareggi, G., Cella, G.:Abnormal factor X (factor X Friuli) coagulation disorder. the heterozygote population. Acta Haemat., 51:40, 1974.
pubmed

86) Gonyea L. M., Crivit, W.:Congenital coagulation deficiency of Stuart factor activity. J. Lab. Clin. Med., 51:398, 1958.

87) Girolami, A., Sticchi, A., Bareggi, G.:Crossover electrophoresis (electrosyneresis) visualization of the abnormal factor X (factor X Friuli). J. Lab. Clin. Med., 80:740, 1972.
pubmed

88) 野村博, 安永幸二郎:先天性第X因子欠乏症における輸注第X因子の消長. 日血会誌, 35:420 (抄), 1972.

89) Girolami, A., Molaro, G., Marco, L.D.:Factor X survival and therapeutic factor X levels in the abnormal factor X (factor X Friuli) coagulation disorder. Acta Haemat., 52:223, 1974.

90) Brody, J. I., Finch, S. C.:Improvement of factor X deficiency during Pregnancy. New Engl. J. Med., 263:976, 1967.

91) Pechet, L.:Elevated factor VII and X in pregnancy, hypercoagulable state. J. Clin. Invest., 39:1015, 1960.

92) Hengstman, H., Klein, D.:Der Einfluss der Weiblichen Sexualhormone auf die Faktoren des Prothrombinkomplexes und den Gerinnungsvorgang. Deutsch Arch. Klin. Med., 205:561, 1959.

93) Girolami, A., Molaro, G., Calligaris, A., Luca, G. D.:Severe congenital factor X deficiency in 5-month old child. Thromb. Diath. Hemorrh., 24:175, 1970.

94) Bachmann, F., Duckert, F., Fluckiga, W., Hitzig, H., Koller, F.:Uber einem neuartigen kongenitalen Gerinnungsdefekt (Mangel an Stuart-Faktor). Thromb. Diath. haemorrh., 1:87, 1957.

95) Owen, C. A., Jr.:The diagnosis of bleeding disorders. 1st ed., Boston:Little Brown, 1969. p. 128.

96) Newcomb, T., Matter, M., Conroy, L., De Marsh, Q. B., Finch, C. E.:Congenital hemorrhagic diathesis of the prothrombin complex. Am. J. Med., 20:798, 1956.

97) 福井弘, 田川徳治, 高井優行, 神末光隆, 岩垣克己:先天性プロトロンビン複合体 (プロトロンビン, 第V, VII, X因子) 欠乏症の1例. 臨床血液, 5:44 (抄), 1964.

98) Dam, H., Schonheyder, F.:Deficiency disease in chicks resembling scurvy. Biochem. J., 28:1355, 1934.
pubmed

99) Kazmier, F. J., Spittell, J. A., Bowie, E. J. W., Thompson, J. H., Owen, C. A.:Release of vitamin K dependent factors by isolated, perfused rat liver. Am. J. Physiol, 214:919, 1968.

100) Hemker, H. C., Loeliger, E. A.:Kinetic aspects of the interaction of blood clotting enzymes III. Demonstration of the existence of an inhibitor of prothrombin conversion in vitamin-K deficiency. Thromb. Diath. haemorrh., 19:346, 1968.

101) Hemker, H. C., Muller, A. B.:Kinetic aspects of the interaction of blood clotting enzymes. VI. Localization of the site of the blood coagulation inhibitor by the protein induced by vitamin K absence (PIVKA). Thromb. Diath. haemorrh., 20:78, 1968.

102) 松岡松三:出血性素因と血栓症. 東京:金原出版, 1969. p. 275.

103) Sells, R. L., Walker, S. A., Owen, C. A.:Vitamin K requirement of the newborn infant. Proc. Soc. Exp. Biol. Med., 47:441, 1941.

104) 山中學, 磯部淳一:Hepaplastin に関する研究. 血液と脈管, 4:557, 1973.

105) Townsend, C. W.:The hemorrhagic disease of the newborn. Arch Pediat., 11:559, 1894.

106) Willi, H.:Die Blutungshankheiten des Nengeborenen. Erg. inn. Med. u Kinderh. N. F., 2:467, 1951.

107) 吉岡慶一郎:新生児の出血傾向. 小児外科, 内科, 4:1081, 1972.

108) 松田正二, 鈴木重統:メレナ. 産科と婦人科, 37:848, 1970.

109) Allison, A. C.:Danger of vitamin K to newborn. Lancet, i:669, 1955.

110) Schwenzer, A. W., Klotsch, B., Roka, L.:Das Gerinnungssystem unter der Geburt. Arch f Gynak., 191:8, 1958.

111) Zuckerman, I. C., Kogut, B., Jacobi, M., Cohen, J. Y.:Studies in human biliary physiology III. The effect of bile and vitamin K on experimentally-produced hemorrhagic diathesis in a human with a total external biliary fistula. Am. J. Digest. Dis., 6:332, 1939.

112) Fanconi, G.:Zoliakie. Deutsch Med. Wschr., 64:1565, 1938.

113) Clark, R. L., Dixon, C. F., Butt, H. R., Snell, A. M.:Deficiency of prothrombin associated with various intestinal disorders; its treatment with the anti hemorrhagic vitamin (vitamin K). Proc. Staff Meet. Mayo Clinic, 14:407, 1939. 文献8. p. 120, No. 46より引用.

114) Moore, M. J., Strickland, W. H., Prichard, R. W.:Sprue with bleeding from hypoprothrombinemia. Arch. Int. Med., 97:814, 1956.

115) Matoth, Y.:Plasma prothrombin in infantile diarrhea. Am. J. Dis. Child., 80:944, 1950.

116) Owen, C. A., Jr.:The diagnosis of bleeding disorders. 1st ed., Boston:Little Brown, 1969. p. 198.

117) Rapoport, S., Wing, M., Guest, G. M.:Hypoprothrombinemiaafter salicylate admmistration in man and rabbits. Proc. Soc. Exp. Biol. Med., 53:40, 1943.

118) Shapiro, S., Redish, M. H., Campbell, H.A.:Studies on prothrombin IV. the prothrombinopeic effect of salicylate in man. Proc. Soc. Exp. Biol. Med., 53:251, 1943.

119) Frick, P. G.:Hemorrhagic diathesis with increased capillary fragility caused by salicylate therapy. Am. J. Med. Sci., 231:402, 1956.
pubmed

120) Jacoby, M.:Ueber die Beziehungen der Leber-und Blutveranderungen bei Phosphorvergiftung zur Autolyse. Hoppe Seyler Z. Physiol. chem., 30:174, 1900.

121) Nolf, P.:De modifications de le coagulation du sang chez le chien apres extirpation du foie. Arch. Int. Physiol. 3:1,1905

122) Olson, J. P., Miller, L. L., Troup, S. B.:Synthesis of clotting factors by the isolated perfused rat liver. J. Clin. Invest., 45:690, 1966.

123) Mattii, R., Ambrus, J. L., Sokal, J. E., Mink, I.:Production of members of the blood coagulation and fibrinolysin systems by the isolated perfused liver. Proc. Soc. Exp. Biol. Med., 116:69, 1964.
pubmed

124) Anderson, G. F., Barnhart, M. I.:Intracellular localization of prothrombin. Proc. Soc. Exp. Biol. Med., 116:1, 1964.
pubmed

125) 松岡松三:血液凝固第2相の異常による出血性素因. 第17回日本医学会総会学術講演集, IV:847, 1967.

126) Rake, M. O.:Intravascular coagulation in acute hepatic necrosis. Lancet, i:533, 1970.
pubmed

127) 松岡松三:肝機能と血液凝固. 最新医学, 20:347, 1965.

128) 山中學, 菊地晃, 山崎健吾:Thrombotest その基礎的検討特にQuick 法との比較について. 最新医学, 19:638, 1965.

129) Fletcher, A. P., Biederman, O., Moore, D., Alkjaersig, N., Sherry, S.:Abnomal plasminogenplasmin system activity (fibrinolysis) in patients with hepatic cirrhosis:Its cause and consequences. J. Clin. Invest., 43:681, 1964.

130) 山本祐夫, 吉村良之介:肝・胆道疾患. medicina, 12:938, 1975.

131) 瀧川清治, 菅原譲, 小栗隆, 加藤作郎, 細井淳:肝疾患の凝固, 線溶に及ぼすビタミンKの影響. 臨床成人病, 1:285, 1971.

132) Quick, A. J.:Hemorrhagic Diseases. 2nd ed., Philadelphia:Lea & Febiger, 1966. p. 116.

133) 日比野進, 浅井紀一, 勝見乙平:白血病と出血性素因. 日本臨床, 17:2152, 1959.

134) 松岡松三:第15回日本医学会総会学術集会記録. IV:88, 1959. 文献127. p. 144. No 97より引用

135) Koller, F., Gasser, C., Krusi, G., De Murelt, G.:Purpura fulminans nach Scharlach mit Faktor V-Mangel und Antithrombinuberschuss. Acta Haemat., 4:33, 1950.

136) Warner, E. D., Owen, C. A.:Hypoprothrombinemia in pernicious anemia. Am. J. Med. Sci., 203:187, 1942.

137) Savacool, J. M.:Prothrombin studies in pulmonary tuberculosis. Am. J. Med. Sci., 201:830, 1941.

138) 佐竹清人:諸種疾患における凝血因子, 肝・心・腎疾患, とくに凝固促進因子の臨床的意義を中心として. 目内会誌, 51:1158, 1962.

139) Stefanini, M., Dameshek, W.:The Hemorrhagic Disorders. 2nd ed., NY:Grune & Stratton, 1962. p. 292.

140) Pina-Cabral, J. M., Justica, B.:Congenital hypoprothrombinemia in a Portuguese family. Thromb. Diath. haem., 30:451-459, 1973.

141) Montgomery, R. R., Otsuka, A., Hathaway, W. E.:Hypoprothrombinemia:case report. Blood, 51:299-306, 1978.
pubmed

142) Owen, C. A. Jr., Henriksen, M. S., McDuMe, F. C., Mann, K. G.:Prothrombin Quick. a newly identified dysprothrombinemia. Mayo Clin. Proc., 53:29-33, 1978.

143) Girolami, A., Coccheri, S., Palareti, G., Poggi, M., Burul, A., Cappellato, G.:Prothrombin Molise:a new congenital dysprothrombinemia, double heterozygosis with an abnormal prothombin and true prothrombin deficiency. Blood, 52:115-125, 1978.

144) Shapiro, S.:Prothrombin San Juan:a complex new dysprothrombinemia. Hemker, H. C.:Prothrombin and related coagulation factors. Leiden University Press, 1975. p. 205-212.

145) Girolami, A.:Prothrombin Padua. ibid. p. 213-222 or J. Lab. Clin. Med., 84:654-666, 1974.
pubmed

146) Kahn, M. J. P.:Prothrombin Brussels. ibid. p. 223-229 or Thromb. Res., 5:141-156, 1974.
pubmed

147) Weinger, R. S., Rudy, C., Moake, J. L., Olson, J. D., Cimo, P. L.:Prothrombin Houston:a dysprothrombin identifiable by crossed immunoelectrofocusing and abnormal Echis carinatus venom activation. Blood, 55:811-816, 1980.

148) 桜川信男:第IX (因子濃縮製剤 (プロトロンビン複合体) の凝固学的性状. 最新医学, 36:1040-1043, 1981.
Medical*Online

149) Seligsohn, V.:Activated factor VII:presence in factor IX concentrates and persistance in the circulation after infusion. Blood, 53:828-837, 1979.

150) Girolami, A.:The congenital factor VII abnormalities (Dysproconvertinemias). The genetic plot thickens. Folia Haematol., 107:131-136, 1980.
pubmed

151) 高松純樹, 林清剛, 緒方完治, 神谷忠, 鯉江捷夫:先天性第VII因子欠乏症の一家系. 臨床血液, 21:834-836, 1980.

152) 大串利弘, 松田重三, 中村一路, 風間睦美, 安部英:複合第IX (因子製剤輸注により正常分娩を経過した先天性第VII因子欠損症の1例. 臨床血液, 19:1272, 1978.

153) Briet, E., Loeliger, E. A., van Tilburg, N. H., Veltkamp, J. J.:Molecular variant of factor VII. Thromb. Haemostas, 35:289～294, 1976.

154) Zazzucconi, M. G., Mandelli, F., Mariani, G., Briet, E., Veltkamp, A.:CRM-positive variant of factor VII deficiency and the detection of heterozygotes with the assay of factor-like antigen. Brit. J. Haematol., 36:127-135, 1977.

155) Girolami, A., Falezza, G., Patrassi, G., Stenico, M., Vettore, L.:Factor VII Verona coagulation disorder:double heterozygosis with an abnormal factor VII and heterozygous factor VII deficiency. Blood, 50:603-610, 1977.
pubmed

156) Girolami, A., Fabris, F., Zanon, R. D. B., Ghiotto, G., Burul, A.:Factor VII Padua:a congenital coagulation disorder due to an abnormal factor VII with a peculiar activation pattern. J. Lab. Clin. Med., 91:387-395, 1978.

157) Girolami, A., Cattarozzi, G., Zanon, D. B., Cella, G., Toffanin, F.:Factor VII Padua 2:another factor VII abnormality with defective ox brain thromboplastin activation and a complex hereditary pattern. Blood, 54:46-53, 1979.

158) Girolami, A., Patrassi, G., Cappellato, G., Casonato, A.:Another family with the factor VII Padua clotting detect. Acta Haemat., 62:4-11, 1979.

159) Mariani, G., Mazzucconi, M. G., Hermans, J., Ciavarella, N., Faiella, A., et al.:Factor VII deficiency:immunological characterization of genetic variants and detection of carriers. Brit. J. Haematol, 48:7-14, 1981.

160) Mori, K., Sakai, H., Nakano, N., Suzuki, S., Sugai, K., Hisa, S., Goto, Y.:Congenital factor X deficiency in Japan. Tohoku J. exp. Med., 133:1-19, 1981.
pubmed

161) Girolami, A., Falomo, R., DeMarco, L., Patrassi, G.:Factor X Friuli coagulation disorder. Acta haemat., 56:27～38, 1976.

162) Chung, K. S., Bezeaud, A., Goldsmith, J. C., McMillan, C. W., Menache, D., Roberts, H. R.:Congenital deficiency of blood clotting factors II, VII, IX (and X. Blood, 53:776-787, 1979.

163) Johnsoll, C. A., Chung, K. S., McGrath, K. M., Bean, P. E., Roberts, H. R.:Characterization of avariant prothrombin in a patient congenitally deficient in factors II, VII, IX and X. Brit. J. Haematol., 44:461-469, 1980.

164) Malia, R. G., Preston, F. E., Mitchell, V. E.:Evidence against vitamin K deficiency in normal neonates. Thromb. Haemostas., 44:159-160, 1980.

165) 吉岡慶一郎, 藤村吉博, 三村良明, 木下清二, 高宮脩:新生児の血液凝固とその障害. 小児科, 21:847～858, 1980.

166) 藤村吉博, 三村良明, 木下清二, 斉藤京子, 吉岡章, 北脇達雄, 吉岡慶一郎:乳児期のビタミンK欠乏症の出血成因に関する研究-特にプロトロンビン- 日児誌, 84:6-13, 1980.

167) 麦島秀雄, 上瀬英彦, 三間屋純一, 中野省三, 片岡健, 北条博厚, 山崎駿:乳児特発性ビタミンK欠乏症の臨床および凝固学的検討. 小児科, 22:199-205, 1981.

168) 飯塚敦夫, 長尾大:乳児特発性ビタミンK欠乏症における異常prothrombin-新生児メレナとの比較. 血液と脈管, 10:649～652, 1979.

P.127 掲載の参考文献

1) Rabe, F., Saloman, E.:Uber Faserstoff mangel im Blute bei einem Falle von Hamophilie, Dtsch. Arch. Klin. Med., 132:240-244, 1920.

2) Mammen, E. F.:Congenital abnormalities of the fibrinogen molecule. Semin. Thromb. Hemostas., 1:184-201, 1974.

3) 斉藤正, 浅井博明:線維素原減少症の一例. 小児科臨床, 7:50～51, 1954,

4) Weiss, H. J., Rogers, J.:Fibrinogen and platelets in the primary arrest of bleeding. Studies in two patients with congenital a fibrinogenemia. N. Engl. J. Med., 285:369-374, 1971.

5) de Vries, A., Rosenberg, T., Kochwa, S., et al:Precipitating antifibrinogen antibody appearing after fibrinogen infusions in a patient with congenital a fibrinogenemia. Am. J. Med., 30:486-494, 1961.

6) Imperato, C. D., Dettori, A. G.:Ipofibrinogenemia congenita coll fibrinoastenia. Helv. Paediatr. Acta, 13:380, 1958.

7) Menache, D.:Dysfibrinogenemia constitutionelle et famiale. Proc. IXth Cong. Eur. Soc. Haematol., Karger, Basel, 1963. p. 1255.

8) Hasselbach, R., Marion, R. B., Thomas, J. W.:Cogenital hypofibrinogenemia in five members of a family. Can. Med. Assoc. J., 88:19, 1963.

9) Beck, E. A.:Abnormal fibrinogen (fibrinogen 'Baltimore') as a cause of a familial hemorrhagic disorder (abstr.). Blood, 24:853-854, 1964.

10) von Felten, A., Duckert, F., Frick, P. G.:Familial disturbance of fibrin monomer aggregation. Br. J. Haematol., 12:667-677, 1966.
pubmed

11) Egeberg, O.:Inherited fibrinogen abnormality causing thrombophilia. Thromb. Diath. Haemorrh., 17:176～187, 1967.

12) Forman, W. B., Boyer, M. H., Ratnoff, O. D.:A hereditary defect in the coagulation of fibrinogen by thrombin-studies in a family with fibrinogen Cleveland-(abstr.). Blood, 30:863, 1967.

13) Mammen, E. F., Prasad, A. S., Barnhart, M. I., et al.:Congenital dysfibrinogenemia-fibrinogen Detroit-. J. Clin. Invest., 48:235-249, 1969.
pubmed

14) Samama, M., Soria, M., Soria, J., et al.:Congenital and familial dysfibrinogenaemia without bleeding tendency. XIIth Cong. Intnatl. Soc. Hematol., 1968. p. 179.

15) Sherman, LA., Gaston, L. W., Spivak, A. R.:Studies on a patient with a fibrinogen variant and hemophilia A (abstr.). J. Lab. Clin. Med., 72:1017, 1968.

16) Funk, C., Straub, P. W.:Hereditary abnormality of fibrin monomer aggregation (fibrinogen Zurich H). (abstr). Europ. J. Clin. Invest., 1:131, 1970.

17) Verstraete, M.:Discussion. Thromb. Diath. Haemorrh., 34 (Suppl.):334, 1970.

18) Hampton, J. W.:Qualitative fibrinogen defect associated with abnormal fibrin stabilization (abstr.). J. Lab. Clin. Med., 72:882, 1968.

19) Zeitz, B. H., Scott, J. L.:An inherited defect in fibrinogen polymerization-fibrinogen Los Angeles-(abstr.). Clin. Res., 18:179, 1970.

20) Gralnick, H. R., Givelber, H. M., Finlayson, J. S.:A familial bleeding disorder associated with dysfibrinogenemia (fibrinogen "Bethesda"). Clin. Res., 18:405, 1970.

21) 井出望, 沼田幸子, 岡武, 他:異常フィブリノゲン血症 (congenital dysfibrinogenemia) と思われる1家系10症例. 日本血液学会雑誌, 34:113, 1971.

22) Janssen, C. L., Vreeken, J.:Fibrinogen Amsterdam-another hereditary abnormality of fibrinogen-. Brit. J. Haematol., 20:287-298, 1971.

23) Streiff, F., Alexandre, P., Vigneron, C., et al.:Un nouveau cas d'omalie constitutionnelle et familiale du fibrinogene sans diathase hemorragique. Thromb. Diath. Haemorrh., 26:565-576, 1971.

24) Winckelmann, G., Augustin, R., Baudilla, K.:Congenital dysfibrinogenemia-report of a new family (fibrinogen 'Weisbaden')-. II nd Cong. Intriatl. Soc. Thromb. Haemost., 1971.

25) Soria, J., Soria, C., Samama, M., et al.:Fibrinogen Troyes-Fibrinogen Metz-two new cases of congenital dysfibrinogenemia-. Thromb. Diath. Haemorrh., 27:619-633, 1972.
pubmed

26) Krause, W. H., Heene, D. L, Lasch, H. G.:Ein reuer Fall von Dysfibrinogenamia. Klin. Wschr.,

27) Aguercif, M., Anner, R., Ritschard, J.:Syndromes de disfibrinognemies congenitales et familiales.-a propos de deux nouvelles families-. Pediatrie, 27:317-323, 1972.
pubmed

28) Gralnick, H. R., Givelber, H. M., Finlayson, J. S.:Congenital dysfibrinogenemia:Fibrinogen Bethesda H. Proc. III Congr. Intern. Soc. Thrombos. Haemostas., 96, 1972.

29) Lacombe, M., Soria, C., Soria, J., et al.:A new case of congenital dysfibrinogenemia without bleeding tendency. The fibrinogen Montreal. Proc. III Congr. Interll. Soc. Thrombos. Haemostas., 114, 1972.

30) Thaler, E.:Discussion. XVIIth Meeting German Ass. Blood. Coagulationists, Munster, 1973.

31) Jacobsen, C. D., Hoak, J. C.:Fibrinogen Iowa City-an abnormal fibrinogen with no clinical symptoms-. Thromb. Res., 2:261-270, 1973.

32) Crum, E. D., Shainoff, J. R., Graham, R. C., et al.:Fibrinogen Cleveland II-an abnormal fibrinogen with defective release of fibrinopeptide A-. J. Clin. Invest., 53:1308-1319, 1974.

33) Martinez, J., Holburn, R. R., Shapiro, S. S., et al.:Fibrillogen Philadelphia-a hereditary hypofibrinogenemia characterized by fibrinogen hypercatabolism-. J. Clin. Invest., 53:600-611, 1974.

34) Soria, J., Soria, C.:Dysfibrinogenemie familiale avec anomalie d'agregation des monomeres-fibrinogene Paris III. Pathol. Biol, 22 [Suppl]:72, 1974.

35) Aznar, J., Fernandez, P., Regafion, F., et al.:Fibrinogen Valencia. A new case of congenital dysfibrinogenemia. Thromb. Diath, Haemorrh., 32:564-577, 1974.

36) Gralnick, H. R., Coller, B. S.:A new congenital dysfibrinogenemia-fibrinogen Bethesda III-. XVth Cong. Intnatl. Soc. Hematol., Jerusalem,, 1974. p. 454.

37) Wohl, R. C., Bradley, T. B.:Impaired monomer aggregation in congenital dysfibrinogenemia (abstr.). Blood, 44:935, 1974.

38) Samori, T., Yatabe, M., Ukita, M., et al.:A new type of congenital dysfibrinogenemi (fibrinogen Tokyo) with defective stabilization of fibrin polymers (abstr.). Vth Cong. Thromb. Haemost., Paris. 1975. p. 64.

39) 鈴木道子, 他:異常フィブリノゲン血症と思われる-家系の検討. 臨床病理, 23 (補):365, 1975.

40) Bosch, N. B., Arocha-Pinango, C.:An abnormal fibrinogen in a Venezuelan family. Vth Cong. Intnatl. Soc. Thromb. Haemost., Paris, 1975. p. 226.

41) Krause, W. H., Huth, K., Heene, D. L, et al.:Hypodysfibrinogenamie:Fibrinogen Gieben II. Klin. Wochenschr., 53:781-782, 1975.

42) D'Angelo, G., Lacomb, M., Lemay, J., et al.:A new congenital dysfibrinogenemia with haemorrhagic diathesis (fibrinogen Montreal H). Vth Cong. Intnatl Soc. Thromb. Haemost., Paris, 1975. p. 223.

43) Burashi, J. A., Sacks, E. S., Quiroga, E., et al.:A new fibrinogen anomaly fibrinogen Buenos Aires. Vth Cong. Intnatl. Soc. Thromb. Haemost., Paris, 1975. p. 224.

44) Soria, J., Soria, C., Bezou, MJ., et al.:Dysfibrinogenemie par anomalie de l'agregation des monomeres-le fibrinogene Clermont-Ferrand-. Cogres Francais d'Hematologie, Vittel, 1975. p. 66.

45) Fucks, G., Egbring, R., Havemann, K.:A new case of dysfibrinogenemia-fibrinogen Marburg-. Vth. Cong. Intnatl. Soc. Thromb. Haemost., Paris, 1975. p. 222.

46) Al-Mondhiry, H. A. B., Bilezikian, S. B., Nossel, H. L.:Fibrinogen:New York"-an abnormal fibrinogen associated with thromboembolism:functional evaluation-. Blood, 45:607-619. 1975.

47) Soria, J., Soria, C., Houbouyan, L., et al.:Fibrinogen Boulogue-a congenital abnormality in aggregation of fibrin monomers. Intnatl. Soc. Haematol. (European & African Div. IIIrd Meeting), London, 1675. p. 2303.

48) McDonagh, R. P.:Fibrinogen "Chapel Hill":A molecular variant with increased susceptibility to Ancrod. Blood, 46:1045, 1975,

49) Barthels, M., Sandvoss, G.:"Fibrinogen Hannover", ein Weiteres atypisches Fibrinogen. Blut, 34:99-106, 1977.
pubmed

50) 高松純樹, 他:異常フィブリノゲン血症の1家系6症例 (抄録). 第19回日本臨床1血液学会総会, 1977. p. 232.

51) Branson, H. E., Schmer, G., Dillard, D. H.:Fibrinogen Seattle:A qualitatively abnormal fibrinogen in a patient with tetralogy of Fallot. Am. J. Clin, Pathol., 67:236-240, 1977.

52) Matthias, F. R., Krause, W. H., Ganssert, S., et al,:Dysfibrinogenamie:Zugleich ein newer Fall:Dysfibrinogentimie Gieben III. Klin. Wochenschr., 55:539-543, 1977.

53) Jobin, F., Vu, L., Delage, J. M.:Fibrinogenes Quebec I et Quebec II:deux nouvelles familles de dysfibrinogenemie. Acta Haematol., 59:119-127, 1978.
pubmed

54) Amsellem, M., Sammama, M., Conard, J., et al.:Dysfibrinogrnrmie congenitale:deux observations. Nouv. Presse. Med., 7:3745-3748, 1978.

55) Denninger, M. H., Finlayson, J. S., Reamer, L. A., et al.:Congental dysfibrinogenemia:Fibrinogen Lille. Thromb. Res., 13:453-466, 1978.

56) Lane, D. A., Cuddigan, BJ., Vanross, M. E., et al.:A new case of dysfibrinogenaemia; Fibrinogen London (abstr.). Br. J. Haematol., 39:148, 1978.

57) Llaven, J. G., Vargas-Linares, M. E., Azaola-Espinoza, P., et al.:An abnormal fibrinogen identified in a Mexican family. 17th. Intnatl. Cong. Hematol, Paris, 1978. p. 938.

58) Soria, J., Soria, C., Haverkate, F., et al.:Description of a new fibrinogen containing an abnormal Bβ-chain. 17th Intnatl. Cong. Hematol, Paris, 1978. p. 940.

59) Godal, H. C., Brosstad, F., Kierulf, P.:Three new cases of an inborn qualitative fibrinogen defect (Fibrinogen Oslo II). Scand. J. Haematol., 20:57-62, 1978.
pubmed

60) Dumitrescu, E., Taubert, W., Nienhaus, K. H., et al.:Observations on a new variant of hereditary dysfibrinogenemia ("Homburd"?) with delayed fibrin polymerization and without clinical abnomality (abstr.). Thromb. Haemost., 42:139, 1979.

61) Fernandez, J., Lasierra, J., Narvaiza, M. J., et al.:Fibrinogen Logrono. A new fibrinogen molecular variant (abstr.) Thromb. Haemost., 42:138, 1979.

62) Lane, R. A., VanRoss, M., Kakkar, V. V., et al.:An abnormal fibrinogen with delayed fibrinopeptide A release (abstr.). Thromb. Haemost., 42:77, 1979.

63) Hansen, M. S., Clemmensen, I.:An abnormal fibrinogen (Copenhagen) associated with severe thromboembolic disease, but with normal adsorption of plasminogen (abstr.). Thromb. Haemost., 42:137, 1979.

64) Chavin, SJ., Andes, W. A., Beltran, W. G., et al.:Fibrinogen New Orleans:An inherited variant with abnormal peptide release (abstr.). Thromb. Haemost., 42:77, 1979.

65) Bottcher, D., Hasler, K., Kottgen, E., et al.:Hereditary hypodysfibrinogenemia with defective release of fibrinogenopeptide A (Fibrinogen Freiburg) (abstr.). Thromb. Haemost., 42:78, 1979.

66) Liu, C. Y., Nossel, H. L., Kaplan, K. L.:Detective thrombin binding by abnormal fibrin associated with recurrent thrombosis (abstr.). Thromb. Haemost., 42:79, 1979.

67) Hensen, A., Boommer, EJ., Gravesen, M., et al.:Familial dysfibrinogenemia:Fibrinogen Haarlem I and II. Ned. Tijdschr. Geneeskd., 125:734-737, 1981.

68) Higgins, D. L., Shafter, J. A.:Fibrinogen Petoskey, a dysfibrinogenemia characterized by replacement of Arg-Aα 16 by a histidyl residue. Evidence for thrombin-catalyzed hydrolysis at a histidyl residue. J. Biol. Chem., 256:12013-12017, 1981.

69) Soria, J., Coupier, J., Samama, M., et al.:Dysfibrinogenaemia without bleeding tendency with abnormal polymerization of fibrin monomers in a case of severe hepatitis, XII Cong. Intnatl. Soc. Hematol., 1968. p. 180.

70) Soria, J., Soria, C., Samama, M., et al.:Dysfibrinogenemies acquises daus les atteintes hepatiques severes. Coagulation, 3:37-44, 1970.

71) Martinez, J., Palascak, J. E., Kwasniak, D.:Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease. J. Clin. Invest., 61:535-538, 1978.
pubmed

72) Duckert, F., Jung, E., Schmerling, D. H.:A hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. Thromb. Diath. Haemorrh., 5:179-186, 1960.

73) Duckert, F.:Documentation of the plasma factor XIII deficiency in man. Ann. N. Y. Acad. Sci., 202:190～199, 1972.

74) Lorand, L., Losowsky, M. S., Miloszewski, KJ. M.:Human factor XIII:Fibrin-stabilizing factor. Prog. Hemost. Thromb., 5:245-290, 1980.

75) 鈴木弘文, 花沢恵子, 福武勝博:先天性第XIII因子 (F. S. F.) 欠乏症の1例 (抄録). 臨床血液, 7:110, 1966.

76) Chen, R., Doolittle, R. F.:y-y crosslinking sites in human and bovine fibrin. Biochemistry, 10:4487～4491, 1971.

77) Folk, J. E., Finlayson, J. S.:The e-(y-glutamyl) lysine crosslink and the catalytic role of transglutaminases. Adv. Protein. Chem., 31:1-133, 1977.

78) McDonagh, R. P., et al.:Studies of the α-chain crosslinking of human fibrin. XVI Internatl. Cong. Hematol. Kyoto (abstr.), 1976. p. 311.

79) Nyman, D., Duckert, F.:Factor XIII, fibrin and collagen. Thromb. Diath. Haemorrh., 34:551, 1975.
pubmed

80) Mosher, D. F.:Cross-linking of cold-insoluble globulin by fibrin-stabilizing factor. J. Biol. Chem., 250:6614～6621, 1975,

81) Mosher, D. F.:Cross-linking of collagen and fibronectin by factor XIIIa. Localization of participating glutaminyl residues to a tryptic fragment of fibronectin. J. Biol. Chem., 255:1181-1188, 1980.
pubmed

82) Sakata, Y., Aoki, N.:Cross-linking of α2-plasmin inhibitor to fibrin by fibri-stabilizing factor. J. Clin, Invest., 65:290-297, 1980.

83) Takagi, T., Konishi, K.:Purification and some properties of fibrin stabilizing factor. Biochim. Biophys. Acta, 271:363-370,1972.
pubmed

84) Chung, S.I., Lewis, M.S., Folk, J.E.:Relationships of the catalytic properties of human plasma and platelet transglutaminases (activated blood coagulation factor XIII) to their submit structure. J. Biol. Chem., 249:940-950, 1974.

85) McDonagh, J., McDonagh, R. P., Myllyla, G., et al.:Factor XIII deficiency:A genetic study of two affected kindreds in Finland. Blood, 43:327-332, 1974.
pubmed

86) Ratnoff, O. D., Steinberg, A. G.:Inheritance of fibrin-stabilizig-factor deficiency. Lancet, i:25～26, 1968.

87) Rutllant, M. L., Gimferrer, E., Vinas, J.:Deficit Congenito del Factor XIII. Sangre, 18:102～110, 1973.

88) Ikematsu, S.:An approach to the metabolism of factor XIII. Acta Haematol. Jap., 44:1499～1505, 1981.

89) Miloszewski, K., Losowski, M. S.:Factor XIII concentrates in the long term management of congenital factor XIII deficiency. Thromb. Diath. Haemorrh., 34:323-324, 1975.

90) Britten, A. F. H.:Congenital deficiency of factor XIII (fibrin stabilizing factor):Report of a cace and review of the literature. Am. J. Med., 43:751-761, 1967.

91) Walls, W. D., Losowsky, M. S.:Congenital deficiency in fibrin stabilizing factor. Coagulation, 1:111～188, 1968.

92) Ottaviani, P., Mandelli, F.:Two cases of haemorrhagic disease arising from stabilizing factor deficiency. Hemostase, 6:317-324, 1966.
pubmed

93) Fisher, S., Rikovar, M., Naor, S.:Factor 13 deficiency with severe hemorrhagic diathesis. Blood, 28:34～36, 1966.

94) Amris, C. J., Hilden, M.:Treatment of factor XIII defiency:Treatment with monthly plasma infusions. JAMA, 209:264-265, 1969.

95) Greenberg, L.H., Schiffman, S., Wong, Y. S. S.:Factor XIII deficiency:Treatment with monthly plasma infusions. JAMA, 209:264-265, 1969.

96) Stanulovic, D., Popovic, K., Lucic, A.:Syndrome of hemorrhage caused by inborn absence of coagulation factor XIII:Case report of the second case discovered in Yugoslavia. Med. Pregl., 22:243-247, 1969.

97) Broccia, G.:Haemorrhagic disease due to hereditary deficiency of factor XIII:Description of a family, Acta Haematol (Basel), 44:177-185, 1970.

98) Hanna, M.:Congenital deficiency of factor XIII:Report of a family from Newfoundland with associated mild deficiency of factor XIII. Pediatrics, 46:611-619, 1970.
pubmed

99) Abels, J., Smit-Sibinga, C., Meyler, L.:Congenital haemorrhagic diathesis with deficiency of factor XIII:A case report and a family study. Thromb. Diath. Haemorrh., 23:340-346, 1970.

100) Ikkala, E.:Transfusion therapy in congenital deficiencies of plasma factor XIII. Ann. N. Y. Acad. Sci., 202:200-203, 1972.
pubmed

101) Calle, B., Vergoz, D., Vie, J. C., et al.:Traitement de l'insuffisance Congenital en Facteur Stabilisant de la Fibrine XII Purifie D'Origine Placentaire. Ann. Pediatr., 24:837-842, 1977.

102) Zimmermann, R., Ehlers, W., Manz, F., et al.:Ein neuer Fall von schwerem Faktor XIII. Mangel. Blut, 35:457-464, 1977.
pubmed

103) Francis, J., Todd, P.:Congenital factor Xm deficiency in a neonate. Br. Med. J., 2:1532, 1978.

104) Lee, S. Y., Chung, S. I.:Biosynthesis and degradation of plasma protransglutaminase (Factor XIII) (abstr.). Fed. Proc., 35:1486, 1976.

105) Streder, von J.:Uber den fibrinstabilisierenden Faktor (FSF) in den verschiednen Lebensabschnittell und bei bestimmten Krankheiten des Kindes. Ann. Pediatr., 203:393-400, 1964.

106) Ottaviani, P., Mandelli, F., Fontana, L, et al.:Comportamento del Fattore Stabilizzante Fibrinico nelle Epatopatie. Prog. Med., 21:115-120, 1965,

107) Yavuzgil, C., Karaca, M., Goksel, V.:Fibrin stabilizing factor (factor XIII) activity in liver cirrhosis. New Istanbul Contrib. Clin. Sci., 9:35-41, 1967.
pubmed

108) Walls, W. D., Losowsky, M. S.:Plasma fibrin stabilizing factor (FSF) activity in normal subjects and patients with chronic liver disease. Thromb. Diath. Haemorrh., 21:134-143, 1969.
pubmed

109) Ottaviani, P., Mandelli, F., Fontana, L., et al.:II Fattore Stabilizzante Fibrinico de Laki e Lorand nelle Sarcomatosi Istiocitarie a Tendenza Sistemica. Prog. Med., 21:10-13, 1965.

110) Cucuianu, M. P., Vasile, U. U., Popescu, T. A., et al.:Clinical studies concerning factor XIII, with special reference to hyperlipaemia. Thromb. Diath. Haemorrh., 30:480-493, 1973.

111) Cucuianu, M. P., Miloszewski, K., Portiu, D., et al.:Plasma factor XIII and platelet factor XIII in hyperlipaemia. Thromb. Haemost., 36:542-550, 1976.

112) Heene, D. L.:Quantitative estimation of fibrin stabilizing factor, alteration of its activity by fibrinolysis. Thromb. Diath. Haemorrh., 17:600-601, 1967.

113) Baggett, R. T., Hampton, J. W., Bird, R. M.:Fibrinolytic bleeding complicated by factor XIII defect. Arch. Intern. Med., 121:539-544, 1968.
pubmed

114) Kopec, M., Latallo, Z. S., Stahl, M., et al.:The effect of proteolytic enzymes on fibrin stabilizing factor. Biochim, Biophys. Acta, 181:437-445, 1968.

115) Zuch, A., Rudobielska, R., Buluk, K.:Aktywnosi Transamidazy Osoczowej (FSF); Stezenie Grup Tiolowych w Okresie Starzenia sie; Starosci, Z. J., Nauk, Lek. Ziemi. Bialostackiej., 1973.

116) Zuch, A., Buluk, K., Rudobielska, M., et al.:Fizjologiczne Zmiany Stezenia Transamidazy i Wolnych Grup Tiolowych w Osoczu Krwi Dzieci. Pol. Tyg. Lek., 24:2061-2063, 1974.

117) Lorand, L., Urayama, T., de Kiewiet, J., et al.:Diagnostic and genetic studies on fibrin stabilizing factor with a new assay based on amine incorporation. J. Clin. Invest., 48:1054-1064, 1969.
pubmed

118) Lewis, J. H.:Hemorrhagic disease associated with inhibitors of fibrin cross-linkage. Ann. N. Y. Acad. Sci., 202:213-219, 1972.
pubmed

119) Lorand, L., Jacobsen, A., Bruner-Lorand, J.:A pathological inhibitor of fibrin crosslinking. J. Clin. Invest., 47:268-273, 1968.

120) Godal, H. C.:An inhibitor of fibrin stabilizing factor (FSF, factor XIII). Scand. J. Haematol., 7:43～48, 1970.

121) Godal, H. C., Ly, B.:An inhibitor of activated factor XIII inhibiting fibrin crosslinking but not incorporation of amine into casein. Scand. J. Haematol., 19:443-448, 1977.
pubmed

122) Lewis, J. H., Szeto, I. L., Ellis, L.D., et al.:An acquired inhibitor to coagulation factor XIII. Johns Hopkins Med. J., 120:401-407, 1967.
pubmed

123) Lorand, L., Maldonado, U., Fradera, J., et al.:Haemorrhagic syndrome of autoimmune origin with a specific inhibitor against fibrin stabilizing factor (factor XIII). Br. J. Haematol., 23:17-27, 1972.

124) Lopaciuk, S., Bykowska, K., McDonagh, J. M., et al.:Differences between type I autoimmune inhibitors of fibrin stabilization in two patients with severe hemorrhagic disorders. J. Clin. Invest., 61:1196-1203, 1978.

125) McDeritt, N. B., McDonagh, J., Taylor, H. L., et al.:An acquired inhibitor to factor XIII. Arch. Intern. Med., 130:772-777, 1972.

126) Graham, J., Yount, WJ., Roberts, H. R.:Immunochemical characterization of a human anti body to factor XIII. Blood, 41:661-669, 1973.

127) Rosenberg, R. D., Colman, R. W., Lorand, L.:A new haemorrhagic disorder with defective fibrin stabilization and cryofibrinogenaemia. Br. J. Haematol., 26:269-284, 1974.
pubmed

128) Otis, P. T., Feinstein, D. I., Rapaport, S. I., et al.:An acquired inhibitor of fibrin stabilization associated with isoniazid therapy:clinical and biochemical observations. Blood, 44:771-781, 1974.
pubmed

129) Milner, G. R., Hott, P. J. L., Bottomley, J., et al.:Practolol therapy associated with a systemic lupus erythematosus-like syndrome and an inhibitor of factor XIII. J. Clin. Pathol., 30:770-773, 1977.

130) Lorand, L, Jacobsen, A.:Isonicotinic acid hydrazide as an inhibitor of transpeptidation. Relevance for blood coagulation. Nature (London), 216:508-509, 1967.
pubmed

131) Lorand, L., Campbell, L. K., Robertson, BJ.:Enzymatic coupling of isoniazid to proteins. Biochemistry, 11:434-438, 1972.
pubmed

132) Matsuda, M., et al.:"Fibrinogen Tokyo H":An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin network. J. Clin. Invest., (in press).

133) 照屋純, 他:第XIII因子インヒビター発現による出血傾向を来した1症例 (抄録). 第5 日本血栓止血学会抄録集, 1982, p. 93.

P.145 掲載の参考文献

1) Nagy, B., et al.:Fibrinolysis associated with human neoplasma;production of plasminogen activator by human tumors. Int. J. Cancer, 191:614-620, 1977.

2) Astrup, T., et al.:Protease content and fibrinolytic activity of human leukocytes. Blood, 29:134～138, 1967.

3) Gralnick, G. R. and Abrell, E.:Studies of the procoagulant and fibrinolytic activity of promyelocy tes in acute promyelocytic leukemia. Brit. J. Heamat., 24:89-99, 1973.

4) Martinez, J., et al.:Hypofibrinogenemia with hemangioma of the liver. Am. J. Clin. Path., 59:192～197, 1973.

5) 三間屋純一, 他:Giant hemangioma with coagulopathyの4症例 (Kasabach-Merritt syndrome). 臨床血液, 14:1046-1053, 1973.

6) Besser, H. and Oser, H.:Evidence of early-stage activation of the clotting mechanism after a symptomatic decompression of professional divers from high pressure exposures. Abstracts of the 16th International Congress of Hematology (Free communications and scientific exhibitions). Kyoto, 1976. p. 344-345.

7) Tamaki, T. and Aoki, N.:Cross-linking of α2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor. BBA, 661:280-286, 1981.

8) Aoki, N., Saito, H., Kamiya, T., Koie, K. and Sakata, Y.:Congenital deficiency ofα2-plasmin inhibitor associated with severe hemorrhagic tendency, J. Clin. Invest., 63:877-884, 1979.

9) Bergqvist, D. and Nilsson, I. M.:Hereditary α2-macroglobulin deficiency. Scand. J. Haematol., 23:433～436, 1979.

10) 松田保:改訂版DIC. 東京:中外医学社, 1979.

11) 松田保, 小河原緑, 三浦玲子, 関俊子, 横内正利, 村上元孝:DIC (汎発性血管内凝固) における血漿 α2-plasmin inhibitorの変動とその意義. 汎発性血管内血液凝固症調査研究班昭和55年度業績集報告, 1981. P. 44-48.

12) Astrup, T. and Feddersen. F.:Demonstration of a tissue factor causing the conversion of native plasminogen to a more reactive form. Thromb. Res., 7:501-504, 1975.
pubmed

13) McNicol, G. P. and Douglas, A. S.:The fibrinolytic enzyme system, Human Blood Coagulation, Haemostasis and Thrombosis. 1st ed. (Biggs, R., ed.), Blackwell:Oxford, 1972. p. 361-392.

14) Buluk, K. and Malofiefew, M.:The pharmacological properties of fibrinogen degradation products. Brit. J. Pharmacol., 35:79-89, 1969.

15) Malofiefew, M.:The biological and pharmacological properties of some fibrinogen degradation products. Scand. J. Haematol., suppl. 13:303-308, 1971.

16) Nilsson, I. M., et al.:Erosive hemorrhagic gastroduodenitis with fibrinolysis and low factor Xm. Ann. Surg. 182:677-682, 1975.

17) Collen, D. and Wilman, B.:Turnover of antiplasmin, the fast. acting plasmin inhibitor of plasma. Blood, 53:313-324, 1979.

18) Collen, D. and DeCock, F.:Emergence in plasma during activation of the coagulation or fibrinolytic systems of neoantigens, associated with the complexes of thrombin or plasmin with their inhibitors. Thromb. Res., 5:777-779, 1974.
pubmed

19) Collen, D., DeCock, F., Cambinso, C. L. and Masson, P.:A latex agglutination test for rapid quantitative estimation of the plasminantiplasmin complex in human plasma. Eur. J. Clin. Invest., 7:21-26, 1977.

20) Collen, D.:On the regulation and control of fibrinolysis. Thromb. Haemostas., 43:77～89, 1980.

21) Todd, A. S.:The blood vessel wall and fibrinolytic activity. Dynamics of Thrombus Formation and Dissolution (Johnson, S. H. and Guesty M. M., eds.), Philadelphia and Toronto:Lippincott, 1969. p. 321-339.

22) Kowalski, E., et al.:Influence of fibrinogen degradation products (FDP) on platelet aggregation, adhesiveness and viscous metamorphosis. Thrombos. Diathes. Haemorrh., 10:406-423, 1964.

23) Larrieu, M. J.:Action of fibrinogen degradabion products and fibrin monomer soluble complexes on platelet aggregation. Scand. J. Haematol., suupl. 13:273-280, 1971.

24) Bennett, M., et al.:Platelet and fibrinogen survival in acute promyelocytic leukemia. Br. Med. J., 3:565, 1976.

25) Vellenga, E. and Mulder, N. H.:Normal levels of antithrombin III in acute leukemia complicated by coagulopathy. Acta Haemat., 63:336-338, 1980.
pubmed

26) Nossel, H. L., et al.:Measurement of fibrinopeptide A in human blood. J. Clin. Invest., 54:43～53, 1974.

27) Marder, V. J. and Budzinski, A. Z.:Degradation products of fibrinogen and cross-linked fibrin; projected clinical applications. Thrombos. Diathes. Haemorrh., 32:49-56, 1974.

28) 風間睦美, 安部英:ゲル濾過法によるFgDPとFDPの鑑別. 医用酵素, 1:679～685, 1975.

29) Peyer, A. and Straub, P. W.:Release of fibrinopeptides from fibrinolytic fibrinogen fragment E. Thrombos. Diathes. Haemorrh., 29:300-312, 1973.

30) Mosesson, M. W., et al.:The essential covalent structure of human fibrinogen evidenced by analysis of derivatives formed during plasmic hydrolysis. J. Biol. Chem., 248:7913-7929, 1973.

31) Marder, V. J. and Budzynski, A. Z.:The structure of the fibrinogen degration pruducts. Progress in Hemostasis and Thrombosis Vol. 2 (Spaet, T. H. ed.), New York and London:Grune and Stratton, 1974. p. 141-174.

32) 福武勝博, 他:FgDPとFDPの鑑別のための臨床検査. 医用酵素, 1:670～678, 1975.

33) 安部英:Defibrination syndrome-その病態把握にかんする疑問点. 日内会誌, 64:441～450, 1975.

34) Lee-Own, V., Gordon, Y. B. and Chard, T.:The detection of neoantigenic sites on the d-dimer peptide isolated from plasmin digested cross linked fibrin. Thromb. Res., 14:77-84, 1979.

35) Albrechtsen, O. K.:The fibrinolytic activity of human tissue. Brit. J. Haematol., 3:284-291, 1957.

36) Schneider, C. L.:Thrombosis versus fibrination;in clinical disease states. Thrombos. Diathes. Haemorrh., suppl. 36:1-43, 1969.

P.158 掲載の参考文献

1) Jaques, L. B.:Anticoagulant Therapy. Pharmacological Principles. Springfield, Ill.:Charles C. Thomas, Publisher, 1965. p. 65-68.

2) Margolius, A., Jr., Jackson, D. P., Ratnoff, O. D.:Circulating anticoagulants. A study of 40 cases and a review of the literature. Medicine, 40:145, 1961.

3) Robboy, S. J., Lewis, E. J., Schur, P. H., Colman, R. W.:Circulating anticoagulants to factor VII. Amer. J. Med., 49:742, 1970.

4) Frick, P. G.:Hemophilia-like disease following pregnancy with transplacental transfer of an acquired circulating anticoagulant. Blood, 8:598, 1953.
pubmed

5) Horowitz, H. I., Fujimoto, M. M.:Acquired hemophilia due to a circulating anticoagulant. Report of 2 cases, with a review of the literature. Am. J. Med., 33:501, 1962.

6) Gobbi, F., Stefanini, F.:Circulating anti. AHF anticoagulant in a patient with lupus erythematosus disseminatus. Effect of a cephalin complex in vivo. Acta Haemat., 28:155, 1962.

7) Green, D.:Spontaneous inhibitors of factor VIII. Brit. J. Haemat., 15:57, 1968.

8) Andersen, B. R., Troup, S. B.:γG-antibody to human antihemophilic globulin (factor VIII). J. Immun., 100:175, 1968.

9) Pechet, L., Snyder, L. M., Chesney, C., Colman, R. W.:Hemostatic defect due to acquired circulating inhibitors against lipid procoagulant and factor VIII. Thromb. Diath. Haemorrh., 32:90, 1974.
pubmed

10) von Kaulla, K. N., Swan, H.:Clotting deviations in man associated with open-heart surgery during hypothermia. J. Thoracic Surg., 36:857, 1958.

11) Yang, H. O., Sanders, B. E.:Improved chromatog Taphic fractionation and characterization of human plasma proteins. Anal. Biochem., 15:232, 1966.

12) Shapiro, S. S.:The immunologic character of acquired inhibitors of antihemophilic globulin (factor VIII) and the kinetics of their interaction with factor VIII. J. Clin. Invest., 46:147, 1967.
pubmed

13) Bidwell, E., Denson, K. W. E., Dike, G. W. R., Augustin, R. and Lloyd, G. M:Antibody nature of the inhibitor to antihemophilic globulin (factor VIII). Nature, 210:746, 1966.

14) Shapiro, S. S., Carroll, K. S.:Acquired factor VIII antibodies:further immunologic and electrophoretic studies. Science, 160:786, 1968.
pubmed

15) Andersen, B. R., Terry, W. D.:Gamma G4-globulin antibody causing inhibitor of clotting factor VIII. Nature, 217:174, 1968.

16) Feinstein, D. I., Rapaport, S. I., Chong, M. M. Y.:Immunologic characterization of 12 factor VIII inhibitors. Blood, 34:85, 1969.

17) Glueck, H. I., Hong, R.:Acirculating anticoagulant in γ1A. multiple myeloma:its modification by penicillin. J. Clin. Invest., 44:1866, 1865.

18) Lusher, J. M., Shuster, J., Evans, R. K., Poulik, M. D.:Antibody nature of an AHG (factor VIII) inhibitor. J. Pediat., 72:325, 1968.
pubmed

19) McKelvey, E. M., Kwaan, H-C.:Circulating anticoagulant in a macroglobulin with factor VIII inhibitory activity. Ann. Intern. Med., 68:1170, 1968.

20) Vszynski, L.:The immunological properties of factor VII. II. The immunoelectrophoretic studies. Thromb. Diath. Haemorrh., 18:325, 1967.

21) Goudemand, M., Foucant, M., Hutin, A., Parquet-Gernez, A.:Les anticoagulants circulants antifactor VII an cours de 1'hemophilie A (nature et mecanisme d:action). Nouv. Rev. Franc. Haemat., 3:703, 1963.

22) Zimmerman, T. S., Ratnoff, O. D., Powell, A. E.:Immunologic differentiation of classic hemophilia (factor VIII deficiency) and von Willebrand's disease. J. Clin. Invest., 50:244, 1971.
pubmed

23) Roberts, H. R., Scales, M. B., Madison, J. T., Webster, W. P., Penick, G. D.:A clinical and experimental study of acquired inhibitors to factor VIII. Blood, 26:805, 1965.
pubmed

24) Hougie, C.:Studies on an acquired anticoagulant directed against factor III. J. Lab. Clin. Med., 70:384, 1967.

25) Biggs, R., Denson, K. W. E., Nossel, H. L.:A patient with an unusual circulating anticoagulant. Thromb. Diath. Haemorrh., 12:1, 1964.

26) Bloom, A. L., Davies, A. J., Rees, J. K.:A clinical and laboratory study of a patient with an unusual factor VIII inhibitor. Thromb. Diath. Haemorrh., 15:12, 1966.
pubmed

27) Bithell, T. C., Bunting, D. L.:The action of factor VIII inhibitors. Clin. Res., 15:103, 1967.

28) George, J. N., Miller, G. M., Breckenridge, R. T.:Studies on Christmas disease:investigation and treatment of a familial acquired inhibitor of factor IX. Brit. J. Haemat., 21:333, 1971.
pubmed

29) Strauss, H. S.:Acquired circulating anticoagulants in hemophilia A. New Eng. J. Med., 281:866, 1969.
pubmed

30) Biggs, R., Bidwell, E.:A method for the study of antihemophilic globulin inhibitors with reference to six cases. Brit. J. Haemat., 5:379, 1959.

31) Tse, D., Fekete, L., Shanbrom, E.:A simple procedure for accurate quantitation of factor VIII inhibitors. Thromb. Diath. Haemorrh., 23:19, 1970.

32) Kurczynski, E. M., Penner, J. A.:Activated prothrombin concentrate for patients with factor III inhibitors. New Eng. J. Med., 291:164, 1974.

33) Sultan, Y., Brouet, J. C., Debre, P.:Treatment of inhibitors to factor VIII with activated prothrombin concentrate. New Eng. J. Med., 291:1087, 1974.
pubmed

34) Abildgaard, C. F., Britton, M., Roberts, R.:Prothrombin complex concentrate (Konyne) for patients with factor VIII inhibitors. Blood, 44:933, 1974.

35) Deykin, D.:Factor VIII inhibitors. New Eng. J. Med., 291:205, 1974.
pubmed

36) Tishkoff, G. H.:Prothrombin complex to treat factor VIII inhibition. New Eng. J. Med., 292:754, 1975.
pubmed

37) Fukui, H., Fujimura, Y., Takahashi, Y., Mikami, S., Yoshioka, A.:Laboratory evidence of DIC under Feiba treatment of a hemophilic patient with intracranial bleeding and high titre factor VIII inlibitor. Thromb. Res., 22:177, 1981.
pubmed

38) Sherman, L. A., Goldstein, M. A., Sise, H. S.:Circulating anticoagulant (antifactor VIII) treated with immunosuppresive drugs. Thromb. Diath. Haemorrh., 21:249, 1969.

39) Bidwell, E.:Acquired inhibitors of coagulants. Ann. Rev. Med., 20:63, 1969.
pubmed

40) Green, D.:Suppression of an antibody to factor VIII by a combination of factor VIII and cyclophosphamide. Blood, 37:381, 1971.
pubmed

41) Fratantoi, J. C., Hilgartner, M., Nachman, R. L.:Nature of the defect in congenital Factor V deficiency:Study in a patient with an acquired circulating anticoagulant. Blood, 39:751, 1972.

42) 飛田系太, 坂本忍, 高久史磨, 吉田信彦, 青木延雄, 坪川明寛, 武藤良知, 溝口秀昭:第V因子阻止因子の出現による後天性凝固異常症の1例. 臨床血液, 21:1589, 1980.

43) Ferguson, J. H., Johnston, C. L., Jr., Howell, D. A.:A circulating inhibitor (anti AcG) specific for the labile factor. V of the blood-clotting mechanism. Blood, 13:382, 1958.
pubmed

44) Lopez, V., Pflugshaupt, R., Butler, R.:A specific inhibitor of human clotting factor V. Acta Haemat. (Basel), 40:275, 1968.

45) Handley, D. A., Duncan, B. M.:A circulating anticoagulant specific for factor V. Pathology, 1:265, 1969.
pubmed

46) Feinstein, D. L, Rapaport, S. I., McGehee, W. G., Patch, M. J.:Factor V anticoagulants:clinical, biochemical, and immunological observations. J. Clin. Invest., 49:1578, 1970.

47) Crowell, E. B., Jr.:A spontaneous factor V inhibitor in an elderly man. Clin. Res., 19:664, 1971.

48) Feinstein, D. I., Rapaport, S. I., Chong, M. M.:Factor V inhibitor:report of a case, with comments on a possible effect of streptomycin. Ann. Intern. Med., 78:385, 1973.
pubmed

49) Lorand, L, Urayama, T., De Kiewiet, J. W. C., Nossel, H. L.:Diagnostic and genetic studies on fibrin-stabilizing factor with a new assay based on amine incorporation. J. Clin. Invest., 48:1054, 1969.

50) Godal, H. C.:An inhibitor to fibin stabilizing factor (FSF, factor XIII). Scand. J. Haemat., 7:43, 1970.

51) Lewis, J. H., Szeto, I. L. F., Ellis, L. D., Bayer, W. L.:An acquired inhibitor to coagulation factor XIII. Johns Hopkins Med. J., 120:401, 1967.

52) Lorando, L., Jacobsen, A., Bruner-Lorand, J.:A pathological inhibitor of fibrin cross-linking. J. Clin. Invest., 47:268, 1968.

53) Rosenberg, R. D., Colman, R. W., Lorand, L.:A new haemorrhagic disorder with defective fibrin stabilization and cryofibrinogenemia. Br. J. Haematol., 26:269, 1974.
pubmed

54) Fiore, P. A., Ellis, L. D., Dameshek, H. L., Lewis, J. H.:XIII inhibitor and antituberculous therapy. Clin. Res., 19:269, 1971.

55) Lewis, J. H.:Hemorrhagic disease associated with inhibitors of fibrin cross-linkage. Ann. N. Y. Acad. Sci., 202:213, 1972.

56) Otis, P. T., Feinstein, D. I., Rapaport, S. L, Patch, M. J.:An acquired inhibitor of fibrin stabilization associated with isoniazid therapy. Clinical and biochemical observations. Blood, 44:771, 1974.

57) Lorand, L., Maldonado, N., Fradera, J., Atencio, A. C., Robertson, B., Urayama, T.:Haemorrhagic syndrome of autoimmune origin with a specific inhibitor against fibrin stabilizing factor (factor XIII). Br. J. Haematol., 23:17, 1972.
pubmed

58) Conley, C. L., Hartmann, R. C.:A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J. Clin. Invest., 31:621, 1952.

59) Lee, S. L., Sanders, M.:A disorder of blood coagulation in systemic lupus erythematosus. J. Clin. Invest., 34:1814, 1955.

60) Frick, P. G.:Acquired circulating anticoagulants in systemic "collagen disease". Blood, 10:691, 1955.
pubmed

61) Meacham, G. C., Weisberger, A. S.:Unusual manifestations of disseminated lupus erythematosus. Ann. Intern. Med., 43:143, 1955.
pubmed

62) Medal, L. S., Lisker, R.:Circulating anticoagulants in disseminated lupus erythematosus. Brit. J. Haemat., 5:284, 1959.

63) Margolius, A., Jackson, D. P., Ratnoff, O. D.:Circulating anticoagulants:a study of 40 cases and a review of the literature. Medicine, 40:145, 1961.

64) Feinstein, D. I., Rapaport, S. I.:Acquired inhibitors of blood coagulation. Progress in Hemostasis and Thrombosis. Vol. 1. (Spaet, T. H., ed.), Grune and Stratton, Inc., 1972. p. 75.

65) Gomes, E. L., Calicchio, T. R., Biggs, R.:The investigation of a patient with an unusual coagulation defect. Thromb. Diath. Haemorrh., 6:308, 1961.
pubmed

66) Boerner, W.:Proof of a dialysable cofactor in normal plasma for an anticoagulant against platelet-factor 3 in three cases (from which two having lupus erythematosus). Folia Haemat. (Leipzig), 79:364, 1962.

67) Yin, E. T., Gaston, L. W.:Purification and kinetics studies on a circulating anticoagulant in a suspected case of lupus erythematosus. Thromb. Diath. Haemorrh., 14:88, 1965.

68) Lechner, K.:A new type of coagulation inhibitor. Thromb. Diath. Haemorrh., 21:482, 1969.
pubmed

69) Ramot, B., Singer, K.:An unusual circulating anticoagulant in systemic lupus erythematosus. Acta Haemat. (Basel), 16:158, 1956.
pubmed

70) Loeliger, A.:Prothrombin as co-factor of the circulating anticoagulant in systemic lupus erythematosus. Thromb. Diath. Haemorrh., 3:237, 1959.

71) Gonyea, L, Herdman, R., Bridges, R. A.:The coagulation abnormalities in systemic lupus erythernatosus. Thromb. Diath. Haemorrh., 20:457, 1968.
pubmed

72) Rapaport, S. I., Ames, S. B., Luvall, B. J.:A plasma coagulation defect in systemic lupus erythematosus arising from hypoprothrombinemia combined with antiprothrombinase activity. Blood, 15:212, 1960.

73) Laurell, A-B, Nilsson, I. M.:Hypergammaglobulinemia, circulating anticoagulant, and biologic false positive Wasserman reaction. J. Lab. Clin. Med., 49:694, 1957.

74) Harvey, A. McG., Shulman, L. E.:Systemic lupus erythematosus and the chronic biologic false-positive test for syphilis. Lupus Erythematosus (Lubois, E. L, ed.). New York:McGraw-Hill Book Co., Inc., 1966.

75) Rivard, G. E., Schiffman, S., Rapaport, S. I.:Cofactor of the "lupus anticoagulant". Thromb. Diath. Haemorrh., 32:554, 1974.
pubmed

76) Corrigan, J. J., Jr., Patterson, J. H., May, N. E.:Incoagulability of the blood in systemic lupus erythematosus. A case due to hypoprothrombinemia and a circulating anticoagulant. Amer. J. Dis. Child., 119:365, 1970.

77) Ley, A. B., Reader, G. G., Sorenson, C. W., Overman, R. W.:Idiopathic hypoprothrombinemia associated with hemorrhagic diathesis, and the effect of vitamin K. Blood, 6:740, 1951.

78) Bonnin, J. A., Cohen, A. K., Hicks, N. D.:Coagulation defects in a case of systemic lupus ery. thematosus with thrombocytopenia. Brit. J. Haemat., 2:168, 1956.

79) Meyer, R. A., Hooley, J. R.:Systemic lupus erythematosus with circulating anticoagulant discovered after postextraction hemorrhage. Oral Surg., 24:22, 1967.
pubmed

80) Perkins, H. A., Acra, D. J.:The circulating anticoagulant in disseminated lupus erythematosus. Thromb. Diath. Haemorrh., 5:250, 1960.
pubmed

81) Bowie, E. J. W., Thompson, J. H., Jr., Pascuzzi, C. A., Owen, C. A., Jr.:Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J. Lab. Clin. Med., 62:416, 1963.

82) Dameshek, W.:Systemic lupus erythelnatous:a complex autoimmune disorder. Ann. Intern. Med., 48:707, 1958.
pubmed

83) Solomon, A., Fahey, J. L.:Plasmapheresis therapy in macroglobulinemia. Ann. Intern. Med., 58:789, 1963.
pubmed

84) Weiss, H. J., Eichelberger, J. W.:Secondary thrombocytopathia:Platelet factor 3 in various diseases. Arch. Intern. Med., 112:827, 1964.

85) Glueck, H. I., Wayne, L, Goldsmith, R.:Abnormal calcium binding associated with hyperglobulinemia, clotting defects, and osteoporosis:A study of this relationship. J. Lab. Clin. Med., 59:40, 1962.
pubmed

86) Castaldi, P. A., Penny, R.:A macroglobulin with inhibitory activity against coagulation factor VIII. Blood, 35:370, 1970.

87) McKelvey, E. M., Kwaan, H. G.:Circulating anticoagulant in a macroglobulin with factor VIII inhibitory activity. Ann. Intern. Med., 68:1170, 1968.

88) Craddock, C. G., Jr., Adams, W. S., Figueroa, W. G.:Interference with fibrin formation in multiple myeloma by an unusual protein found in blood and urine. J. Lab. Clin. Med., 42:847, 1953.
pubmed

89) Lackner, H., Hunt, V., Zucker, M. B., Pearson, J.:Abnormal fibrin ultrastructure, polymerization and clot retraction in multiple myeloma. Br. J. Haematol, 18:625, 1970.
pubmed

90) 神谷忠, 他:循環抗凝固因子による出血傾向, 内科シリーズNo. 27. 出血傾向のすべて (前川正, 編集), 東京:南江堂, 1977p. 217-228

91) 出口克己, 他:循環抗凝固因子. 臨床検査Mook No. 9. 東京:金原出版, 1982. p. 107-114.

2. 血栓性疾患

P.193 掲載の参考文献

1) Woolf, N., et al.:The occurrence of lipoprotein in thrombi. J. Path. Bac., 91:383-387, 1966.

2) Duffer, A. H. C., et al.:The effect of fat feeding on fibrinolysis, "Stypven" time and platelet aggregation. J. Atheroscl. Res., 7:225-235, 1967.

3) Knudsen, J. B., et al.:Changes in platelet functions, coagulation and fibrinolysis in uncomplicated cases of acute myocardial infarction. Thromb. Haemost., 42:1513-1522, 1979.

4) Steel, P., et al.:Effects of clofibrate and sulfinpyrazone on platelet survival time in coronary artery disease. Circulation, 52:473-476, 1975,

5) Schwartz, M. B., et al.:Platelet aggregates in ischemic heart disease. Thromb. Haemost., 43:185-188, 1980.
pubmed

6) Wiener, L, et al.:Thromboxane release in coronary artery disease patients during acute myocardial ischemia. Proc. Florence International Meeting on Myocardial Infarctian. ed. by D. T. Mason, G. G. Neri Serneri and M. F. Oliver. Excerpta Medica, Amsterdam. 1979. p. 388-398.

7) Holmsen, H., et al.:The blood platelet release reaction. Scand. J. Haematol. Suppl. 8:3-26, 1969.
pubmed

8) Moncada, S., et al.:An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature, 263:663-665, 1976.

9) Sinzinger, H., et al.:Prostacyclin synthesis in human and experimental atherosclerosis. Atherosclerosis, 34:345-347, 1979.
pubmed

10) Crutchley, J., et al.:The effect of aspirin and dipyridamole on the degradation of adenosine diphosphate by cultured cells derived from bovine pulmonary artery. J. Clin. Invest., 66:29-35, 1980.

11) Mustard, J. F. and Packham, M. A.:The role of blood and platelets in atherosclerosis and the compositions of atherosclerosis. Thromb. Diathes. Haemorrh.. 33:444-456, 1975.

12) Spaet, T. H., et al.:Intimal injury and regrowth in the rabbit aorta medial smooth muscle cells as a source of neo intima. Circ. Res., 36:58-70, 1975.

13) 松田保:凝固線溶と動脈硬化. Geriat. Med., 13:335-339, 1975.

14) Kwaan, H. C.:Possible effects of risk factors on fibrinolysis. Adv. Exp. Med. Biol. 104:295-300, 1978.
pubmed

15) Marsh, N. A. & Shaper, A. G.:Fibrinolytic activitiy and risk factors for atherosclerosis. ibid., 82:540-544, 1977.

16) Balta, N., et al.:Investigations on some coagulability tests in atherosclerosis. Rev. Roum. Morphol. Embryol. Physiol. Physiologie, 12:143-148, 1975.

17) 田中健蔵, 岩田康:血管壁の組織線溶活性. 脈管学, 10:227～235, 1979

18) Kadish, J. L.:Fibrin and atherogenesis-a hypothesis. Atheroscl., 33:409-413, 1979.
pubmed

19) Kadish, J. L., et al.:The effect on cultured vascular endothelial cells. Tissue Cell, 11:99-108, 1979.
pubmed

20) Adams, C. W. M., et al.:Permeability in atherosclerosis-fluorescence test in green light with typan blue. Atheroscl., 27:353-359, 1977.

21) Ross, R. & Glomset, J. A.:The pathogenesis of atherosclerosis. New Eng. J. Med. 295:369-377, 420-425, 1976.

22) Ross, R.:Platelets:Cell proliferation and atherosclerosis. Metabolism, 28:410-414, 1979.
pubmed

23) Spaet, T. H., et al.:Thrombus, atherosclerosis and endothelium. Amer. Heart J., 87:661-668, 1974.
pubmed

24) Stemerman, M. B., et al.:The subendothelial microfibril and platelet adhesion. Lab. Invest., 24:179-186, 1971.
pubmed

25) Harker, L. A., et al.:Endothelium and arteriosclerosis. Clin. Haematol., 10:283-296, 1981.
pubmed

26) Girolami, A., et al.:Factor X Friuli coagulation disorder. Acta Haematol., 54:120-125, 1975.
pubmed

27) 中尾喜久, 他:悪性腫瘍と血栓症. 日本臨牀, 21:142～150, 1963.

28) Bryan, C. S.:Nonbacterial thrombotic endocarditis with malignant tumors. Amer. J. Med., 46:787-793, 1969.
pubmed

29) Byrd, R. B.:Bronchogenic carcinoma and thromboembolism. J. A. M. A., 202:1019-1022, 1967.
pubmed

30) Catovsky, D., et al.:Thromboembolic complications in myelomatosis. Brit. Med. J., 3:438-439, 1970.
pubmed

31) Lester, E.:Inferior-vena-caval thrombosis in malignant renal lesions. J. A. M. A., 198:1167-1170, 1966.

32) Rohner, R. F., et al.:Mucinous malignancies, venous thrombosis and terminal endocarditis with emboli;A syndrome. Cancer, 19:1805-1812, 1966.

33) Meyer, J. S. & Boxer, M.:Leukemic cellular thrombi in pulmonary blood vessels in subleukemic myelogenous leukemia following chloramphenicol induced aplastic anemia. Cancer, 32:712-721, 1973.
pubmed

34) Mayr, A. C., et al.:Thrombozytose bei malignen Tumoren. Schweiz. med. Wschr., 103:1026-1029, 1973.

35) Barlattani, M., et al.:Thrombelastografia in varil manifestazioni neoplastiche durante. Terapia Med. Rad. Chir. Clin. Te., 49:221-258, 1969.

36) Miller, S. P., et al.:Coagulation disorders in cancer. I. Clinical and laboratory studies. Cancer, 20:1452-1465, 1967
pubmed

37) Davis, R. B., et al.:Comparative studies of blood coagulation and platelet aggregation in patients with cancer and non-malignant diseases. Ann. Int. Med., 71:67-80, 1969.

38) Soong, B. C. F. & Miller, S. P.:Coagulation disorders in cancer. III. Fibrinolysis and inhibitor. Cancer, 25:867-874, 1970

39) Gordon, S. C., et al.:Cancer procoagulant A:Afactor X activating procoagulant from malignant tissue. Thromb. Res., 6:127-137, 1975.

40) Donati, M. B. & Poggi, A.:Malignancy and haemostasis, Br. J. Haematol, 44:173-182, 1980.
pubmed

41) Thornes, R. D.:Oral anticoagulant therapy of human cancer. J. Med., 5:83-91, 1974,

42) Thornes, R. D.:Adjuvant therapy of cancer via the cellular immune mechanism or fibrin by induced fibrinolysis and oral anticoagulants. Cancer, 35:91-97, 1975.
pubmed

43) Elias, E. G., et al.:Heparin and chemotherapy in the management of inoperable lung carcinoma. Cancer, 36:129-136, 1975.
pubmed

44) Wright, I. S.:Final report by the Ad. Hoc Committee for the evaluation of a possible etiologic relation with thromboembolic conditions submitted to the commissioner of the FDA. H. E. W., 1963.

45) Bottiger, L. E. & Westerholm, B.:Oral contraceptives and thromboembolic disease, Acta Med. Scand., 190:455-463, 1971.
pubmed

46) Vessey, M. P. & Doll, R.:Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report. Brit. Med. J., 2:651-657, 1969.
pubmed

47) Drill, V. A. & Calhown, D. W.:Oral contraceptives and thromboembolic disease, II. Estrogenic content of oral contraceptives. J. A. M. A., 219:593-596, 1972.

48) Tooke, J. E. & McNicol, G. P.:Thrombotic disorders associated with pregnancy and the pill. Clin. Haematol., 10:613-630, 1981.
pubmed

49) Meade, T. W., et al.:Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50 and 30μg oestrogen preparations. Br. Med. J., 1:1157-1161, 1980.

50) 青木延雄:血栓の形成とその制御機構. 心筋梗塞と血栓 (青木延雄, 細田瑳一, 松田道生, 編), 東京:メジカルビュー社, 1981. p. 2-9.

51) O'Brien, J. R.:The prothrombotic state. in Recent Advances in Blood Coagulation (Poller, L., ed.) Edinburgh:Churchill Livingstone, 1977. p. 241-266.

52) Wessler, S.:The current status of the hyper-coagulable state. in Venous and Arterial Thrombosis (Joist, J. H. and Sherman, L. A., eds.), New York:Grune & Stratton, 1979. p. 23-31.

53) 前川正, 他:Consumption coagulopathyにおける凝血学的変化の成立機転について. 日血会誌, 34 (Suppl. 1):65-74, 1971.

54) Tanaka, H., et al.:Effect of endotoxin on kinetics of antithrombin III. Thromb. Haemost., 42:374, 1979.

55) McKay, D. G.:Intravascular coagulation-acute and chronic disseminated and local coagulation. in Coagulation (Schmur, G. and Stranjord, P. E., eds.), New York:Academic Press, 1973. p. 45-72.

56) Owen, C. A., Jr. & Bowie, E. J. W.:Chronic intravascular coagulation and fibrinolysis (ICF) syndromes. Sem. Thromb. Hemost., 3:268-290, 1977.

57) Cooper, H. A., et al.:Evaluation of patients with increased fibrinolytic split products (FSP) in their serum. Mayo Clin. Proc., 49:654-657, 1974.
pubmed

58) Sharp, A. A.:Diagnosis and arrangement of disseminated intravascular coagulation. Br. Med. Bull., 33:265-272, 1977.

59) Stewart, G. J.:The role of hypercoagulability in thrombosis. Br. J. Haemat., 40:359-362, 1978.

60) 前川正, 他:凝血能亢進と血栓症. 日老会誌, 8:111-117, 1971.

61) Gonmori, H., et al.:Vitamin K dependent clotting factors and their inhibitor:with special reference to prothrombin and antithrombin IH. Acta Haemat. Jap., 44:1466-1478, 1981.

62) 田中昇三:脳血栓症における1血小板粘着凝集能. 北関東医. 学, 28:265-276, 1978

63) Mustard, J. F, et al.:Platelet economy. Br. J. Haemat., 12:1-24, 1966.

64) Steele, P., et al.:Platelet survival time and thromboembolism in patients with mitral valve prolapse. Circulation, 60:43-45, 1979.
pubmed

65) Kutti, J. & Weinfeld, A.:Platelet survival and platelet production in acute myocardial infarction. Acta Med. Scand., 205:501-504, 1979.
pubmed

66) Harker, L. A. & Hazzard, W.:Platet kinetic studies in patients with hyperlipoproteinemia:effects of clofibrate therapy. Circulation, 60:492-496, 1979

67) Fuster, V., et al.:Platelet survival and the development of coronary artery disease in the young adult:effect of cigarette smoking, strong family history and medical therapy. Circulation, 63:546-551, 1981.

68) Jones, R. L., et al.:Platelet survival in patients with diabetes mellitus. Diabetes, 30:486-489, 1981.
pubmed

69) Tytgat, G. N., et al.:Metabolism and distribution of fibrinogen. H. Fibrinogen turnover in polycythemia, thrombocytosis, haemophilia A, congenital afibrinogenemia and during streptokinase therapy. Br. J. Haemat., 22:701-717, 1972.

70) Jeyasingh, K., et al.:Decline in blood activity of 125I-fibrinogen in venous thrombosis. Lancet, 2:294-296, 1970.

71) Lyman, G. H., et al.:Fibrinogen kinetics in patients with neoplastic disease. Cancer, 41:1113-1122, 1978.
pubmed

72) Cederholm-Williams, S. A., et al.:The metabolism of fibrinogen and plasminogen related to diabetic retinopathy in man. Europ. J. Clin. Invest., 11:133-138, 1981.

73) Harker, L. A. & Slichter, S. J.:Platelet and fibrinogen consumption in man. New Eng. J. Med., 287:999-1005, 1972.
pubmed

74) Blomback, B. & Carlson, LA.:Turnover of 1311 fibrinogen in coronary heart disease and lipemia. J. Atheroscl. Res., 3:242-244, 1963.

75) O'Neill, B. & Firkin, B.:Platelet survival studies on coagulation disorders, thrombocythemia and conditions associated with atherosclerosis. J. Lab. Clin. Med., 64:188-201, 1964.

76) Schulman, E. D., et al.:Platelet survival and morphology in homocystinuria. New Eng. J. Med., 295:1283-1286, 1976.

77) Karpatkin, S.:Heterogeneity of human platelets. II. Functional evidence suggestive of young and old platelets. J. Clin. Invest., 48:1083-1087, 1969.

78) Hirsh, J., et al.:The effect of platelet age on platelet adherence to collagen. J. Clin. Invest., 47:466-473, 1968.
pubmed

79) 永井隆:血小板粘着・凝集能の亢進に関する一考察・北関東医学, 25:321-326, 1975.

80) Karpatkin, S.:Human platelet senescence. Annual Review of Med., 23:101-128, 1972.

81) Bolton, A. E., et al.:Three approaches to the radioimmunoassay of human β-thromboglobulin. Br. J. Haemat., 33:233-238, 1976.

82) Chen, Y.C. & Wu, K. K.:A comparison of methods for the study of platelet hyperfunction in thromboembolic disorders. Br. J. Haemat., 46:263-268, 1980.

83) Bolton, A. E., et al.:A radioimmunoassay for platelet factor 4. Thromb. Res., 8:51-58, 1976.
pubmed

84) Steele, P. & Rainwater, J.:Relationship of plasma anti-heparin activity and platelet survival time in coronary disease. Amer. Heart J., 99:438-442, 1980.
pubmed

85) Okuno, T. & Crockatt, D.:Platelet factor 4 activity and thromboembolic episodes. Amer. J, Clin. Path., 67:351-355, 1977.

86) Francis, P. B. & Willson, J. E., III.:Correlation of the serial-dilution protamine sulfate test with models of "hypercoagulability" and thrombosis in dogs. Amer. J. Clin. Path., 67:356-361, 1977.

87) Serneri, G. G., et al.:High molecular weight fibrinogen complexes in the assessment of hypercoagulability. in Haemostasis and Thrombosis. edited by Serneri, G. G. N. and Prentice, C. R. M., London:Academic Press, 1979. p. 123-139.

88) Davies, J. A. & McNicol, G. P.:Blood coagulation in pathological thrombus formation and the detection in blood of a thrombotic tendency. Br. Med. Bull, 40:359-362, 1978.

89) Nossel, H. L. & Bord, E. S.:Radioimmunoassay of fibrinopeptides in relation to intravascular coagulation and thrombosis. New Eng. J. Med., 295:428-432, 1976.

90) Wilner, G. D., et al.:Effect of extravascular clotting on fibrinopeptide A levels in blood. J. Lab. Clin. Med., 91:205-213, 1978.
pubmed

91) Nossel, H. L., et al.:Measurement of desarginine fibrinopeptide B in human blood. J. Clin. Invest., 67:809-816, 1981.

92) 松沢義之:冠疾患の凝血学的研究. 北関東医学, 9:1253-1273, 1959.

93) 松田保:血小板・凝固系と梗塞の発症. 心筋梗塞と血栓 (青木・細田・松田編), メジカルビュー社, 1981. p. 33-38.

94) 前川正, 他:血栓症の診断. 医用酵素, 1:274-287, 1974.

95) O'Brien, J. R.:Diagnosis of venous thrombosis. Progress in Hemostasis and Thrombosis, 2, (Speat, T. H. ed.), N. Y.:Grune & Stratton, 1974. p. 311-332.

96) Baroldi, G.:Coronary thrombosis. Am. Heart J., 91:683-688, 1976.
pubmed

97) Erhardt, LR. & Sjogren, A.:Attempted diagnosis of ventricular mural thrombi in acute myocardial infarction using 125I-labeled fibrinogen. Acta Med. Scand., 200:127-130, 1976.
pubmed

98) 万年徹:脳血管障害の補助診断. 脳血管写. 脳卒中のすべて (沖中重雄, 編), 南江堂, 1971. p. 241～249.

99) 山田英夫:血栓・塞栓症の診断. 血栓症, 第2版, (田中健蔵, 前川正, 松田保, 編), 東京:日本メディカルセンタ-, 1982. p. 187-204.

100) Kakkar, V. V.:The diagnosis of deep-vein thrombosis using 125I-fibrinogen test. Arch. Surg., 104:152-159, 1972.

101) Haeger, K.:Problem of acute deep-vein thrombosis. Angiol., 20:219-223, 1969.

102) Report of a Steering Committee of a Trial sponsored by MRC:The effect of aspirin on postoperative venous thrombosis. Lancet, 2:441-444, 1972.

103) Flanc, C. V., et al.:The detection of venous thrombosis of the legs using 125Iodine-labeled fibrinogen. Br. J. Surg., 55:742-747, 1968.

104) Rhodes, B. A., et al.:Radioactive urokinase for blood clot scanning. J. Nucl. Med., 13:646-648, 1972.
pubmed

105) Siegel, B., et al.:A Doppler ultrasound method for diagnosing lower extremity venous disease. Surg. Gynecol. Obstet., 127:339-350, 1968.

106) Dmochowski, J. R., et al.:Impedance measurement in the diagnosis of deep-vein thrombosis. Arch. Surg., 104:170-73, 1972.
pubmed

107) Wheeler, H. B., et al.:Impedance phlebography. Arch. Surg., 104:164-169, 1972.
pubmed

108) 前川正:凝血亢進状態の薬物療法・臨床薬理学大系IIA, 中山書店, 1975. p. 409-452.

109) 田中健蔵, 他 (編):血栓症, 第2版・東京:日本メディカルセンター: 1975

P.215 掲載の参考文献

1) Merskey, C.:Defibrination syndrome. Human Blood Coagulation. Haemostasis and Thrombosis, 1st ed., Oxford:Blackwell, 1972. p. 444-475.

2) Preston, F. E., Malia, R. G., Sworn, M. J., Blackburn, E. K.:Intravascular coagulation and E. coli septicaemia. J. Clin. Path., 26:120-125, 1973.

3) Colman, R. W., Robboy, S. J., Minna J. D.:Disseminated intravascular coagulation (DIC);An approach. Amer. J. Med., 52:679-689, 1972.
pubmed

4) 松田保, 村上元孝, 大津正一, 嶋田裕之:敗血症における血管内凝固症候群. 臨床医, 1:586-589, 1975.

5) Klastersky, J., Weerts, D.:Recent experience with bacteremia in patients presenting cancer. Europ. J. Cancer, 9:69-76, 1973.

6) Boyd, J. F.:Disseminated fibrin thromboembolism among neonatus dying with 48 hours of birth. Arch. Disease Child, 42:401-409, 1967.

7) Boyd, J. F.:Disseminated fibrin thromboembolism among neonatus dying more than 48 hours after birth. J. Clin, Path., 22:663-677, 1969.

8) Kunzer, W., Karitzky, D., Pringsheim, W.:Atemnotsyndrom und disseminierte intrasale Gerinnung. Dtsch. med. Wschr., 95:2141-2144, 1970.
pubmed

9) Robboy, S. J. Minna, J. D., Colman, R. W., Birndorf, N. I., Lopas, H.:Pulmonary hemorrhage syndrome as a manifestation of disseminated intravascular coagulation; Analysis of ten cases. Chest, 63:718-721, 1973.
pubmed

10) 松田保, 村上元孝, 大津正一, 亀山正邦, 杉浦昌也, 白倉卓夫, 嶋田裕之:老年者の血管内凝固症候群, 血液と脈管, 7:796-800, 1976.

11) Brain, M. C., Assoprdi, J. G., Baker, L. R. I., Pineo, G. F., Roberts, P. D., Dacie, J. V.:Microangiopathic haemolytic anaemia and mucinforming adenocarcinoma. Brit. J. Haemat., 18:183-193, 1970.

12) Schneider, C. L.:Disseminated intravascular coagulation; thrombosis versus defibrination, in clinical disease states. Thrombos. Diathes. haemorrh. Suppl., 36:1-43, 1969.

13) Preston, F. E., Malia, R. G., Sworn, M. J., Timperley, W. R., Blackburn, E. K.:Disseminated intravascular coagulation as a consequence of cerebral damage. J. Neurol. Neurosurg. & Psychiat., 37:241-248, 1974.
pubmed

14) Quigley, H. J.:Peripheral leucocyte thromboplastin in promyelocytic leukemia. Fed. Proc., 26:648, 1967.

15) Saba, H. I., Herion, J. C., Walker, R. L, Robert, H. R.:The procoagulant activity of granulocytes. Proc. Soc. Exper. Biol. Med., 142:614-620, 1973.

16) Gralnick, H. R., Abrell, E.:Studies of the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukemia. Brit. J. Haemat., 24:89-99, 1973.
pubmed

17) 松田保:改訂版DIC. 東京:中外医学社, 1979.

18) Leavey, R. A., Kahn, S. B., Brodsky, I.:Disseminated intravascular coagulation, A complication of chemothreapy in acute myelomonocytic leukemia. Cancer, 26:142-145, 1970.

19) Edson, J. R.:Mechanisms and dynamics of intravascular coagulation. Geriatrics, 29 (2):65-78, 1974.
pubmed

20) Lerner, G. R., Goldstein, R. and Cummings, G.:Endotoxin induced intravascular clotting; evidence that it is mediated by neutrophil production of tissue factor. Thromb. Res., 11:253-261, 1977.

21) Turpie, A. G. G., McNicol, G. P., Douglas, A. S.:Ancrod ("Arvin"). A New Anticoagulant, Human Blood Coagulation, Haemostasis and Thrombosis, 1st ed., Oxford:Blackweel, 1972. p. 429-443.

22) Egeberg, N.:Coagulation studies in patients treated with Defibrase. Acta Med. Scand., 194:291-302, 1973.

23) Matsuda, T., Hideno, K., Ogawara, M., Kodama, N., Murakami, M.:Therapeutic defibrination by bothrops marajoensis-venom Acta Haem. Jap, 38:299-305, 1975.

24) Rodriguez. Erdmann, F.:Studies on the pathogenesis of the generalized Shwartzman reaction; 3. trigger mechanism for the activation of the prothrombin molecle. Thrombos. Diathes Haemorrh., 12:470-483, 1964.

25) Rodriguez. Erdmann, F.:Intravascular activation of the clotting system with phospholipids; production of the generalized Shwartzman reaction (GSR). Blood, 26:541-553, 1965.

26) Mckay, A. V. P., Muller, B. G.:Hageman factor and the generalized Shwartzman reaction (GSR). Fed. Proc., 27:436, 1968.

27) Mason, J. W., Colman, R. W.:The role of Hageman factor in disseminated intravacular coagulation induces by septicemia, neoplasia, or liver disease. Thrombos. Diathes haemorrh., 26:325-331, 1971.

28) Robbins, J. E., Stetson, C. A.:An effect of antibody-antigen interaction on blood coagulation. J. Exper. Med., 109:1-8, 1959.

29) Starzl, T. E., Boeming, H. J., Amemiya, H., Wilgon, C. B., Dixon, F. J., Giles, G. R., Simpson, K. M., Halgrmson, C. G.:Clotting changes, including disseminated intravascular coagulation, during rapid renal-homograft rejection. New Engl. J. Med., 283:383-390, 1970.

30) Pfueller, S. L., Luscher, E. F.:Studies of the mechanisms of the human platelet release reaction induced by immunologic stimuli; I. Complement-dependent and complement-independent reactions. J. Immunol., 112:1201-1210, 1974.
pubmed

31) Ream, V. J., Deykin, D., Gurewich, V., Wessler, S.:The aggregation of human platelets by bacterial endotoxin. J. Lab. Clin. Med., 66:245-252, 1965.
pubmed

32) Evensen, S. A., Elgjio, R. F.:Antibody-induced platelet injury:Its potency as a trigger of intravascular clotting. Scand. J. Haemat., 9:61-72, 1972.

33) Bernheimer, A. W., Schwarz, L.L.:Effects of staphylococcal and other bacterial toxins on platelets in vitro. J. Path. Bact., 89:209-223, 1965.

34) Hawiger, J., Marney, S. R., Jr., Colley, D. G., DesPrez, R. M.:Complement dependent platelet injury by staphylococcal protein A. J. Exp. Med., 136:68-80, 1972.

35) Biggs, R.:The natural inhibitors of blood coagulation, Human Blood Coagulation, 3rd ed., Oxford:Blackwell, 1963. p. 97.

36) Schwick, H. G., Heimburger, N.:Biochemie der Antithrombine. Thrombos. Diathes haemorrh. suppl., 44:5-16, 1971.

37) Egeberg, O.:Inherited antithrombin deficiency causing thrombophilia. Thrombos, Diathes haemorrh., 13:516-530, 1965.

38) 松田保, 村上元孝, 大津正一, 嶋田裕之:癌と血管内凝固症候群. J. Med. Enzymol. (Tokyo), 1:737-743, 1975.

39) Remuzzi, G., Misiani, R., Mecca, G., deGaetano, G., Donati, M. B.:Thrombotic thrombocytopenic purpura-a deficiency of plasma factor regulating platelet-vessel wall interaction? N. Engl. J. Med., 299:311, 1978.

40) 松田保, 秀野啓子, 木村緑, 児玉直子, 村上元孝, 白倉卓夫:血管内凝固症候群におけるプラスミノゲンの変動. 第14回プラスミン研究会報告集, 1974. p. 227-230.

41) 田渕正康, 田中秀雄, 村井善郎, 白倉卓夫, 井上達, 松田保:著明な栓球増多を伴い多彩な経過をとった真性多血症の1剖検例. 臨床血液, 15:1066～1067, 1974.

42) 松田保, 児玉直子, 秀野啓子, 木村緑, 松崎俊久, 村上元孝, 山之内博:老年者の血液粘度. 血液と脈管, 7:146-150, 1976.

43) Broersma, R. J., Bullemer, G. D., Mammen, E. F.:Blood coagulation changes in hemorrhagic shock and acidosis. Thrombos. Diathes haemorrh. suppl., 36:171-176, 1969.

44) Gladner, J., Murtaugh, P. A., Folk, J. E., Laki, K.:Nature of peptides released by thrombin. Ann. New York Acad. Sci., 104:47-52, 1963.

45) Osbahr, A. J., Gladner, J. A., Laki, K.:Studies on the physiological activity of the peptide released during the fibrinogen-fibrin conversion. B. B. A., 86:535-542, 1964.

46) Colman, R. W., Osbahr, A. J.:Demonstration of a new vasoconstrictor, bovine peptide B. Nature, 215:292-293, 1967.

47) Bayley, T., Clements, J. A., Osbahr, A. J.:Pulmonary and circulatory effects of fibrinopeptides. Circ. Res., 21:469-485, 1967.
pubmed

48) Buluk, K., Malofiejew, M.:The pharmacological properties of fibrinogen degradation products. Brit. J. Pharmacol., 35:79-89, 1969.

49) Malofiejew, M.:The biological and pharmacological properties of some fibrinogen degradation products. Scand. J. Haemat. Suppl., 13:303-308, 1971.

50) 村上元孝, 松田保, 恩地一彰, 梅田俊彦, 河村洋一, 西野哲夫, 平沢謙太郎, 平丸三樹, 万見新太郎, 加藤正義:Consumption-coagulopathy. 臨床血液, 10:110-118, 1969.

51) Pareti, F. L, Capitanio, A., Mannucci, P. M.:Acquired storage pool disease in platelets during disseminated intravascular coagulation. Blood, 48:511-515, 1976.

52) Mant, M. J., Hirsh, J., Pineo, G. F., Luke, K. H.:Prolonged prothrombin time and partial thromboplastin time in disseminated intravascular coagulation not due to deficiency of factors V and VIII. Brit. J. Haemat., 24:725-734, 1973.

53) Mckay, D. G.:Intravascular coagulation-acute and chronic-disseminated and local. Coagulation. New York and London:Academic Press, 1973. p. 45-68.

54) Plow, E. F.:Leukocyte elastase release during blood coagulation; a potential mechanism for activation of the alternative fibrinolytic pathway. J. Clin. Invest., 69:564-572, 1982.
pubmed

55) Stossel, T. P., Levy, R.:Intravascular coagulation associated with pneumococcal bacteremia and symmetrical peripheral gangrene. Arch. Intern. Med., 125:876-878, 1970.
pubmed

56) Goodwin, J. N., Berne, T. V.:Symmetrical peripheral gagrene. Arch. Surg., 108:780-784, 1974.

57) Mittermayer, C., Vogel, W., Burchardi, H., Birzle, H., Wiemers, K., Sandritter, W.:Pulmonale Mikrothrombosierung als Ursache der respiratorischen Insufficienz bei Verbrauchskoagulopathie (Schocklunge). Dtsch. Med. Wschr., 95:1999-2002, 1970.
pubmed

58) 松田保:血管内凝固症候群. 感染症, 4:161-172, 1974.

59) DeVos, M., VanNiemen, L., Baele, G.:Disseminated intravascular coagulation during a fatal mycoplasma pneumoniae infection. Acta haemat., 52:120-123, 1974.

60) Tomar, R. H., Kolchins, D.:Complement and coagulation; serum beta, c-beta, a in disseminated intravascular coagulation. Thrombos. Diathes haemorrh., 27:389-395, 1972.

61) McNicol, G. P., Douglas, A. S.:The Fibrinolytic enzyme system, Human Blood Coagulation, Haemostasis and Thrombosis, 1st ed., Oxford:Blackwell, 1972. p. 361-392.

62) 松田保:内科領域におけるFDP. 目血会誌, 35:628-636, 1972.

63) 松田保:DICの治療. 医学のあゆみ, 109:91-96, 1979.

64) DIC の治療 (臨血第23回総会シンポジウム). 臨床血液, 23:803-846, 1982.

65) Mant, J. J., Garner, E.:Severe, acute disseminated intravascular coagulation; a reappraisal of its pathophysiology, clinical significance and therapy based in 47 patients. Am. J. Med., 67:557-563, 1979.

66) Schipper, G. G., Jenkins, C. S. P., Kahle, L. H. and ten Cate, J. W.:Antithrombin-III transfusion in dissemillated intravascular coagulation. Lancet, i:854-856, 1978.

67) 青木延雄, 吉田信彦, 山中恒夫:アンチトロンビンIII濃縮分画によるDIC の治療. 医学のあゆみ, 109:970-975, 1979.

68) Green, D.:Acute promyelocytic leukemia in a patient with hemophilia. Thrombos. Diathes haemorrh., 27:516-522, 1972.

69) Merskey, C., Johnson, A. J.:Diagnosis and treatment of intravascular coagulation. Thrombos. Diathes haemorrh. suppl., 21:555-563, 1966.

70) Mosseson, M. W., Colman, R. W., Sherry, S.:Chronic intravascular coagulation syndrome:Report of a case with special studies of an associated plasma cryoprecipitate ("cryfibrinogen"). New Engl. J. Med., 278:815-821, 1968.

71) Zachrski, L. R., Walworth, C., McIntyre, O. R.:Antiplatelet therapy for thrombotic thrombocytopenic purpura. New Engl. J. Med., 285:408-409, 1971.

72) Giromini, M., Mouvier, C. A., Dami, R., Demizot, M., Jeannet, M.:Effect of dipyridamole and aspirin in thrombotic microangiopathy. Brit. Med. J., 1:545-546, 1972.

73) Sutor, A. H., Schindera, F., Jacobi, H., Kunzer, W.:Haemolytic. uraemic syndrome:Thrombocyturia after treatment with streptokinase and aspirin. Lancet, ii:762, 1972.

74) Berbereich, F. R., Cuene, S. A., Chard, R. L., Jr., Hartmann, J. R.:Thrombohemolytic thrombo cytopenic purpura, Three cases with platelet and fibrinogen survival studies. J. Pediat., 84:503-509, 1974.

75) Hardaway, R. M.:Disseminated intravascular coagulation in experimental and clinical shock. Amer. J. Cardiol., 20:161-173, 1967.
pubmed

76) Monnens, L., Lleynen, F., Schreitlen, E.:Fibrinolytic treatment of the hemolytic-uremic-syndrome. Lancet, i:692, 1972.

77) Muntean, E., Goruup, U.:Disseminierte intravasale Gerinnung und akutes Nierenversagen bei einem Saugling mit Streptokinase und Peritonealdialyse behandelt. Wien. Klin. Wschr., 87:792-796, 1975.

78) Edwards, IR.:Malaria with disseminated intravascular coagulation and peripheral tissue necrosis successfully treated with streptokinase. Br. Med. J., 280:1252-1253, 1980.
pubmed

79) Jones, F. E., Black, P. J., Cameron, J. S., Chantler, C., Gill, D., Maisey, NN., Ogg, C. S., Saxton, H.:Local infusion of urokinase and heparin into renal arteries in impending renal cortical necrosis. Br. Med. J., 4:547-549, 1975.

80) 真木正博:薬剤による凝固・線溶異常. 内科, 34:62-69, 1974.

81) Wessbach, G., Lenk, H., Braun, W., Domula, M., Friedel, D.:Fibrinolytische Therapie bei DIC im Kindesalter. Folia Haematol, 104:801-809, 1977.

82) Dubber, A. H. C., McNicol, G. P., Douglas, A. S.:Acquired hypofibrinogenaemia; the defibrination syndrome; a study of patients. Scot. Med. J., 12:138-151, 1967.

83) McKay, D. G., MUIIer, B. G.:Therapeutic implications of disseminated intravascular coagulation. Amer. J. Cardiol., 20:392-410, 1967.

84) Ratnoff, O. D.:Epsilon aminocaproic acid-a dangerous weapon. New Engl. J. Med., 280:1124-1125, 1969.
pubmed

85) Kazmier, F. J., Bowie, E. J. W., Hagedorn, A. B., Owen, C. A., Jr.:Treatment of intravascular coagulation and fibrinolysis (ICF) syndromes. Mayo Clin. Proc., 49:665-672, 1974.

86) 村上元孝, 松田保, 万見新太郎, 平丸三樹:Trasylol の線溶・凝血系に及ぼす影響. 血液と脈管, 2:411-418, 1971.

87) Fine, N. L, Applebaum, J., Elguezabal, A., Castleman, L.:Multiple coagulation defects in association with dissecting aneurysm. Arch. Intern. Med., 119:522-526, 1967.
pubmed

88) Kazmier, F. J., Didisheim, P., Fairbanks, V. F., Ludwing, J., Dayne, W. S., Bowie, J. W.:Intravascular coagulation and arterial disease. Thrombos. Diathes haemorrh. suppl., 36:295-303, 1969.

89) Dennis, L. H., Stewart, J. L., Conrad, M. E.:A consumption coagulation defect in congenital heart disease and its treatment with heparin. J. Pediat., 71:407-410, 1967.
pubmed

90) Braun, W., Weinmann, G., Schwela, S.:Probleme der Verbrauchskoagulopathie bei konnatale Herzfehlern. Folia. Haemat., 97:50-55, 1972.

91) Ihenacho, H. N. C., Breeze, G. R., Fletcher, D. J., Stuart, J.:Consumption coagulopathy in congenital heart disease. Lancet, i:231-234, 1973.

92) Beltrami, G. M., Bucher, U.:Thrombozytopenie bei chronischem Cor pulmonale. Thrombos. Diathes haemorrh., 16:443-468, 1966.

93) Redleaf, P. D., Davis, R. B., Kucinski, C., Hoilund, L.:Amyloidosis with an unusual bleeding diathesis; observations on the use of epsilon amino caproic acid. Ann. Intern. Med., 58:347-354, 1963.
pubmed

94) Bowie, E. J. W., Maldonando, E., Brown, A. L., Didisheim, P., Owen, P. A., Jr.:Intravascular coagulation in systemic amyloidosis. Thrombos. Diathes haemorrh. suppl., 36:305-312, 1969.

95) Ratnoff, O. D., Colopy, J. E., Pritchard, J. A.:The blood clotting mechanism during normal parturition. J. Lab. Clin. Med., 44:408-415, 1954.
pubmed

96) Kleiner, G. J., Merskey, C., Johnson, AJ., Markus, W. B.:Defibrination in normal and abnormal parturition. Brit. J. Haemat., 19:159-178, 1970.

97) Astrup, T.:Fibrinolysis in the organism. Blood, 11:781-806, 1956.
pubmed

98) Duguid, J. B.:Pathogenesis of atherosclerosis. Lancet, ii:925-927, 1949.

99) Kincaid-Smith, P., Laver, M. C., Fairley, K. F.:Dipyridamole and anticogulants in renal disease due to glomerular and vascular lesions:A new approach to therapy. Med. J. Aust., 1:145-151, 1970.

100) 亀山正邦, 山之内博, 東儀英夫, 松田保, 村上元孝:播種性血管内凝固症候群 (DIC) と脳血管障害. 神経内科, 3:149-156, 1975.

101) Boyd, J. F.:Disseminated fibrin thromboembolism among stillbirths and neonatal deaths. J. Path. Bact., 90:53-63, 1965.
pubmed

102) Robboy, S. J., Colman, R. W., Minna, J. D.:Pathology of disseminated intravascular coagulation (DIC); analysis of 26 cases. Human Pathology, 3:327-343, 1972.
pubmed

103) Sugiura, M., Hiraoka, K., Ohkawa, S., Ueda, K., Matsuda, T., Murakami, M.:Aclinicopathological study on cardiac lesions in 64 cases of disseminated intravascular coagulation. Jpn. Heart J., 18:57-69, 1977.

104) Remberger, K.:Immunofluorescence studies on intravascular coagulation and microthrombosis in the perinatal period and their relation to hyaline membrane disease. Beitr. Path., 150:70-75, 1973.

105) Margaretten, W., Csavossay, I., McKay, D. G.:An electron microscopic study of thrombin-induced disseminated intravascular coagulation. Blood, 29:169-181, 1967.
pubmed

106) Simpson, J. G., Stalken, A. L.:The concept of disseminated intravascular coagulation. Clinics in Hematology, 2:189-198, 1973.

107) Smith, J. P., Yates, P. O.:The thrombotic syndrome associated with carcinoma. J. Path. Bact., 70:111-117, 1955.
pubmed

108) Waller, B. F., Knapp, W. S., Edward, J. E.:Marantic valvular vegetations. Circulation, 48:644-650, 1973.

109) Whitehead, R.:Ischaemic enterocolitis:Expression of the intravascular coagulation. Gut., 12:912-917, 1971.
pubmed

110) Fine, J.:Septic shock. J. A. M. A., 188:427-432, 1964.
pubmed

111) Bialostozky, D., Contreas, R., Tinjeros, C. A., Franco-Browder, S.:Gastrointestinal hemorrhagic necrosis. Amer. J. Med., 46:90-95, 1969.

112) Lerner, R. G., Goldstein, R., Cummings, G.:Endotoxin induced disseminated intravascular clotting; evidence that it is mediated by neutrophil production of tissue factor. Thromb. Res., 11:253-261, 1977.
pubmed

113) Edwards, R. L., Rickles, F. R.:On the origin of leukocyte procoagulant activity. Thromb. Res., 13:307-308, 1978.
pubmed

114) Thiagarajan, P., Niemetz, J.:Procoagulant-tissue activity of circulating peripheral blood leukocytes; results of in vivo studies. Thromb. Res., 17:891-896, 1980.
pubmed

115) Leby, G. A., Ebington, T. S.:Lymphocyte cooperation is required for amplification of macrophage procoagulant activity. J. Exp. Med., 151:1232-1244, 1980.

116) Edwards, R. L., Rincles, F. R., Cronlund, M.:Abnormalities of blood coagulation in patients with cancer; mononuclear cell tissue factor generation. J. Lab. Clin. Med., 98:917-928, 1981.

117) McKay, D. G., Margaretten, W.:Disseminated intravascular coagulation in virus diseases. Arch. Intern. Med., 120:129-152, 1967.
pubmed

118) Dennis, L. H., Reisberg, B. E., Crosbie, J., Crozier, D., Conrad, M. E.:The original haemorrhagic fever; yellow fever. Brit. J. Haemat., 17:455-462, 1969.
pubmed

119) Davison, A. M., Thomsom, D., Robson, J. S.:Intravascular coagulation complicating influenza A virus infection. Brit. Med. J., 1:654-655, 1973.

120) Rubio, T., Riley, H. D., Jr., Nida, J. R., Brooksaler, F., Nelson, J. D.:Thrombocytopenia in Rocky Mountain spotted fever. Amer. J. Dis. Child, 116:88-96, 1968.
pubmed

121) Dennis, L. H., Eichelberger, J. W., Inman, M. M., Conrad, M. E.:Depletion of coagulation factors in drug-resistant Plasmodium falciparum malaria. Blood, 29:713-721, 1967.
pubmed

122) Barrett, C. E., Ugoretz, R. J., Braude, A. I.:Disseminated intravascular coagulation in trypano somiasis. Arch. Intern. Med., 131:574-577, 1973.

123) Mavligit, G. M., Binder, R. A., Crosby, W. H.:Disseminated intravascular coagulation in miliary tuberculosis. Arch. Intern. Med., 130:388-389, 1972.
pubmed

124) Doughten, R. M., Pearson, H. A.:Disseminated intravascular coagulation associated with Aspergillus endocarditis. J. Pediat., 73:576-582, 1968.
pubmed

125) Gigon, J. P., Tholen, H., Schmutzler, R., Scheidegger, S., Stamm, H., Koller, F.:Intravaskulare Gerinnung und allergische Vaskulitis mit Nierenrindennekrose (bei Morbus Klippel-Trenaunay). Dtsch. med. Wschr., 89:1881-1887, 1964.

126) Johnson, A. C., Merskey, C.:Diagnosis of diffuse intravascular clotting:Its relation to secondary fibrinolysis and treatment with heparin. Thrombos. Diathes haemorrh. suppl., 20:161, 1966.

127) Nicholson, G., Tomkin, G. H.:Successful treatment of dissminated intravascular coagulopathy complicating diabetic coma. Brit. Med. J., 4:450, 1974.

128) Rock, R. C., Bone, J. R., Nemerson, Y.:Heparin treatment of intravascular coagulation accompanying hemolytic transfusion reactions. Transfusion, 9:57-61, 1969.

129) Sohan, R. S., Sun, S. C., Colcolough, H. L, Burch, G. E.:Heat stroke; an electron microscopic study of endothelial cell damage and disseminated intravascualr coagulation. Arch. Intern. Med., 122:43-47, 1968.

130) Bachmann, F.:Evidence for hypercoagulability in heat stroke. J. Clin. Invest., 46:1033, 1967.

131) Weber, M. B., Blakely, J. A.:The haemorrhagic diathesis of heat stroke; a consumption coagulopathy successfully treated with heparin. Lancet, i:1190-1192, 1969.

132) Mehta, B., Briggs, D. K., Sommers, S. C., Karpatkin, M.:Disseminated intravascular coagulation following cardiac arrest; a study of 15 patients. Amer. J. Med. Sci., 26:353-363, 1972.

133) Hardaway, R. M.:Disseminated intravascular coagulation in shock. Thrombos. Diathes haemorrh. suppl., 36:159-170, 1969.

134) Lasch, H. G.:Coagulation disturbances in shock. Postgrad. Med. J., 45:539-542, 1969.
pubmed

135) Bergmann, H., Vinazzer, H., Necek, S.:Kardiogenic Schock mit schwerer Verbrauchskoagulopathie. Wien. med. Wschr., 123:585-587, 1973.

P.250 掲載の参考文献

1) Biggs, R.:Human Blood Coagulation, Haemostasis and Thrombosis. Oxford:Blackwell Scientific Publications, 1972. p. 133-135.

2) 橋本仙一郎, 他:自動血球計数器による血小板数算定. 臨床病理, 16 (補):167, 1968.

3) 山口延男:血小板計数法ことに自動血球計数器による血小板計数法の意義と問題点. MCCニュース, 35:14, 1970.

4) 安部英:抗凝固剤使用上の問題点. 検査, 17:1120, 1973.

5) Biggs, R.:Human Blood Coagulation, Haemostasis and Thrombosis. Oxford:Blackwell Scientific Publications, 1972. p. 142-146.

6) 西垣登代子, 他:止血機構検査におよぼす温度の影響 (プロトロンビン時間). 臨床病理, 16:208-209, 1968.
Medical*Online

7) 福武勝博:赤血球沈降速度 (赤沈) の国際標準測定法. 臨床病理, 22:137-138, 1974.
Medical*Online

8) Miale, J. B.:Laboratory Medicine Hematology, 4th ed. Saint Louis:C. V. Mosby, 1972. p. 1284.

9) Miale, J. B., Wilson, M. P.:Studies on the thromboplastin generation test. 1. Method and clinical applications. Amer. J. Clin. Path., 26:969-972, 1956.

10) 寺岡敦子, 仲本恭子:トロンボブラスチン形成試験の検討. 臨床病理, 16 (補):177, 1968.

11) Biggs, R.:Human Blood Coagulation, Haemostasis and Thrombosis. Oxford:Blackwell Scientific Publications, 590-591, 1972.

12) Miale, J. B.:Laboratory Medicine Hematology, 4th ed. Saint Louis:C. V. Mosby, 1972. p. 1284.

13) Horowitz, H. L., et al.:Assay of Plasmathromboplastin antecedent (PTA) with artifically depleted normal plasma. Blood, 22:35-42, 1963.

14) Miale, J. B.:Laboratory Medicine Hematology, 4th ed. Saint Louis:C. V. Mosby, 1972. p. 1291-1292.

15) 橋本仙一郎, 他:吸着血漿試薬および血清試薬の検討. 臨床病理, 20:834-835, 1972.
Medical*Online

16) Biggs, R.:Human Blood Coagulation, Haemostasis and Thrombosis. Oxford:Blackwell Scientific Publication, 1972. p. 590.

17) 橋本仙一郎:トロンビン時間法によるフィブリノーゲンの定量. 臨床病理, 21:615-620, 1973.
Medical*Online

18) 橋本仙一郎:線溶測定の現状とその問題点. プラスミン研究会報告集, 14:1-24, 1975.

19) 橋本仙一郎:市販病的血漿の使用経験. 血液と脈管, 5:811-814, 1974.

20) 橋本仙一郎:標準血漿の比較. 血液と脈管, 6, 1975.

21) 橋本仙一郎, 他:血液凝固因子の欠乏血漿試薬の検定. 臨床血液, 14:405-406, 1973.

22) 橋本仙一郎:第VIII因子の測定とスクリーニング. 血液凝固-研究の進歩とその臨床-. 東京:日本臨牀社. 1981. p. 3728-3736.

23) 信越化学:信越シリコン. P 6-3 C:18-19, 1973.

24) Svendsen, L., Blomback, B., Blomback, M., et al.:Synthetic chromogenic substrates for determination of trypsin, thrombin and thrombin-like enzymes. Thrombosis Res., 1:267-278, 1972.

25) Blombtick, M., Blomback, B., Olsson, P., et al.:The assay of antithrombin using a synthetic chromogenic substrate for thrombill. Thrombosis Res., 5:621-632, 1974.

26) Morita, T., Kato, H., Iwanaga, S., et al.:New fluorogenic substrates for α-thrombin, Factor Xa, Kallikreins, and urokinase. J. Biochem., 82:1495-1498, 1977.

27) A new assay method for α-thrombin, Factor Xa, Kallikreins and urokinase using peptide-MCA substrates.:p. 1-5, in pamphlet published by Protein Research Foundation, Minoh, Osaka, 1977.

28) Iwanaga, S., Morita, T., Harada, T., et al.:Chromogenic substrates for horseshoe crab clotting enzyme. Its application for the assay of bacterial endotoxin. Haemostasis, 7:183-188, 1978.
pubmed

29) 岩永貞昭:ペプチド合成基質・凝固・線溶・キニン (青木延雄・岩永貞昭編), 東京:中外医学社, 1979. p. 445-455.

30) Iwanaga, S., Morita, T., Kato, H., et al.:Fluorogenic peptide substrates for proteases in blood coagulation, kallikrein. kinin and fibrinolysis systems. Kinins:II Biochemistry, Pathophysiology, and Clinical Aspects (Fujii, S., Moriya, H. and Suzuki, T. ed.), New York:Plenum Publishing Corporation, 1979. P. 147～163.

31) Iwanaga, S., Kato, H., Maruyama, I., et al.:Fluorogenic peptide substrates for proteases in blood coagulation, kallikrein-kinin and fibrinolysis systems:substrate for plasmin and Factor XIa. Thrombos. Haemostas., 42:49, 1979.

32) Robbins, K. C. and Summaria, L.:Plasminogen and plasmin. Method in Enzymology, New York:Academic Press, 1976. p. 257-273.

33) 鈴木宏治, 西岡淳二, 橋本仙一郎:螢光性ペプチド基質を用いた尿中ウロキナーゼの測定. 臨床病理, 27:218-222, 1979.
Medical*Online

34) 橋本仙一郎, 鈴木宏治:MCA法による血漿フ゜レカリクレイン, 第X因子および尿中ウロキナーゼの測定. Biomedical Journal, 3:783-788, 1979.

35) 諸井将明, 青木延雄:α2-プラスミンインヒビター. 凝固・線溶・キニン (青木延雄, 岩永貞昭編), 東京:中外医学社, 1979. p. 361-369.

36) 真木正博, 曽我賢次:発色基質による凝固・線溶・キニン産生系の測定とその臨床応用. クリニカルニュース, 1:85-95, 1980.

37) 加藤正俊, 藤巻道男:合成ペプチド基質による凝固因子の測定. 検査と技術, 8:585-593, 1980.

38) 中村節子, 滝沢徳正, 五十嵐紀子, 他:発色性ペプチド基質による血漿プレカリクレイン測定法の検討. 臨床病理, 28:670-674, 1980.
Medical*Online

39) Messmore, H. L, Fareed, J.:Synthetic chromogenic and fluorogenic peptides:valuable new approach to coagulation analysis. Prog. Clin. Enzymol. (Proc. Int. Symp. ), 2:262-271, 1980.

40) 鈴木宏治, 西岡淳二, 橋本仙一郎:螢光性合成基質 (3104-V) を用いた血漿プラスミノゲンの測定法. 臨床病理, 28:804-807, 1980.

41) 鈴木宏治, 西岡淳二, 橋本仙一郎:2種の螢光性合成基質に対するUKならびにSK活性化プラスミンの反応性の差異. 日本血液学会雑誌, 44:690-698, 1981.

42) Seghatchian, J.:The values of synthetic substrates in the improvement of diagnostic tests for hemostatic function. Ric. Clin. Lab., 11:11-25, 1981.
pubmed

43) Messmore, H. L., Fareed, J., Kniffin, J., et al.:Synthetic substrate assays of the coagulation enzymes and their inhibitors. Comparison with clotting and immunologic methods for clinical and experimental usage. Ann. N. Y. Acad. Sci., 370:785～797, 1981.

44) Bell, W. R., Dauer, R. J.:Automated method for antithrombin m using chromogenic substrate S 2238. Aust. J. Med. Lab. Sci., 2:49-53, 1981.

45) Coleman, P. L., Green, G. DJ.:A sensitive, coupled assay for plasminogen activator using a thiol ester substrate for plasmin. Ann. N. Y. Acad. Sci., 370:617-626, 1981.

46) Schrader J. Koestering, H., Zuechner, C., et al.:Rapid tests for antithrombin III determination:a comparison between Partigen plates and a chromogenic substrate. Laboratoriumsmedizin, 5:211-218, 1981.

47) Griffin, J. H., Evatt, B., Zimmerman, T. S., et al.:Deficiency of protein C in congenital thrombic disease. J. Clin. Invest., 68:1370-1373, 1981.

48) Triplett, D. A.:Synthetic substrates:a revolution in the diagnostic coagulation laboratory. Clin. Lab. Annu., 1:243-287, 1982.

49) Laurell, C. B.:Electroimmunoassay. Scand. J. Clin. Lab. Invest., 29 (Suppl. 124):21-37, 1972.

50) Hoyer, L.W.:Immunologic studies of antihemophilic factor IV. Radioimmunoassay of AHF antigen. J. Lab. Clin. Med., 80:822-833, 1972.
pubmed

51) Counts, R. B.:Solid-phase immunoradiometric assay of factor VIII protein. Brit. J. Haemat., 31:429-436, 1975.
pubmed

52) Zimmerman, T. S., Ratonoff, O. D. and Powell, A. E.:Immunologic differentiation of classic hemophilia (factor VIII deficiency) and von Willebrand's disease. With observation on combined. deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor (factor VIII). J. Clin. Invest., 50:244～255, 1971.

53) 藤巻道男, 加藤正俊, 緇莊和子:ロケット電気泳動・電気泳動法のすべて. 東京:医歯薬出版, 1981. p. 134-138.

54) 藤巻道男, 福武勝幸:その他の凝血因子 (II因子, VIII因子, IX因子, XIII因子) Immunohaematology-免疫と血液-, 2:235-244, 1981.

55) Nilehn, J. E., et al.:Plasma prothrombin during treatment with dicumarol (1, II). Scand. J. Clin. Lab. Invest., 22:17 (1), 23 (II), 1968.

56) 高橋薫, 他:Antithrombin III 異常症の一家系. 日本血液学会雑誌, 44:1195-1203, 1981.

P.262 掲載の参考文献

1) Adelson, E.:Fibrinogen metabolism. Fibrinogen (Laki, K. ed.), New York:Marcel Dekker, Inc., 1968. p. 225-240.

2) Laki, K.:Introduction and Summary. Fibrinogen (Laki, K. ed.), New York:Marcel Dekker, Inc., 1968. p. 1-24.

3) Fowler, W. E. and Erickson, H. P.:Trinodular structure of fibrinogen. Confirmation by both shadowing and negative stain electron microscopy. J. Mol. Biol., 134:241, 1979.

4) Blomback, B., Grondahl, N. J., Hessel, B., Iwanaga, S. and Wallen, P.:Primary structure of human fibrinogen and fibrin. J. Biol. Chem., 248:5806, 1973.
pubmed

5) Chen, R. and Doolittle, R. F.:Isolation, characterization, and location of a donoracceptor unit from cross-linked fibrin. Proc. Nat. Acad. Sci. U. S. A., 66:472, 1970.
pubmed

6) 岩永貞昭, 中村伸:フィブリノーゲンおよびその誘導体について. 臨床科学, 9:605, 1973

7) Doolittle, R. F., Bouma, III, H., Cottrell, B. A., Strong, D. and Watt, K. W. K.:The covalent structure of human fibrinogen. The Chemistry and Physiology of the Human Plasma Proteins. (Bing, D. H., ed.) New York, Oxford, Toronto, Sydney, Frankfurt, Paris:Pergamon Press, 1979. p. 77～95.

8) Pizzo, S. U., Schwartz, M. L., Hill, R. L. and McKee, P. A.:The effect of plasmin on the subunit structure of human fibinogen. J. Biol. Chem., 247:636, 1972.

9) Mosher, D. F.:Cross-linking of cold-insoluble globulin by fibrin-stabilizing factor. J. Biol. Chem., 250:6614, 1975.

10) Sakata, Y. and Aoki, N.:Cross-linking of α2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J. Clin. Invest., 65:290, 1980.

11) Ware, A. G., Guest, M. M. and Seegers, W. H.:Fibrinogen:with special refetence to its preparation and certain properties of the product. Arch. Biochem., 13:231, 1947.
pubmed

12) Ferguson, J. H.:Some experiences with blood clotting mechanisms. The Blood Cells and Plasma/Proteins (Tullis, J. T. ed.), New York:Academic Press. p. 93.

13) Cohn, E. J., Gurd, R. R. N., Surgenor, D. M., Barnes, B. A., Brown, R. K., Derouaux, G., Gillespie, J. M., Kahnt, F. W., Lever, W. F., Liu, C. H., Mittelman, C., Mouton, R. F., Schmid, K. and Uroma, E.:A system for the separation of the components of human blood; quantitative procedures for the separation of the protein components of human plasma. J. Am. Chem. Soc., 72:465, 1950.

14) Matsuda, M., Iwanaga, S. and Nakamura, S.:A simple, large scale method for preparation of plasminogen. free fibrinogen. Thrombosis Research, 1:619, 1972.

15) Laki, K.:The polymerization of proteins:The action of thrombin on fibrinogen. Arch. Biochem. Biophys., 32:317, 1951.
pubmed

16) Blomback, B. and Blomback, M.:Purification of human and bovine fibrinogen. Arkiv. Kemi., 10:415, 1956.

17) Bergstrom, K. and Wallen, P.:Removal of contaminating plasminogen from purified bovine fibrinogen. Arkiv, Kemi., 17:503, 1961.

18) Mosesson, M. W.:The preparation of human fibrinogen free of plasminogen. Biochim. Biophys. Acta, 57:204, 1962.
pubmed

19) Berg, W. and Kosan. Bengsten, K.:Separation of human fibrinogen and plasminogen by means of gel filtration. Thromb. Diath. Haemorrh., 9:151, 1963.

20) Deutsch, D. G. and Mertz, E. T.:Plasminogen:Purification from human plasma by affinity chromatography. Science, 170:1095, 1970.
pubmed

21) Finlayson, J. S. and Mosesson, M. W.:Chromatographic heterogeneity of animal fibrinogens. Biochim. Biophys. Acta, 82:415, 1964.
pubmed

22) Finlayson, J. S.:Chromatographic Purification of Fibrinogen (Laki, K. ed.), New York:Marcel Decker, Inc., 1968. p. 39.

23) Mosesson, M. W., Finlayson, J. S., Umfleet, R. A. and Galanakis, D.:Human fibrinogen heterogeneities. I. Structural and related studies of plasma fibrinogens which are high solubility catabolic intermediates. J. Biol. Chem., 247:5210, 1972.
pubmed

24) Mosesson, M. W., Finlayson, J. S. and Umfleet, R. A.:Human fibrinogen heterogeneity. III. Identification of γ chain variants. J. Biol. Chem., 247:5223, 1972.

25) Ratnoff, O. D. and Menzie, C.:New method for determination of fibrinogen in small samples of plasma. J. Lab. Clin. Med., 37:316, 1951.
pubmed

26) Huseby, R. M. and Bang, N. U.:Isolation and assay of fibrinogen. c. Modified Ratnoff and Menzie Method. Thrombosis and Bleeding Disorders (Bang, N. U., et al. eds.), Stuttgart:Georg Thieme Verlag, New York, London:Academic Press, 1971. p. 233.

27) Weber, K. and Osborn, M.:The reliability of molecular weight determination by dodecyl sulfate. polyacrylamide gel electrophoresis. J. Biol. Chem., 244:4406, 1969.
pubmed

28) 林健志, 大場義樹:SDS-ポリアクリルアミドゲル電気泳動法. 核酸・蛋白質・酵素, 17:304, 1971.

29) McDonaugh, J., Messel, H., McDonaugh, R. P., Murano, G. and Blombtick, B.:Molecular weight analysis of fibrinogen and fibrin chains by an improved sodium dodecyl sulfate gel electrophoresis method. Biochim. Biophys. Acta, 257:135, 1972.

P.275 掲載の参考文献

1) Morawitz, P.:Die Chemie der Blutgerinnung. Ergebniss der Physiology, 4:307-423, 1905.

2) Hammerstein, O.:Weitere Beitrage Zur Kentnis der Fibrinbildung. Z. Physiol. Chem., 28:98, 1899.

3) Schmidt, A.:Uber den Faserstoff und die Ursachen seiner Gerinnung. Arch. Anat. Physiol., 1:545, 1861.

4) Bordet, J., Pelange, L.:Analyse et synthese der Processes de la Coagulation. Ann. et Bull. Soc. Reg. de Sci. Med. et Nat. de Bruxelles., 72:87, 1914.

5) Seegers, W. H., Smith, H. P., Warren. E. D. and Brinkhous, K. M.:The purification of prothrombin. J. Biol. Chem., 123:751-754, 1938.

6) McCoy, LE., Seegers, W. H.:Preparation of bovine prothrombin complex and purified prothrombin. Thrombosis Res., 1:461-472, 1972.

7) McFarlane, R. G.:An enzyme Cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature, 202:498-499, 1964.

8) Davie, E. W., Ratnoff, O. D.:Waterfall sequence for intrinsic blood clotting. Science, 145:1310-1312, 1964.
pubmed

9) Seegers, W. H.:Solving the Riddle of Blood Clotting. Thromb. Diathes. haemorrh. (suppl.), LIV:9-30, 1973.

10) Goldstein, R., et al.:Preparation and properties of prothrombin. J. Biol. Chem., 234:2857-2866, 1959.
pubmed

11) Moore, H. C., et al.:Isolation and purification of bovine and canine prothrombin. Biochem. Biophys. Acta, 111:174-180, 1965.
pubmed

12) Magnusson, S.:Preparation and carbohydrate analysis of bovine prothrombin. Arkiv. Kemi., 23:285-298, 1965.

13) Ingwall, J. S., Sheraga, H. A.:Purification and properties of bovine prothrombin. Biochemistry, 8:1860-1869, 1969.

14) 櫻川信男, 他:牛プロトロンビンの精製と性状について. 血液と脈管, 3:1453, 1972.

15) Ingwall, J. S. and Sheraga, H. A.:Purification and properties of bovine prothrombin. Biochemistry, 8:1860-1869, 1969.

16) Lundblad, R. L.:A rapid method for the purification of bovine thrombin and the inhibition of the purified enzyme with phenylmethylsulfonyl fluoride. Biochemistry, 10:2501-2505, 1971.
pubmed

17) Bajaj, S. P., et al.:Simultaneous isolation of bovine prothrombin and factor X. Activation of prothrombin by trypsin-activated factor X. J. Biol Chem., 248:7729-7741, 1973.
pubmed

18) Latallo, Z. S.:Thrombin Clotting Assay. Throbosis and Bleeding Disorders (Bang, N. U. ed.), New York:Academic Press, 1971. p. 183-186.

19) Cole, E. R., et al.:Procedures for the quantitative determination of autoprothrombin C. Thrombos. Diathes. haemorrh., 8:434-441, 1962.

20) Ware, A. G., Seegers, W. H.:Two stage procedure for the quantitative determination of prothrombin concetration. Amer. J. Clin. Path., 19:471-482, 1949.

21) 松岡松三, 櫻川信男:プロトロンビンニ段測定法の検討. 綜合臨牀, 25:141-147, 1976.

22) Lowry, O. H., et. al.:Protein estimation with the Folin-ciocalteau reagent. J. Biol. Chem. 193:265-275, 1951.

23) Barthels, M., Seegers, W. H.:Substitution of lipid with bile salts in the formation of thrombin. Thromb. Diathes. haemorrh., 22:13-27, 1969.

24) Reno, R. S., Seegers, W. H.:Two stage procedure for the quantitive determination of autoprothrombin III concentration and some application. Thromb. Diathes. haemorrh., 68:198-210, 1967.

25) Shapiro, S. S., Waugh, D. E.:The purificrtion of human prothrombin. Thrombos. Diathes. haemorrh., 16:469-490, 1966.

26) Lanchantin, G. F., et al.:Preparation of human plasma prothrombin and some of its sedimentation properties. J. Biol. Chem., 238:238-243, 1963.
pubmed

27) Heystek, J., et al.:The purification of human factor II (prothrombin) and the preparation of a specific antiserum. Vox Sang, 27:214-226, 1974.
pubmed

28) Malhotra, O. P.:Purification and properties of normal and abnormal protrombins. Thrombos. Diathes. heamorrh. (Suppl.), LIX:27-43, 1974.

29) 松岡松三, 櫻川信男:蛇毒iEchis carinatusを用いたプロトロンビン測定法. 最新医学, 30:1253-1260, 1975.

30) Sakuragawa, N., et al.:Comparative studies of the purification methods of prothrombin. Acta Med. Biol. (Niigata), 25:119-124, 1977.

31) 松本光民, 他:アフィニティクロマトグラフィーによるプロトロンビンの抽出法. 第37回日本血液学会総会に発表.

32) 櫻川信男:血栓形成における凝固因子の意義 (1) トロンビン. 興和医報, 特集「血栓症」.

33) Seegers, W. H., et al.:Preparation and properties of thrombin. Arch. Biochem. Biophys., 128:194-201, 1968.
pubmed

34) Heldebrant, C. M., Mann, K. G.:The activation of prothrombin. I. Isolation and preliminary characterization of intermediates. J. Biol. Chem., 248:3642-3652, 1973.
pubmed

35) Magnusson, S.:Preparation of highly purified bovine thrombin and determintion of its N-terminel amino acid residues. Arkiv. Kemi., 24:349-358, 1965.

36) Miller, K. D., Kopeland, W. H.:Isolation of human thrombin. Proc. Soc. Exptl. Biol. Med., 111:512-514, 1962.

37) Baughman, D. J., Waugh, D. F.:Bovine thrombin. Purification and certain properties. J. Biol. Chem., 242:5252-5259, 1962.

38) McCoy, L. E., et al.:Purification and biochemistry of thrombin. Thrombos. Diathes. haemorrh. (Suppl.), LVII:125-132, 1974.

39) Schmer. G.:The purification of bovine thrombin by affinity chromatography of benzamidine-agarose. Hoppe-Seyler's Z. Physiol. Chem., 353:810-814, 1972.

40) Lanchantin, G. F. et al.:Two forms of human thrombin. J. Biol. Chem., 248:5956-5966, 1973.
pubmed

41) Miller, K. D., Copeland, W. H.:Human thrombin:Isolation and stability. Exp. mol. path., 4:431 N 437, 1965.

42) Berg, W., et al.:Human and bovine plasminogen-free thrombin, purified by method of gel filtration and ion exchange chromatography. Thrombos. Diathes. heamorrh., 15:501-510, 1966.

43) Fenton, J. W., et al.:Large-scale preparation and preliminary characterization of human thrombin. Biochim. biophys. Acta, 229:26-32, 1971.
pubmed

44) Denson, K. W. E.:The preparation of general reagents and coagulation factors. Human Blood Coagulation Haemostasis and Thrombosis (Biggs, R. ed.), London:Blackwell Scientific Publications, 1972. p. 594.

45) Sakuragawa, N., et al.:Purificatoin and some characterization of human thrombin. Acta Med. Biol. (Niigata), 23:65-73, 1975.

46) Thompson, A. R., Davie, E. W.:Affinity chromatography of thrombin. Biochim. biophys. Acta, 250:210-215, 1971.
pubmed

47) Schwert, G. W., Takenaka, Y.:A spectrophotometric determination of trypsin and chymotrypsin. Biochim. Biophys. Acta, 16:570-575, 1955.
pubmed

48) 櫻川信男, 他:フィブリン平板法の検討. 臨床検査, 19:980-984, 1975.

49) Spackman, D. H., et al.:Automatic recording apparatus for use in the chromatography of amino acids. Anal. Chem., 30:1190-1206, 1958.

50) 櫻川信男, 小出武比古:トロンビンの凝固線溶および血小板へおよぼす影響ならびにその生化学的性状. 新潟医学会雑誌, 89:91-100, 1975.

51) Aoki, N., et al.:Properties of bovine Ac-globulin concentrates and methods of preparation. Canad. J. Bioch. Physiol., 41:2409-2421, 1963.

52) Papahadjopoulous, D., et al.:Purification and properties of bovine factor V:A change of molecular size during blood coagulation. Biochemistry, 3:264-270, 1964.

53) Barton, P. G., Hanahan, D. J.:The preparation and properties of a stable factor V from bovine plasma. Biochem. Biophys. Acta, 133:506-518, 1967.
pubmed

54) Esnouf, M. P., Jobin, F.:The isolation of factor V from bovine plasma. Biochem. J., 102:660-665, 1967.
pubmed

55) Dombrose, F. P., Seegers, W. H.:Purification of bovine plasma Ac-globulin (factor V). Thromb. Diathes. heamorrh. (Suppl.), LVII:241-254, 1974.

56) Surgenor, D. M., et al.:Preparation of factor V for clinical use. Vox Sang, 5:77-78, 1960.

57) Blomback, B., Blomback, M.:Purification and stabilization of factor V. Nature, 198:886-887, 1963.
pubmed

58) Nemerson, Y., Pitlick, F. A.:The Tissue Factor Pathway of Blood Coagulation. Progress in Hemostasis and Thrombosis 1. (Spaet, T. H., ed.), New York:Grune & Stratton, 1972. p. 1-37.

59) Williams, W. J., Norris, D. G.:Purification of a bovine plasma protein (factor VII) which is required for the activity of lung microsomes ill blood coagulation. J. Biol. Chem., 241:1847-1856, 1966.

60) Hogenauer, E., et al.:Isolation and characterization of blood clotting factors VH and X. Thrombos. Diathes. haemorrh., 19:304-306, 1968.

61) Tishkoff, G. H., et al.:Preparation of highly purified prothrombin complex. I. Crystalization, biological activity, and molecular properties. J. Biol. Chem., 243:4151-4167, 1968.
pubmed

62) 高橋薫, 櫻川信男:凝固線溶系因子の精製と代謝, 第7報. ヒト第VII因子, 第IX因子および第X因子の精製. 第16回日本臨床血液学会総会に発表, 1974.

63) Shaw, S., et al.:Assessment of factor VII and factor X. Thrombos. Diathes. haemorrh., 15:294-300, 1966.

64) Gladhaug, A., Prydz, H.:Purification of the coagulation factor VII and X from human serum. Some properties of factor VII. Biochim. Biophys. Acta, 215:105-111, 1970.

65) Radcliff, R. D., Barton, P. G.:Comparisons of the molecular forms of activated bovine Factor X. J. Biol. Chem., 248:6788-6795, 1973.

66) Seegers, W. H., et al.:Further observations on the purification and properties of autoprothrombin III (Factor X). Thrombosis Res., 1:209-220, 1972.

67) Fujikawa, K., et al.:Bovine Factors X1 and X2 (Stuart Factor). Isolation and characterization. Biochemistry, 11:4882-4891, 1972.
pubmed

68) Jackson, C. M., Hanahan, D. J.:Studies on bovine factor X, II. Characterization of purified factor X. Observations on some alterations in zone electrophoretic and chromatographic behavior occurring purification. Biochemistry, 7:4506～4517, 1968.

69) Lechner, K., Deutsch, E.:Activation of factor X. Thrombos Diathes. haemorrh., 13:314-329, 1965.

70) Kahn, M. J. P., Bourgain, R. H.:A simplified preparation procedure of factor X by paper electrophoresis. Hemostasis, 5:413-415, 1965.

71) Kingdon, H. S., et al.:The reaction between activated plasma thromboplastin. Antecedent and diisopropylphosphofluoridate. Biochemistry, 3:166-173, 1964.
pubmed

72) Radcliff, R. D., Barton, P. G.:The purification and properties of activated factor X. J. Biol. Chem., 247:7735-7742, 1972.

73) Saito, H., et al.:Partial purification of plasma thromboplastin antecedent (factor XI) and its activation by typsin. J. Clin. Invest., 52:850-861, 1973.

74) Hecic, L.W., Kaplan, A. P.:Substrates of Hagerran factor. I. Isolation and characterization of human factor XI (PTA) and inhibition of the activated enzyme by α1-antitrypsin. J. Exp. Med., 140:1615-1630, 1974.

75) Movat, H. Z., Ozgl-Auwar, A. H.:The contact phase of blood coagulation:Clotting factors XI and XII, their isolation and interaction. J. Lab. Clin. Med., 84:861-878, 1974.

76) Speer, R. J., Ridgway, M.:The formation and "Decay" of XIIa. Thrombos. Diathes. haemorrh., 18:259-267, 1967.

77) Schiffman, S., Lee, P.:Preparation, characterization, and activation of a highly purified factor XI:evidence that a hitherto unrecognized plasma activity. Participates in the interaction of factor XI nd XU. Brit. J. Haemat., 27:101～114, 1974.

78) 櫻川信男:プロトロンビン活性化機構. 日本臨牀, 32:901-909, 1974.

79) Schoenmakers, J. G., et al.:Hageman factor, A novel sialoglycoprotein with esterase activity. Biochim. Biophys. Acta, 101:166-176, 1965.
pubmed

80) Revak, S. D., et al.:Structure changes accompanying enzymatic activation of human Hageman factor. J. Clin. Invest., 54:619-627, 1974.
pubmed

81) Wuepper, K. D.:Prekallikrein Deficiency in Man. J. Exp. Med., 138:1345-1355, 1973.

82) Nemerson, Y., Spaet, T. H.:The activation of factor X by extracts of rabbit brain. Blood, 23:657-668, 1967.

83) Cochrane, C. G., et al.:Activation of Hageman factor in solid and fluid phase. J. Exp. Med., 138:1564-1583, 1973.
pubmed

84) McMillin, C. R., et al.:The secondary structure of human Hageman factor (factor XII) and its alteration by activating agents. J. Clin. Invest., 54:1312-1322, 1974
pubmed

85) Movat, H. Z., Ozge-Anwar, A. H.:The contact phase of blood:clotting factor XI and XII, their isolation and interaction. J. Lab. Clin. Med., 84:861-878, 1974.

86) Heck, L. W., Kaplan, A. P.:Substrate of Hageman factor. I. Isolation and characterization of human factor XI (PTA) and inhibition of the activated enzyme by α1-antitrypsin. J. Exp. Med., 140:1615-1630, 1974.

87) Mammen, E. F., Grammens, G.:The purification and some properties of bovine Hageman factor. Thrombos, Diathes. haemorrh., 18:306-307, 1967.

88) Hecht, E., et al.:Thromboplastin:Nomenclature and preparation of protein-free material different from platelet factor 3 or lipid activator. Am. J. Physiol., 193:584-592, 1958.
pubmed

89) Langdell, R. D., et al.:Effect of antihemophilic factor on one-stage clotting tests. J. Lab. Clin. Med., 41:637-647, 1953.
pubmed

90) Hvatum, M., Prydz, H.:Studies on tissue thromboplastin-its splitting into two separatable parts. Thromb. Diath. haemorrh., 21:217-222, 1969.

91) Nemerson, Y., Pitlick, F. A.:Purification and characterization of the protein component of tissue factor. Biochemistry, 9:5100-5105, 1970.
pubmed

P.288 掲載の参考文献

1) Pavlovsky, A.:Contribution to the pathogenesis of hemophilia. Blood, 2:185, 1947.

2) Biggs, R., Douglas, A. S., Macfarlane, R. G., Davie, J. V., Pitney, W. R., Merskey, C. and O`Brien, J. R.:Christmas disease;acondition previously mistaken for hemophilia. Br. Med. J., 2:1378-1382, 1952.

3) Aggeler, P. M., White, S., Glendenning, M.B., Page, E. W., Leake, T. B. and Bates, G.:Plasma thromboplastin component (PTC) deficiency;a new disease resembling hemophilia. Pro. Soc. Exp. Biol. Med., 79:692-694, 1952.

4) Cohn, E. J., Strong, L. E., Hughes, W. L., Mulford, D. J., Ashworth, J. N., Melin, M. and Taylor, H. L.:A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J. Am. Chem. Soc., 68:459～475, 1946.

5) Pool, J. G. and Shannon, A. E.:Production of high-potency concentrates of antihemophilic globulin in a crossed-bag system. New Eng. J. Med., 273:1443, 1965.

6) Biggs, R., ed.:Human Blood Coagulation, Haemostasis and Thrombosis. Blackwell Scientific Publications, 1976. p. 249-309.

7) Hershgold, E.J. and Sprawls, S.:Molecular properties of purified human, bovine and porcine antihemophilic globulin (AHG). Fed, Proc., 25:317, 1966.

8) Johnson, A. J., Newman, J., Howell, M. B. and Puszkin, S.:The preparation and some properties of a clinically useful, high purity antihemophilic factor (AHF). Thromb. Diath. Haemorrh., Suppl. 26:377, 1967.

9) van Mourik, J. A. and Mochtar, I. A.:Purification of antihemophilic factor (factor VIII) by gel chromatography. Biochim. Biophys. Acta, 221:677-679, 1970.
pubmed

10) Zimmerman, T. S., Ratnoff, O. D. and Powell, A. E.:Immunologic differentiation of classic hemophilia (factor VIII deficiency) and von Willebrand's disease. With observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. J. Clin. Invest., 50:244～254, 1971.

11) Hershgold, E. J., Davison, A. M. and Janszen, M. E.:Isolation and some chemical properties of factor VIII (antihemophilic factor). J. Lab. Clin. Med., 77:185-205, 1971a.

12) Green, D.:A simple method for the purification of factor VIII (antihemophilic factor) employing snake venom. J. Lab. Clin. Med., 153-158, 1971.

13) Marchesi, S. L., Shulman, N. R. and Gralnick, H. R.:Studies on the purification and characterization of human factor W. J. Clin. Invest., 51:2151-2161, 1972.

14) Legaz, M. E., Schmer, G., Counts, R. B. and Davie, E. W.:Isolation and characterization of human factor VIII (antihemophilic factor). J. Biol. Chem., 248:3946-3955, 1973.
pubmed

15) Shapiro, G. A., Andersen, J. C., Pizzo, S. V. and McKee, P. A.:The subunit structure of normal and hemophilic factor VIII. J. Clin. Invest., 52:2198-2210, 1973.
pubmed

16) McKee, P. A., Andersen, J. C. and Switzer, M. E.:Molecular structural studies of human factor VIII. Ann. N. Y. Acad. Sci., 240:8-33, 1975.
pubmed

17) 福井弘, 三上貞昭, 奥田忠美, 村嶋徳昭:ヒト血漿よりの第VIII因子と第VIII因子の同時分離について. 日血誌, 39:163-169, 1976.

18) Furlan, M., Jakab, T. and Beck, E. A.:Dissociation of human factor VIII by rhizopus lipase. Thromb. Res., 10:431-443, 1977.
pubmed

19) Fujikawa, K., Thompson, A. R., Legaz, M. E., Meyer, R. G. and Davie, E. W.:Isolation and characterization of bovine factor IX (Christmas factor). Biochemistry, 12:4938-4945, 1973.
pubmed

20) Osterud, B. and Flengsrud, R.:Purification and some characterization of the coagulation factor IX (from human plasma. Biochem. J., 145:469-474, 1975.

21) Andersson, L.-O., Borg, H. and Miller-Andersson, M.:Purification and characterization of human factor IX (. Thromb. Res., 7:451-459, 1975.
pubmed

22) Rosenberg, J. S., McKenna, P. W. and Resenberg, R. D.:Inhibition of human factor IX (a by human antithrombin. J. Biol. Chem., 250:8883-8888, 1975.

23) Suomela, H.:Human coagulation factor IX (;Isolation and characterization. Eur. J. Biochem., 71:145-154, 1976.
pubmed

24) Thompson, A. R.:Factor IX antigen by radioimmunoassay;Abnormal factor IX (protein in patients on warfarin therapy and hemophilia B. J. Clin. Invest., 59:900-910, 1977.
pubmed

25) Osterud, B. and Rapaport, S. I.:Activation of factor IX (by the reaction product of tissue factor and factor VII;Additional pathway for initiating blood coagulation. Proc. Natl. Acad. Sci. USA, 74:5260-5264, 1977.
pubmed

26) DiScipio, R. G., Hermodson, M. A., Yates, S. O. and Davie, E. W.:A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S. Biochemistry, 16:698-706, 1977.

27) Vennrod, A. M., Orstavik, K. H., Laake, Fagerhol, M. and Ly, B.:Purification of humanfactor IX. Thromb. Res., 11:663-672, 1977.

28) Chung, K.-S., Madar, D. A., Goldsmith, J. C., Kingdon, H. S. and Roberts, H. R.:Purification and characterization of abnormal factor IX (Christmas factor) molecule;Factor IX Chapel Hill. J. Clin. Invest., 62:1078-1084, 1978.

29) Fujimura, Y., Sakai, T., Mathuyama, I., Mikami, S., Yoshioka, A. and Fukui, H.:A simultaneous purification of human prothrombin and factor IX. Blood & Vessel, 13:195-203, 1982.

30) Pepper, D. S. and Prowse, C.:Chromatography of human prothrombin complex on dextran sulphate agarose. Thromb. Res., 11:687-692, 1977.
pubmed

31) Bajaj, S. P., Rapaport, S. I., Prodonos, C. ank Russell, W. A.:Heterogeneity in human prothrombin;analysis of cause. Blood, 58:886-891, 1981,

32) 青木延雄, 岩永貞昭, 編:凝固・線溶・キニン. 中外医学社, 1979. p. 127-139

33) Yoshioka, A., Mikami, S., Nishino, M., Okubo, Y., Takahashi, Y. and Fukui, H.:Heterogeneity of factor VIII. related antigen in several factor VIII concentrates. Proc. 2nd ISTH, Tokyo, 1981. p. 193-202.

34) 片山幸一, 藤川和雄, 千谷晃一:ビタミンK依存性血液凝固因子-構造, 機能, 生合成-.蛋白質・核酸・酵素, 24:924-941, 1979.

35) Coan, M. H., Fournel, M. A. and Mozen, M. M.:Properties of commercial factor IX concentrates. Ann. N. Y. Acad. Sci., 370:731-746, 1981.
pubmed

36) Kisiel, W. and Hanahan, D. J.:Purification and characterization of human factor H. Biochim. Biophys. Acta, 304:103-113, 1973.

37) Madalas, F., Parkin, J. D. and Castaldi, P. A.:Prothrombin isolation and assay. AJEBAK., 52:925-931, 1974.

38) Jovin, T., Chrambach, A. and Naughton, M. A.:An apparatus for preparative temperature. regulated polyacrylamide gel electrophoresis. Analy. Biochem., 9:351-369, 1964.

P.300 掲載の参考文献

1) Stenflo, J.:A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization. J. Biol. Chem., 251:355-363, 1976.
pubmed

2) Kisiel, W.:Human plasma protein C. Isolation, characterization, and mechanism of activation by α-thrombin. J. Clin. Invest., 64:761-769, 1979.

3) Ferunlund, P. and Stenflo, J.:Amino acid sequence of the light chain of bovine protein C. J. Biol. Chem., 257:12170-12179, 1982.

4) Stenflo, J. and Ferunlund, P.:Amino acid sequence of the heavy chain of bovine protein C. J. Biol. Chem., 257:12180-12190, 1982.

5) Drakenberg, T., Ferunlund, P., Roepstorff, P. and Stenflo, J.:β-hydroxyaspartic acid in vitamin K-dependent protein C. Proc. Natl. Acad. Sci. USA, 80:1802-1806, 1983.

6) McMullen, B. A., Fujikawa, K., Kisiel, W., Sasagawa, T., Howald, W. N. and Kwa, E. Y.:Complete amino acid sequence of the light chain of human blood coagulation factor X:Evidence for identification of residue 63 as β-hydroxyaspartic acid. Biochemistry, 22:2875～2884, 1983.

7) Ferunlund, P. and Stenflo, J.:β-hydroxyaspartic acid in vitamin K-dependent proteins. J. Biol. Chem. (in press) 1983.

8) McMullen, B. A., Fujikawa, K. and Kisiel, W.:The occurrence of β-hydroxyaspartic acid in the vitamin K-dependent blood coagulation zymogens.:Biochim. Biophys. Res. Commun. (in press) 1983.

9) Kisiel, W., Ericsson, L. H. and Davie, E. W.:Proteolytic activation of protein C from bovine plasma. Biochemistry, 15:4893-4900, 1976.
pubmed

10) Owen, W. G. and Esmon, C. T.:Functional properties of an endothelial cell cofactor for thrombin:catalyzed activation of protein C. J. Biol. Chem., 256:5532-5535, 1981.
pubmed

11) Esmon, N. L, Owen, W. G. and Esmon, C. T.:Isolation of a membrane. bound cofactor for thrombin-catalyzed activation of protein C. J. Biol. Chem., 257:859-864, 1982.
pubmed

12) Comp, P. C., Jacocks, R. M., Ferrell, G. L. and Esmon, C. T.:Activation of protein C in vivo. J. Clin. Invest., 70:127-134, 1982.
pubmed

13) Nesheim, M. E., Myrmel, K. H., Hibbard, L. and Mann, K. G.:Isolation and characterization of single chain bovine factor V. J. Biol. Chem., 254:508-517, 1979.
pubmed

14) Dahlback, B.:Human coagulation factor V. Purification and thrombin-catalyzed activation. J. Clin. Invest., 66:583-591, 1980.
pubmed

15) Suzuki, K., Dahlback, B. and Stenflo, J.:Thrombin-catalyzed activation of human coagulation Factor V. J. Biol. Chem., 257:6556-6564, 1982.
pubmed

16) Suzuki, K., Stenno, J., Dahlback, B. and Teodorsson, B.:Inactivation of human coagulation factor V by activated protein C. J. Biol Chem., 258:1914-1920, 1983.

17) Walker, F. J.:Regulation of activated protein C by protein S. The role of phospholipid in Factor V inactivation. J. Biol. Chem., 256:11128-11131, 1981.
pubmed

18) Suzuki, K., Nishioka, J. and Hashimoto, S.:Regulation of activated protein C by thrombin modified protein S. J. Biochem, 94:699-705, 1983.
pubmed

19) Kane, W. H. and Majerus, P. W.:The interaction of human coagulation Factor Va with platelets. J. Biol. Chem., 257:3963-3969, 1982.
pubmed

20) Tracy, P. B., Nesheim, M. E. and Mann, G.:Proteolytic alternation of Factor Va bound to platelets. J. Biol. Chem., 258:662-669, 1983.

21) Dahlback, B. and Stenflo, J.:Inhibitory effect of activated protein C on activation of prothrombin by platelet bound Factor Xa. Eur. J. Biochem., 107:331-335, 1980.
pubmed

22) Vehar, G. A. and Davie, E. W.:Preparation and properties of bovine Factor W. Biochemistry, 19:401-410, 1980.

23) Fay, P. J., Chavin, S. I., Schroeder, D., Yang, F. E. and Marder, V. J.:Purification and characterization of a highly purified human Factor VIII consisting of a single type of polypeptide chain. Proc. Natl. Acad. Sci. USA, 79:7200～7204, 1982.

24) Comp, P. C. and Esmon, C. T.:Generation of fibrinolytic activity by infusion of activated protein C into dogs. J. Clin. Invest., 68:1221-1228, 1981.

25) Griffin, J. H., Evatt, B., Zimmerman, T. S., Kleiss, A. and Wideman, T. S.:Deficiency of protein C in congenital thrombotic disease. J. Clin. Invest., 68:1370-1373, 1981.

26) Bertina, R. M., Broekmans, A. W., van der Linden, I. K. and Mertens, K.:Protein C deficiency in Dutch family with thrombotic disease. Thromb. Haemostas., 48:1-5, 1982.

27) Broekmans, A. W., Veltkamp, J. J. and Bertina, R. M.:Clinical manifestations of isolated protein C deficiency. Thrombos. Haemostas., 50:343, 1983.

28) Fasching, I., Bertina, R. M., Lechner, K., Niessner, H. and Korninger, Ch.:Hereditary protein Cdeficiency in two Austrian families. Thrombos. Haemostas., 50:343, 1983.

29) Marciniak, E., Farley, C. H. and DeSimone, P. A.:Familial thrombosis due to antithrombin III deficiency. Blood, 43:219-231, 1974.

30) Marlar, R. A. and Griffin, J. H. l Deficiency of protein C inhibitor in combined Factor V/VIII deficiency disease. J. Clin. Invest., 66:1186-1189, 1980.

31) Suzuki, K., Nishioka, J. and Hashimoto, S.:Purification from human plasma and characterization. J. Biol. Chem., 258:163-168, 1983.
pubmed

32) Tollefsen, D. M., Majerus, D. W. and Bland, K. M.:Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J. Biol. Chem., 257:2162-2169, 1982.

33) Suzuki, K., Nishioka, S. and Hashimoto, S.:Inhibition of activated protein C by protein C inhibitor. (in contribution).

34) Canfield, W. M. and Kisiel, W.:Evidence of normal functional levels of activated protein C inhibitor in combined Factor V/VIII deficiency disease. J. Clin. Invest., 70:1260-1272, 1982.
pubmed

35) Giddings, J. C., Sugrue, A. and Bloom, A. L.:Quantitation of coagulant antigens and inhibition of activated protein C in combined factor VIII deficiency. Brit. J. Haematol., 52:495-502, 1982.

36) Suzuki, K., Nishioka, J., Hashimoto, S., Kamiya, T. and Saito, H.:Normal titer of functionaland immunoreactive protein C inhibitor in plasma of patients with congenital combined deficiency of Factor V and VIII. Blood, (in press) 1983.

37) Kisiel, W. and Davie, E. W.:Protein C. Methods Enzymol. (Lorand, L. ed.), 80, New York:Academic Press, 1981. p. 320-332,

38) 橋本信一, 森田隆司, 岩永貞昭:ウシ血漿からのビタミンK依存性血液凝固因子の系統的分離法について. 生化学, 53:673, 1981.

39) Suzuki, K., Nishioka, J., Yamada, Y. and Hashimoto, S.:Physiological relation of protein Cand protein C inhibitor in blood coagulation and fibrinolysis. (in contribution).

40) Ohno, Y., Kato, H., Morita, T., Iwanaga, S., Takada, K., Sakakibara, S. and Stenflo, J.:A new fluorogenic peptide substrate for vitamin K-dependent blood coagulation factor, bovnie protein C. J. Biochem., 90:1387-1395, 1981.
pubmed

P.310 掲載の参考文献

1) Markus, G., DePasquale, J. I. and Wissler. F. C.:Quantitative determination of the binding ofε-aminocaproic acid to native plasminegen. J. Biol. Chem., 253:727-732, 1978.

2) Rickli, E. E. and Otavski, W. I.:A new method of isolation and some properties of heavy chain of human plasmin. Eur. J. Biochem., 59:441-447, 1975.

3) Alkjaersig, N.:The purification and properties of human plasminogen. Biochem. J., 93:173-182, 1964.

4) Abiko, Y., Iwamoto, H. and Tomikawa, M.:Prasminogen-plasmin system. V. A stoichiometric equiliblium complex of plasminogen and a synthetic inhibitor. Biochim. Biophys. Acta, 185:424-431, 1969.

5) Brockway, W. and Castellino, F.:Measurement of the binding of antifibrinolytic amino acids to various plasminogens. Arch. Biochem. Biophys., 151:194-199, 1972
pubmed

6) Mori, M. and Aoki, N.:Isolation and characterization of α2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator. induced clot lysis. J. Biol. Chem., 251:5956-5965, 1976.

7) Wiman, B. and Collen, D.:Purification and characterization of human antiplasmin, the fast acting plasmin inhibitor in plasma. Eur. J. Biochem., 78:19-26, 1977.

8) Christensen, U. and Climmensen, I.:Kinetic properties of the primary inhibitor of plasmin from human plasma. Biochem. J., 163:389-391, 1977.
pubmed

9) Wiman, B. and Collen, D.:On the kinetics of the reaction between human antiplasmin and plasmin. Eur. J. Biochem., 84:573-578, 1978.
pubmed

10) Wiman. B., Boman, L. and Collen, D.:On the kinetics of the reaction between human anti-plasmin and a low-molecular-weight form of plasmin. Eur. J. Biochem., 87:143-146, 1978.

11) Wiman, B. and Collen, D.:Molecular mechanism of physiological fibrinolysis. Nature, 272:549-550, 1978.
pubmed

12) Dentsch, D. G. and Mertz, E. T.:Plasminogen;Purification from human plasma by affinity chromatography. Science, 170:1095-1096, 1970.

13) Castellino, F. J., et al.:Amino terminal acid sequences and carbohydrate of the two major forms of rabbit plasminogen. Biochem. Biophys. Res. Commun., 53:845-851, 1973.
pubmed

14) Wirn, E. S., Sheau-Ping, H. U., Hochschwender, S. M. and Laursen, R. A.:Studies on the lysin-binding sites human plasminogen (the effect of light structure on the birlding of lysin ana logo to plasminogen). Eur. J. Biochem., 104:579-586, 1980.

15) McClintock, D. K., Englert, M. E., Dzibkowski, D., Snedeket, E. H. & Bell, P. H.:Two distinct pathways of the streptokinase-mediated activation of highly purified human plasminogen. Biochemistry, 13:5334-5344, 1974.

16) Wallen, P. and Wiman, B.:II. Separation and partial characterization of different molecular form of human plasminogen. Biochim. Biophys. Acta, 257:122-134, 1972.

17) Sodetz, J. M., Brockway, W. J. and Castellino, FJ.:Multiplicity of rabbit plasminogen. Physical characterization. Biochemistry, 11:4451-4458, 1972.
pubmed

18) Parikh, I., March, S. and Cuatecasas, P.:Topics in the methodology of substitution reactions with agarose. Methods Enzymol., 34:77-80, 1974.

19) Linger, H. R., Hoylaerts, M. and Collen, D.:Isolation and characterization of human plasma protein with affinity for the lysine binding sites in plasminogen. J. Biol. Chem., 255:10214-10222, 1980.

20) Harpl, P. C.:α2-plasmin inhibitor and α2-macrogobulin plasmin complexes in plasma. J. Clin. Invest., 68:46-55, 1981.

21) March, S. C., Parikh, I. and Cuatrecasas, P.:Simplified method for cyanogen bromid activation of agarose for affinity chromatography. Anal. Biochem., 60:149-152, 1974.
pubmed

22) Chase, T., Jr. and Shaw, E.:Titration of trypsin plasmin and thrombin with p-nitrophenyl p-guanidinobenzoate HCI. Method Enzymol., 19:20-27, 1970.

23) Wiman, B. and Wallin, P.:Eur. J. Biochem., 36:25-31, 1973.

24) Takada, A. and Takada, Y.:Enzymatic properties of plasmin converted from acid-treated and native Glu and Lys-plasminogen by urokinase. Thrombos. Res., 21:593-601, 1981.

25) Castellino, F. J., et al.:Amino terminal amino acid sequences and carbohydrate of the two major forms of rabbit plasminogen. Biochem. Biophys. Res. Commun., 13:845-851, 1973.

26) Hayes, M. L., et al.:Carbohydrate compositions of the rabbit plasminogen isoenzymes. Arch. Biochem. Biophys., 171:651-655, 1975.
pubmed

27) 五十嵐紀子, 大久保由子, 瓜田有三, 他:アフィニティクロマト応用による新しい線溶系の測定法. 東邦医会誌, 21:478-489, 1974.

28) 真木正博:線維素溶解酵素の測定法. プラスミン測定法文献集, 東京:第一製薬, p. 12-19.

29) 五十嵐紀子, 松本光民, 竹内節夫, 浅田敏雄:アフィニティクロマトグラフィを用いる線溶能の検査. 臨床検査, 17:713-722, 1973.

30) 五十嵐紀子, 松本光民, 大久保山子, 他:リジンセファロースを用いて得られたプラスミノーゲン・ブリー・フィブリノーゲン. 東邦医会誌, 20:78-82, 1973.

31) Astrup, J. and Mollertz, S.:Fibrin plate method for estimating fibrinolytic activity. Arch. Biochem., 40:346-351, 1952.

32) Hedner, V. and Nilson, M. E.:Determination of plasminogen in human by a casein method. Thromb. Diath. Haemorrh., 14:545-561, 1965.

33) Philip, S. N.:Measurement of an activator in human serum. J. Exp. Med., 106:423-437, 1957.

34) Robbins, K. C., Bernabe, P., et al.:The primary structure of human plasminogen. 1. The NH-terminal sequences of human plasminogen and the S-carboxymethyl heavy (A) and light (B) chain derivatives of plasmin. J. Biol Chem., 247:6557～6762, 1972.

35) Sherry, S., Lindenmeyer, R. L., Fletscher, A. P. and Alkjaersing, N.:Studies on enhanced fibrinolytic activity in man. J. Clin. Invest., 38:810-822, 1959.

36) 五十嵐紀子, 松本光民, 竹内節夫, 他:TNP法による蛋白分解酵素の測定. II. トリクロル酢酸沈殿上澄使用のTNP法. 東邦医会誌, 19:7-13, 1972.

37) Gaffney, P. J., Brasher, M., Lord, K., et al.:Activation of plasminogen as a feature of its assay. Haemostasis, 6:72-88, 1977.
pubmed

38) Wallen, P., Wiman, B.:Characterization of human plasminogen. II. Separation and partial characterization of different molecular forms of human plasminogen. Biochim. Biophys. Acta, 257:122-134, 1972.
pubmed

39) Chase, T. Jr. and Shaw, E.:Biochemistry, 8:2212, 1969.
pubmed

P.315 掲載の参考文献

1) Aoki, N.:Preparation of plasminogen activator from vascular trecs of human cadavers. Its comparison with urokinase. J. Biochem., 75:731-741, 1974.

2) Aoki, N. and von Kaulla, K. N.:The extraction of vascular plasminogen activator from human cadavers and description of some of its properties. Am. J. Clin. Path., 55:171-179, 1971.
pubmed

3) Highsmith, R. F.:Isolation and properties of a plasminogen activator derived from canine vascular tissue. J. Biol. Chem., 256:6788-6795, 1981.

4) 柴忠明, 竹内節夫, 他:プラスミノーゲンアクチベーターの研究. 1. フィブリン平板法, 人尿及び屍体心臓血. 日血誌, 37:853-862, 1974.

5) Bachman, F., Fletcher, A. P., et al.:Partial purification and properties of the plasminogen activator from pig heart. Biochem., 3:1578-1585, 1964.

6) 柴忠明:Affinity-chromatography による組織, 体液中の plasminogen activator の分離及び測定法に関する検討. 1. 東邦医会誌, 20:88-93, 1973.

7) 岡本歌子, 永松陽子, 他:人乳における plasminogen 活性化系の研究:1. 人乳中の plasminogen activator および proactivator の分離とその分子量. 日血会誌, 37:57-67, 1974.

8) Rijken, D. C., et al.:Purification and partial characterization of plasminogen activator from human uterins tissue. Biochem. Biophys. Acta, 580:140-153, 1979.

9) Ali, S. J. and Evans, L.:Purification of rabbit kidney cytokinase and comparison of its properties with human urokinase. Biochem. J., 109:293-503, 1968.

10) Sixth International Congress on Fibrinolysis. Lansanne, July 20-23, 1982. Hemostasis international journal on haemostasis and thrombosis research. Abstracts, 1982.

11) De Renzo, E. C., Siiteri, P. K., Hutchings, B. L. and Bell, P. H.:J. Biol. Chem., 242:533, 1967.
pubmed

12) Moroi, M., Aoki, N.:Isolation and characterization of α2. plasmin inhibitor from human plasma. Anovel proteinase inhibitor which inhibits activator induced clot lysis. J. Biol. Chem., 251:5956-5965, 1976.

13) Wiman, B.:Affinity-chromatographic purification of human α2-antiplasmin. Biochem. J., 191:229-232, 1980.

14) Fenton, II, J. W., Fasco, M. J., Stackrow, A. B., et al.:J. Biol. Chem., 252:3587-3598, 1977.

15) Okamoto, U., Horie, N., Nagamatsu, Y., et al.:Distribution of plasminogen-activator in human milk samples collected at various days after delivery. Acta Haematol. Jap., 43:743-746, 1980.

16) Okamoto, U., Horie, N., Nagamatsu, Y., et al.:Plasminogen-activator in human early;its partial purification and characterization. Thrombos. Haemostas., 45:121-126, 1981.

17) Sottrup-Jensen, L., Claeys, H., Zajdel, M., Peterson, T. E. and Magnusson, S.:Progress in Chemical Fibrinolysis and Thrombolysis (Davidson, J. F., Rowan, R. M., Samama, M. and Desnoyers, P., eds.), Vol. 3, New York:Raven Press, 1977. p. 191～209.

18) 風間睦美:講座:線溶阻害因子. J. Med. Enzymol., 1:122-143, 1975.

19) Steinbuch, M., et al.:Specific technique for the isolation of human α2-macroglobulin. Nature, 205:1277, 1961.

20) Harpel, P. C.:Human α2-macroglobulin. Methods Enzymol., 45:639-652, 1976.

21) Harpel, P. C., Hayes, M. B. and Hugli, T. H.:Heat induced fragment of humanα2-macroglobulin. J. Biol. Chem., 254:8669-8678, 1979.

22) Shamash, Y., Rimon, A.:The plasmin inhibitors of human plasma. III. Purification and partial characterization. B. B. A., 121:135, 1966.

23) Moroi, M., Yamasaki, M.:Purification and some properties of human α1-antitrypsin. Scientific papers of the college of general education university of Tokyo, 24:99-109, 1974.

24) Lauritsen, O. S.:Inhibition of plasminogen activation and plasmin activity after euglobulin precipitation and acidification of plasma. Scand. J. Clin. Lab. Invest., 23:121-124, 1969.
pubmed

25) 青木延雄:プラスミノーゲン, アクチベーター(ウロキナーゼ等による血栓溶解に対する血中の阻害因子について), 医用酵素, 1:45, 1974.

26) Wakabayashi, K., et al.:Some properties of antiplasmin substance from rabbit platelet. Thromb. Diath. Haemorrh., 24:76, 1970.
pubmed

27) Schreiber, A. D., et al.:Inhibition by C1 INH of Hageman factor fragment activation of coagulation fibronolysis and kinin generation. J. Clin. Invest., 52:1402-1409, 1973.

28) Okamoto, S., Okamoto, U.:Amino-methyl-cyclohexane carboxyiic acid:AMCHA. A new potent inhibitor of the fibrinolysis. Keio J. Med., 11:105-115, 1962.

29) Dubber, A. H. C., McNicol, G. P., Donglas, A. S. and Melander, B.:Some properties of the antifibrinolytically active isomer of aminomethylcyclohexane carboxylic acid. Lancet, ii:1317-1319, 1964.

30) Steichele, D. F., Herschlein, H. J.:Zur antifibrinolytischen wirkung des Trypsin Kallikrein-in-activators. Medizinsche Welt, 42:2170-2172, 1961.

31) ウロキナーゼ技術懇話会制定, 1981年7月28日

32) 馬場節子, 他:発色性ペプチド基質を用いたプラスミンインヒビターの測定法の検討. 液と脈管, 12:490-492, 1981

P.337 掲載の参考文献

1) Stefanini, M., Dameshek, W.:The Hemorrhagic Disorders. 2nd Ed., New York, London:Grune and Stratton, 1962. P. 442-443.

2) 梅垣健三:凝固スクリーニング試験の選定. 臨床病理, 14:159-164, 1966.

3) 梅垣健三:血液凝固測定の問題点, スクリーニング検査の範囲のもの. 臨床検査, 12:951-959, 1968.

4) 浅井紀一:凝固スクリーニング検査. 臨床病理, 特集16号:35-47, 1969.

5) 梅垣健三:血液凝固検査の標準化. 臨床検査, 15:1086-1091, 1971.

6) 藤巻道男:臨床検査技術全書3. 血液検査. 東京:医学書院, 1972. p. 462-464, 480-514.

7) 安永幸二郎:日本血液学全書3. 臨床血液総論. 東京:丸善, 1964. p. 161-170.

8) 安永幸二郎, 他:血小板数算定法の問題点. 臨床検査, 12:929-936, 1968.

9) 山中學:第5回血液検査室医師会議報告. 臨床病理, 18:294-296, 1970.

10) 山中學:臨床検査技術全書. 3. 血液検査. 東京:医学書院, 1972. p. 89-97.

11) Rees, H. M., Ecker, E. E.:An improved method for counting blood platelets. J. A. M. A., 80:621-622, 1923.

12) Yasunaga, K., et al.:The normal platelet count in Japanese. Acta Hemat. Jap., 31 (2) suppl.:48-55, 1968.

13) Stefanini, M., Dameshek, W.:The Hemorrhagic Disorders, 2nd Ed. New York, London:Grune and Stratton, 1962. P. 460-462.

14) Brecher, G., etal.:The reproducibility and constancy of the platelet count. Am. J. Clin. Path., 23:15-26, 1953.
pubmed

15) 黒川一郎, 他:栓球算定法の検討. 臨床病理, 16 (補):161, 1968.

16) Fonio, A.:Uber ein neues Verfahren der Blutplattchen Zahlung. Dstch. Zsch. Chir., 117:176-194, 1912.

17) 森田久男:血小板に関する研究の二, 三. 綜合臨牀, 5:1125-1132, 1956.

18) 小宮悦造:臨床血液学. 東京:南山堂, 1964. p. 657-660.

19) Duke, W. W.:The pathogenesis of purpura haemorrhagica with especial blood platelets. Arch. Int. Med., 10:455-460, 1962.

20) Ivy, A. C., et al.:The bleeding tendency in jaundice. Surg. Gynec. and Obst., 60:781-784, 1935.

21) Borchgrevink, C. F., Waaler, B. A.:The secondary bleeding time. A new method for the differentiation of haemorrhagic diseases. Acta Med. Scand., 162:361-374, 1958.
pubmed

22) Mielke, C. H., et al.:The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood, 34:204, 1969.
pubmed

23) 小林紀夫:血餅退縮試験. 臨床検査, 14:767-771, 1970.

24) Tocantins, L. M.:Blood Coagulation, Hemorrhage and Thrombosis, 1st Ed., New York:Grune and Stratton, 1964. p. 41-43.

25) 吉田邦男:日本血液学全書, 6-II, 術式. 東京:丸善, 1965. p. 829.

26) 山中學:臨床検査技術全書. 3. 血液検査. 東京:医学書院, 1972. p. 475-478.

27) Macfarlane, R. G.:Asimple method for measuring clot retraction. Lancet, i:1199-1201. 1939.

28) 最上平太郎:血餅凝縮に関する研究. 大阪医学雑誌, 10:1961-1973, 1958.

29) Fonio, A. B.:Uber die dritte Phase der Blutgerinnung und Uber die Funktion der Strukturelemente der Trombozyten. Erg. inn. Med. u. Kinderh. N. F., 4:1-51, 1953.

30) Stefanini, M., Dameshek, W.:The Hemorrhagic Disorders, 2nd Ed. New York, London:Grune and Stratton, 1962. P. 474-475.

31) Rumpel, T.:Hautblutungen bei scarlach, Muncher Med. Wchnschr., 56:1404-1410, 1909.

32) Stefanini, M., Dameshek, W.:The Hemorrhagic Disorders. 2nd Ed., New York, London:Grune and Stratton, 1962. P. 468-469.

33) 加藤勝治:血液学研究法. 東京:南山堂, 1948. p. 166.

34) 浮田実:凝固検査に必要な準備. 臨床病理, 14:165-170, 1966.

35) Lee, R. I., White, P. D.:A clinical study of the coagulation time of blood. Am. J. Med. Sci., 145:495-503, 1913.

36) 福井弘, 神末光隆:凝固時間. 臨床病理, 14:171-180, 1966.

37) 臨床病理学会血液検査室医師会議:血液検査室における標準方式 (1). 臨床病理, 14:196-197, 1966.

38) 山中學:正常値, 2版. 東京:医学書院, 1973. p. 87-91.

39) 梅垣健三:全血凝固時間. medicina, 12:498-499, 1975.

40) 梅垣健三:正常値, 2版. 東京:医学書院, 1973. p. 101-104.

41) Quick, A. J., et al.:A study of the coagulation defect in hemophilia and in jaundice. Am. J. Med. Sci., 190:501-511, 1935.

42) 安部英:日本血液学全書. 6-II. 術式. 東京:丸善, 1965. p. 774-780.

43) 山中學:プロトロンビン時間. 臨床病理, 14:181-186, 1966.

44) 臨床病理学会血液検査室医師会議:血液検査室における標準方式 (1). 臨床病理, 14:197-198, 1966.

45) 梅垣健三:プロトロンビン時間-その数値をどう読むか. 日本臨牀, 27:1000-1011, 1969.
Medical*Online

46) 安永幸二郎:プロトロンビン時間-その数値をどう読むか. 日本臨牀, 29:598-607, 1971.

47) 寺田秀夫:正常値, 2版. 東京:医学書院, 1973. p. 92-96.

48) Hougie, C., Twomey, J. J.:Haemophilia BM:a new type of factor-IX (deficiency. Lancet, i:698-700, 1967.
pubmed

49) Denson, K. W. E., et al.:An investigation of three patients with Christmas disease due to an abnormal type of factor IX. J. Clin. Path., 21:160-165, 1968.

50) Owren, P. A.:Thrombotest. A new method for controlling anticoagulant therapy. Lancet, ii:754-758, 1959.

51) Biggs, R., Douglas, A. S.:The thromboplastin generation test. J. Clin. Path., 6:23-29, 1953.

52) 梅垣健三:トロンボプラスチン生成試験. 日本臨牀, 22:1811-1818, 1964.
Medical*Online

53) 勝見乙平:トロンボプラスチン生成試験の標準化. 臨床病理, 14:187-193, 1966.

54) 山中學, 他:トロンボプラスチン形成試験における血小板とその代用物の作用態度について. 日本臨牀, 22:1818-1823, 1964.

55) 前川正, 他:Thromboplastin生成試験法-特に血小板及び組織のThromboplastic Activityの測定に関する検討. 日本臨牀, 22:1823-1827, 1964.

56) Hicks, N. D., Pitney, W. R.:A rapid screening test for disorders of thromboplastin generation. Brit. J. Haemat., 3:227-237, 1957.
pubmed

57) Langdell, R. D., et al.:Effect of antihemophilic factor on one-stage clotting tests. J. Lab, Clin. Med., 41:637-647, 1953.
pubmed

58) Rodman, N. F., et al.:Diagnosis and control of the hemophiloid states with the partial thromboplastin test. Am. J. Clin. Path., 29:525-538, 1958.

59) 藤巻道男, 他:部分トロンボプラスチン時間, PTT・KPTT測定法. 臨床検査, 10:313-318, 1966.

60) 梅垣健三, 吉矢久人:部分トロンボプラスチン時間の検討. 奈医誌, 20:515-521, 1969.

61) Margolis, J.:The kaolin clotting time. A rapid one-stage method for diagnosis of coagulation defects.. J. Clin. Path., 11:406-409, 1958.

62) Proctor, R. R., Rapaport, S. L:The partial thromboplastin time with kaolin. Am. J. Clin. Path., 36:212-219, 1961.

63) 梅垣健三:フィプロメーター. 臨床検査, 17:1341-1344, 1973.

64) 梅垣健三:自動測定によるPTT測定. 血液と脈管, 5:794-797, 1974.

65) 神前五郎, 田中健一:トロンベラストグラム. 綜合臨牀, 12:1058-1063, 1963.

66) 安部英:日本血液学全書. 6-II. 術式. 東京:丸善, 1965. p. 816-819.

67) Lorand. L., Dickenman, R. C.:Assay method for the "Fibrin-stabilizing Factor." Proc. Soc. Exp. Biol., 89:45-48, 1955.
pubmed

68) 松岡松三:出血性素因と血栓症. 東京:金原出版, 1969. p.128-129.

69) Hougie, C.:Hematology. MacGraw-Hill Book Comp., A Blakiston Publication, 1972. p.1412.

70) Stefanini, M., Dameshek, W.:The Hemorrhagic Disorders, 2nd Ed. New York, London:Grune and Stratton, 1962. p.505-506.

71) 福武勝博:日本血液学全書. 6-II. 術式. 東京:丸善, 1965. p.797-803.

P.364 掲載の参考文献

1) Hardisty, R. M., et al.:A one-stage factor VIII (antihemophilic globulin) assay and its use on venous and capillary plasma. Thromb. Diath. haemorrh., 7:215-229, 1962.
pubmed

2) Langdell, R. D., et al.:Effect of antihemophilic factor on one-stage clotting test. J. Lab. Clin. Med., 41:637-647, 1953.

3) Egeberg, O.:Assay of antihemophilic A, B and C factors by one-stage cephalin systems. Scand. J. Clin. Lab. Invest., 13:140-152, 1961.

4) Ratnoff, O. D., et al.:Some problems in the measurement of antihemophilic activity. The Hemo. philias, International Conference on Hemophilia, Washington D. C.:1963. (Briukhous, K. M. ed.), University of North Carolina Press, Chapel Hill. N. C. 3.

5) 藤巻道男, 他:第VII因子測定法の改良. 日血会誌, 31:15-22, 1968.

6) Pitney, W. R.:The assay of antihemophilic globulin in plasma. Brit. J. Haemat., 2:250-264, 1956.

7) Belgna, LL.:Asimple method for the assay of factor VIII. Blood, 5:637-645, 1960.

8) Laurell, C. B.:Electro immunoassay. Scand. J. Clin. Lad. Invest., 29 (Suppl. 124):21-37, 1972.

9) 神谷忠, 他:第VIII因子, 第IX因子. 臨床病理, 特集27号:100-116, 1976.

10) Zimmerman, T., Ratnoff, O., Littell, S.:Detection of carriers of classic hemophilia using an immunologic assay for antihemophilic factor (Factor VIII). J. Clin. Invest., 50:255-258, 1971.

11) Howard, M. A., et al.:Ristocetin a new tool in the investigation of platelet aggregation. Thromb. Diath. haemorrh., 26:362-369, 1971.
pubmed

12) Weiss, H. J., et al.:Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation-relationship to factor VIII procoagulant activity and antigen content. J. Clin. Invest., 52:2708-2716, 1973.

13) Allain, J. P., et al.:Platelets fixed with paraformaldehyde:a new reagent for assay of von Willebrand factor and platelet aggregating factor. J. Lab. Clin. Med., 85:318-328, 1975.
pubmed

14) Macfarlane, D. E. & Zucker, M. B.:A method for assaying von Willebrand factor (ristocetin cofactor). Thromb. Diath. haemorrh., 34:306-308, 1975.
pubmed

15) Olson, J. D., et al.:Ristocetin induced aggregation of gel filtered platelets. Blood, 42:1021, 1975.

16) Olson, J. D., et al.:Evaluation of ristocetin-Willebrand factor assay and ristocetin-induced pletelet aggregation. Am. J. Clin. Path., 63:210-218, 1975.

17) Rapaport, S. I., et al.:Relation between levels of plasma thromboplastin component and prothrombin time by the P & P and quick method in patients receiving warfarin. New Engl. J. Med., 267:125-130, 1962.

18) Biggs, R., et al.:The preparation and assay of a Christmas factor concentration and its use in the treatment of two patients. Brit. J. Haemat., 7:349-364, 1961.

19) 藤巻道男, 他:血漿因子の凝血学的検査-第1相-. 臨床病理, 特集16号:75-84, 1969.

20) Ness, P. M., et al.:A simple enzyme-immunoassay (EIA) test for factor VIII-related antigen (VIII agn). Thrombos. Haemostas. (Stuttg.), 42:848, 1979.

21) 奥田忠美, 福井弘, 他:Enzyme immunoassayによる第VIII因子関連抗原の測定. 臨床血液, 21:938-945, 1980.

22) 高宮脩, 他:Laurell法による第XII因子抗原の定量法. 血液と脈管, 11:26-29, 1980.

23) Waaler, B. A.:Contact activation in the intrinsic blood clotting system. Scand. J. Clin. Lab. Invest., 11 (Suppl. 37):1959.

24) Horowitz, N. I., et al.:Assay of plasma thromboplastin antecedent (PTA) with artifically depleted normal plasma. Blood, 22:35-43, 1963.

25) Rapaport, S. I., et al.:A simple specific one-stage assay for plasma thromboplastin antecedent activity. J. Lab. Clin. Med., 57:771, 1961.
pubmed

26) Loeliger, E. A., et al.:Coaguiation studies in a case of Hageman trait. Thromb. Diath. haemat., 5:187-194, 1960.

27) Niewiarowski, S., et al.:Studies on the adsorption and activation of the Hageman factor (factor XII) by collagen and elastin. Thromb. Diath. haemorrh., 14:387-400, 1965.
pubmed

28) 神谷忠, 他:第VIII因子, 第IX因子. 臨床病理, 27:100-116, 1976.

29) 伊藤正一, 他:血友病保因者検出に関する研究, とくに免疫学的凝固因子測定を中心として. 臨床血液, 16:216, 1975.

30) Bertina, R. M.:Genetic variants of factor IX. Haemophilia. Based on symposia held during the XIIIth Congress of the World Federation of Haemophilia, Castle House Publications Ltd., 1981.

31) Hougie, C., et al.:Haemophilia BM:A new type of factor-IX deficiency. Lancet, i:698-700, 1967.
pubmed

32) 福井弘:血友病の臨床病理. 立山シンポジウム1 凝固・線溶・血小板研究-基礎と臨床. 東京:宇宙堂八木書店, 1982.P.64.

33) Orstavik, K. H., et al.:Electroimmunoassay of factor IX in hemophilia B. Thrombosis Res., 7:373, 1975.

34) 碇久雄:血友病B保因者の第IX因子. 奈良医大雑誌, 80:655-662, 1969.

35) Elodi, S.:Variants of hemophilia B. Thromb. Diath. Haemorrh., 28:489-495, 1972.
pubmed

36) Thompson, A. R.:Factor IX antigen by radioimmunoassay in heterozygotes for hemophilia B. Thromb. Res., 11:193-203, 1977.
pubmed

37) Peake, I. R., Bloom, A. L.:Immunoradiometric assay of procoagulant factor-VIII antigen in plasma and serum and its reduction in hemophilia. Lancet, i:473-475, 1978.
pubmed

38) Peake, I. R., Bloom, A. L., et al.:An immuoradiometric assay for procoagulant factor VIII antigen:Results in hemophilia, von Willebrand's disease and fetal plasma and serum. Brit. J. Haemat., 42:269-281, 1979.
pubmed

39) Hathaway, W. E., et al.:Evidence for a new plasma thromboplastin factor. I. Case report, coagulation studies and physicochemical properties. Blood, 26:251, 1965.

40) Saito, H., et al.:Fletcher factor activity in plasmas of various species. Proc. Soc. Exp. Biol. Med., 147:519, 1974.
pubmed

41) Colman, R. W., et al.:The kallikreinogen-kallikrein enzyme system of human plasma. Ann. Int. Med., 71:763-773, 1969.
pubmed

42) 真木正博:血漿カリクレイン, その測定とDICとの関連について. 医用酵素, 3:4-12, 1978.

43) 千葉陽一, 他:血漿カリクレイン系因子測定の臨床的意義. 臨床血液, 19:214-220, 1978.

44) Amundsen, E., et al.:Activation of human plasma prekallikrein. Influence of activators, activation time and temperature and inhibitors. Thrombos. Res., 13:625-636, 1978.

45) 中村節子, 他:発色性ペプチド基質による血漿プレカリクレイン測定法の検討. 臨床病理, 28:670-674, 1980.
Medical*Online

46) Saito, H. and Poon, M. C.:Radioimmunoassay for a human plasma prekallikrein (Fletcher factor). Fed. Proc., 36:329, 1977.

47) Saito, H., et al.:Human plasma prekallikrein (Fletcher factor) clotting activity and antigen in health and disease. J. Lab. Clin. Med., 92:84-95, 1977.

48) Saito, H., et al.:Fitzgerald factor (high molecular weight kininogen) clotting activity in human plasma in health and disease in various animal plasmas. Blood, 48:941, 1976.
pubmed

49) 斉藤英彦:接触因子に関する進歩. Fletcher因子およびFitzgerald因子をめぐって. 臨床検査, 20:31, 1977.

50) Ueno, A., Ohishi, S., et al.:Enzyme immunoassay of bradykinin using β-D-galactosidase as a labeling enzyme. Biochem. Pharmacol, 30:1659, 1981.

51) Mancini, G., et al.:Immunochemical quantitation of antigens by single radial diffusion. Immunochem., 2:235, 1965.

52) Kasper, C. K., Osterud, B., Minami, J. Y., et al.:Hemophilia B:Characterization of genetic variants and detection of carriers. Blood, 50:351, 1977.
pubmed

53) Reisner, H. M., Barrow, E. S., Graham, J. B.:Radioimmunoassay for coagulant factor VIII-related antigen (VIII:CAg). Thromb. Res., 14:235, 1979.
pubmed

P.379 掲載の参考文献

1) Quick, A. J.:The prothrombin in hemophilia and in obstructive jaundice. J. Biol. Chem., 109:1xxiii, 1935.

2) 寺田秀夫:プロトロンビン時間. 正常値 (小酒井望, 阿部正和, 編集), 2版. 東京:医学書院, 1973. P.92-96.

3) 松岡松三, 櫻川信男:プロトンビン時間. Medicina, 12:500-501, 1975.

4) 山中學:プロトロンビン時間. 臨床病理, 14:181-186, 1966.

5) 松岡松三, 他:Hepaplastin test (HPT) に関する基礎的ならびに臨床的研究血液と脈管, 4:1181-1200, 1973.

6) Owren, P. A.:Thrombotest. A new method for controlling anticoagulant therapy. Lancet, ii:754-758, 1959.

7) Owren, P. A.:The interrelationship between normotest and thrombotest. Farmakotherapi, 25:1-63, 1969.

8) 松岡松三, 塚田恒安:プロトロンビン時間, トロンボテスト. 正常値と異常値の間 (日野原重明, 河合忠, 編集), 東京:中外医学社, 1972. p.187-193.

9) Ware, A. G., Stragnell, R.:An improved one stage prothrombin method. Amer. J. Clin. Path., 22:791-797, 1952.

10) Owren, P. A., Aas, K.:The control of dicumarol therapy and the quantitative datermination of prothrombin and proconvertin. Scand. J. Clin. Lab. Invest., 3:201-208, 1951.
pubmed

11) 櫻川信男:血管内凝固症候群の病態生理. 内科学会雑誌, 掲載予定,

12) Stenflo, J., et al.:Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc. Natl. Acad, Sci., 71:2730-2733, 1974.
pubmed

13) Hemker, H. C., et al.:Demonstration of three proteins induced by vitamin K absence (PIVKAs). Thrombos. Diathes. haemorrh (Suppl.), LIX:45-52, 1974.

14) Seegers, W. H., et al.:Isolation and some properties of thrombin-E and other prothrombin derivatives. Thrombosis. Res., 4:829-860, 1974.

15) 松岡松三, 櫻川信男:蛇毒 (Echis carinatus venom) を用いたプロトロンビン測定法. 最新医学, 掲載予定.

16) Laki, K.:The polymerization of protein:the action of thrombin on fibrinogen. Arch. Biochem. Biophys., 32:317-324, 1951.
pubmed

17) 松岡松三:血液凝固検査, 2版. 東京:金原出版, 1965. p. 125-129.

18) 鈴木弘文:凝血検査における免疫学的手技の応用. 臨床病理, 16:135-142, 1970.

19) 松本光民, 他:アフィニティクロマトグラフィーによるプロトロンビンの抽出法. 第37回日本血液学会総会にて発表.

20) 櫻川信男:血栓形成における凝固因子の意義. (1) トロンビン. 興和医報, 特集「血栓症」.

21) Ware, A. G., Seegers, W. H.:Two stage procedure for the quantitative determination of prothrombin concentration. Amer. J. Clin. Path., 19:471-482, 1949.

22) 松岡松三, 櫻川信男:プロトロンビンニ段測定法の検討. 綜合臨牀.

23) Latallo, Z. S.:Thrombin Clotting Assays (Bang, N. V., et al. eds.), New York:Academic Press, 1971. p.183-186.

24) 櫻川信男, 小出武比古:トロンビンの凝固線溶および血小板へおよぼす影響ならびにその生化学的性状. 新潟医学会雑誌, 89:91-100, 1975.

25) Sirridge, M. S.:Laboratory Evaluation of Haematology. Philadelphia:Lee & Febiger, 1974. p. 145-148.

26) Seegers, W. H.:Prothrombin. Cambridge, Massachusetts, Harvard University Press, 1962. p. 410-414.

P.391 掲載の参考文献

1) 松田道生:出血・凝固検査法, 特にスクリーニング検査. 臨床検査, 18:1475-1480, 1974

2) Ratnoff, O. D. and Menzie, C.:New method for determination of fibrinogen in small samples of plasma. J. Lab. Clin. Med., 37:316, 1951.
pubmed

3) Lowry, O. H., Rosebrough, N. J., Farr, A. L. and Randall, R. J.:Protein measurement with the Folin reagent. J. Biol. Chem., 193:265, 1951.
pubmed

4) Huseby, R. M. and Bang, N. U.:Fibrinogen in Thrombosis and Bleeding Disorders (Bang, N. U., Beller, F. K., Deutsch, E. and Mammen, E. F. ed.), Stuttgart:Georg Thieme Verlag, New York, London:Academice Press, 1972. p. 236.

5) Fowell, A. H.:Turbidimetric method for fibrinogen assay. Amer. J. Clin. Path., 25:340, 1955.

6) Clauss, A.:Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haemat., 17:237, 1957.
pubmed

7) 副島正美, 菅原潔:紫外部吸収スペクトル法 (UV法) 蛋白質の定量法, 生物化学実験法, A.一般分析法3 (瓜谷郁三, 志村憲助, 中村道徳, 船津勝, 編), 東京:東京大学出版会, 1969. p. 104-109.

8) Laki, K.:The polymerization of proteins:the action of thrombin on fibrinogen. Arch. Biochem. Biophys., 32:317, 1951.
pubmed

9) Blomback, B. and Blomback, M.:Purification of human and bovine fibrinogen. Arkiv. Kemi., 10:415, 1956.

10) Castelan, D. J., Hirsh, J. and Martin, M.:Latex-bound antifibrinogen test for plasma fibrinogen assay. J. Clin. Path., 21:638-642, 1968.
pubmed

11) Merskay, C. L., Lalezari, P. and Johnson, A.:A rapid, simple sensitive method for measuring fibrinolytic split products in human serum. Soc. Exper. Biol. (N. Y.), 131:871, 1969.

12) 藤巻道男, 池松正次郎, 竹内泉:FDPの検出法と臨床的意義. 日本臨牀, 31:798, 1973.
Medical*Online

13) Mancini, G., Carbonara, A. O. and Heremens, J.:Immunological quantitation of antigen by single radial immunodiffusion. Immunochemistry, 2:235, 1965.

14) Beock, E. A.:Abnormal fibrinogen (fibringen "Baltimore" ) as a cause of a familial hemorrhagic disorder. Blood, 24:853, 1964.

15) Mammen, E. F., Prasad, A. S. and Barnhart, M.:Congenital dysfibrinogenemia:Fibrinogen Detroit. J. Clin. Invest., 48:235, 1969.
pubmed

16) Beck, E. A.:Congenital variants of human fibrinogen. Fibrinogen (Laki, K. ed.), New York:Dekker M., Inc., 1968. p. 269.

17) Menache, D.:Abnormal fibrinogens. A review. Thromb. Diath. Haemorrh. (Stuttg.), 29:525, 1973.

18) Gralnick, H. R., Coller, B. S., Fratantoni, J. C. and Martinez, J.:Fibrinogen Bethesda III:A hypodysfibrinogenemia. Blood, 53:28, 1979.

19) Egeberg, O.:Inherited abnormality causing thrombophilia. Thromb. Diath. Haemorrh., 17:176, 1967.
pubmed

20) Hampton, J. W.:Qualitative fibrinogen defect associated with abnormal fibrin stabilization. J. Lab. Clin. Med., 72:882, 1968.

21) Martinez, J., Holburn, R. R., Shapiro, S. S. and Erslev, A. J.:Fibrinogen Philadelphia:A hereditary hypofibrinogenemia characterized by fibrinogen hypercatabolism. J. Clin. Invest., 53:600, 1974.
pubmed

22) Funck, C. and Straub, P. W.:Hereditary abnormality of fibrin monomer aggregation (Fibrinogen Zurich II). Eur. J. Clin. Invest., 1:131, 1970.

23) Krause, W. H., Heene, D. L. and Lasch, H. G.:Congenital dysfibrinogenemia (Fibrinogen Giessen). Thromb. Diath. Haemorrh., 29:547, 1973.
pubmed

24) Mammen, E. F., Prasad, A. S., Barnhart, M. I. and Au, C. C.:Congenital dysfibrinogenemia:Fibrinogen Detroit. J. Clin. Invest., 48:235, 1969.
pubmed

25) Funck, C., Stocker, K. and Straub, P. W.:Reptilase in diagnosis and evaluation of dysfibrinogemia with observation in a new fibrinogen variant. Abstr. of 13 th Internat. Congr. Hematology, Munich, 1970. Aug.

26) Forman, W. B., Ratnoff, O. D. and Boyer, M. H.:An inherited qualitative abnormality in plasma fibrinogen:Fibrinogen Cleveland. J. Lab. Clin. Med., 72:455, 1968.

27) von Felten, A. F., Duckert, F. and Frick, P.:Gerinnungsstorung ohne hamorrhagische Diathese infolge verzogerter Aggregation der Fibrinmolekule. Schweizerische Medizinische Wochenschrift., 95:1453, 1965.

28) Jacobsen, C. D. and Hoak, J. C.:Fibrinogen Iowa city:an abnormal fibrinogen with no clinical symptoms. Thrombosis Research, 2:261, 1973.

29) Jackson, D. P. and Beck, E. A.:Inherited abnormal fibrinogens. Hemophilia and New Hemorrhagic States (Brinkhous, K. M. ed.), Chapel Hill:University of North Carolina Press, 1970. p. 225.

30) Gralnick, H. R., Givelber, H. M. and Finlayson, J. S.:A new congenital abnormality of human fibrinogen, Fibrinogen Bethesda II. Thromb. Diath. Haemorrh., 29:562, 1973.
pubmed

31) Jansen, C. L. and Vreeken, J.:Fibrinogen Amsterdam, another hereditary abnormality of fibrinogen. Brit. J. Haematol., 20:287, 1971.

32) Soria, J., Soria, C., Samama, M., Poirot, E. and Kling, C.:Fibrinogen Troyes-fibrinogen Metz:two new cases of congenital dysfibrinogenemia. Thromb. Diath. Haemorrh., 27:619, 1972.
pubmed

33) Nossel, H. L., Yudelman, I., Canfield, R. E., Butler, Jr. V. P., Spanondis, K., Wilner, G. D. and Qureshi, G. D.:Measurement of fibrinopeptide A in human blood. J. Clin. Invest., 54:43, 1974.

34) Bilezikian, S. B., Nossel, H. L., Butler, Jr., V. P. and Canfield, R. E.:Radioimmunoassay of human fibrinopeptide B and kinetics of fibrinopeptide cleavage by different enzymes. J. Clin. Invest., 56:438, 1975.

35) Mosesson, M. W. and Beck, E. A.:Chromatographic, ultracentrifugal, and related studies of fibrinogen "Baltimore". J. Clin. Invest., 48:1656, 1969.

36) Streiff, F., Alexandre, P., Vigneron, C., Soria, J., Soria, C. and Mester, L.:A new case of dysfibrinogenemia:The fibrinogen "Nancy", 2nd Congress of the International Society on Thrombosis and Haemostasis. Oslo, Norway, Abstr. 1971. p. 60.

37) Menache, D.:Congenital and familial abnormal fibrinogen. Thromb. Diath. Haemorrh. Suppl., 13:173, 1964.

38) Samama, M., Soria, J., Soria, C. and Bousser, J.:Congenital and familial dysfibrinogenemia with-out bleeding tendency. Abstracts of simultaneous sessions of 12th Congress of the International Society of Haematology, New York, 1968. p. 179.

39) Blomback, M., Blomback, B., Mammen, E. F. and Prasad, A. S.:Fibrinogen Detroit, a molecular defect in the N terminal disulfide knot of human fibrinogen. Nature, 218:134, 1968.

40) Higgins, D. L. and Shafer, J. A.:Fibrinogen Petoskey, a dysfibrinogenemia characterized by replacement of Arg-Aα 16 by a histidyl residue. J. Biol Chem., 256:12013, 1981.

41) Krause, W. H., Heene, D. L. and Lasch, H. G.:Congenital dysfibrinogenemia (Fibrinogen Giessen). Thromb. Diath. Haemorrh., 29:547, 1973.
pubmed

P.407 掲載の参考文献

1) 森邦雄, 他:Factor XIIIの血中動態並びに各種血液生化学成分との関連について. 血液と脈管, 9:575-579, 1978.

2) Yamada, K. and Yamada, Z.:Active and potentially active forms of fibrin stabilizing factor (Factor XIII) in various disorders and in neonatal infants. Keio J. Med., 17:125, 1968.

3) Ambrus, C. M., et al.:Changes in fibrin-stabilizing factor levels in relation to maternal hemorrhage and neonatal disease. Pediat. Res., 4:82, 1970.
pubmed

4) Losowsky, M. S. and Walls, W. B.:Abnormal fibrin stabilization in renal failure. Thromb. Diath. Haemorrh., 22:216, 1969.

5) Melissinos, K., et al.:Le facteur XIII au cours de l'insuffisiance renal, Etude de 96 malades. Coagulation., 4:209, 1971.

6) lll辺英彰, 他:腎疾患におけるXIII因子について. 医学のあゆみ, 110:485-487, 1979.

7) 上辻秀和, 他:小児腎疾患におけるフィブリノゲン (フィブリン), 第VIII, XIII因子の動態. 日腎会誌, 22:23-39, 1980.

8) Egbring, R., et al.:Factor XIII deficiency in various patients with acute leukemia. Verh. Dtsch. Gell. Inn. Med., 77:97, 1971.

9) Rodeghiero, F., Barbui, T., Battista, R., et al.:Molecular subunit and transamidase activity of factor XIII during disseminated intravascular coagulation in acute leukemia. Thromb. Haemost., 43:6-9, 1980.
pubmed

10) Hedner, U., et al.:F. XIII in a clinical material. Scand. J. Haematol., 14:114, 1975.

11) Mandel, E. E. and Gehold, W. M.:Plasma fibrin-stabilizing factor acquired deficiency ill various disorders. Amer. J. Clin. Path., 52:547, 1969.

12) Kloczko, J., Zuch, A., Bielawiec, M. and Buluk, K.:Factor XIII (FSF-fibrin stabilizing factor) in pathological states with thrombin generation. Hematologica, 65:629-635, 1980.

13) Yoshioka, K., Miyata, H. and Maki, S.:Significance of decreased factor XIII in Henoch Schonlein purpura. Acta Pediatr. Jpn., 22:51-55, 1980.

14) Walls, W. D. and Losowsky, M. S.:Plasma fibrin stabilizing factor (FSF) activity in normal subjects and patients with chronic liver disease. Thromb. Diath. Haemorrh., 21:134, 1969.
pubmed

15) Nussbaum, M. and Morse, B. S.:Plasma fibrin stabilizing factor activity in various diseases. Blood, 23:669, 1964.
pubmed

16) Ratnoff, O. D.:The hemostatic defects of liver disease. Hemostasis, Biochemistry, Pathology, Physiology (Ogston, D. and Beunett, B., eds.), N. Y.:Wiley, 1977. p. 446.

17) Biland, L., Duckert, F., Prisender, S. and Nyman, D.:Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen. Thromb. Haemost., 39:646-656, 1978.
pubmed

18) Gierhake, F. W.:Faktor-XIII-Konzentration und Wundheilung. Dtsch. Med. Wschr., 95:1472, 1970.
pubmed

19) 松田道生:創傷治癒と第XIII因子, シンポジウム第XIII因子をめぐる諸問題. 日血会誌, 40:995-1002, 1977.

20) 毛利喜久男, 他:外科領域におけるファクターXIII欠乏症候と創傷治癒. 現代の診療, 20:137-152, 1978.

21) Kidess, E., Miller, H., Preisner, A. and Briel, R.:Factor XIII levels in relation to gynaecological operations. Arch. Gynaecol., 227:163, 1979.

22) Baer, U., Bauknecht, J., Stangl, Th. and Haering, R.:Verminderung von Wundheilungsstorungen durch preoder postoperative quantitative Faktor. XIII-Substitution. Zentralbl. Chir., 105:642-651, 1980.

23) Cucuianu, M. P., et al.:Clinical studies concerning Factor XIII; with special reference to hyperlipemia. Thromb. Diath. Haemorrh., 30:480, 1973.

24) 浦山功:XIII因子, 日本臨牀, 32:915, 1974.
Medical*Online

25) 呉光雄:糖尿病性網膜症における血液凝固第XIII因子に関する研究 (第2報). 糖尿病, 20:1051-1055, 1979.

26) 作田茂, 佐藤敬, 他:脳血管障害後遺症患者血漿における第XIII因子濃度. 血液と脈管, 10:180-185, 1979.

27) Loewy, A. G., et al.:Fibrinase. I. Purification of substrate and enzyme. J. Biol. Chem., 236:2625, 1961.
pubmed

28) Tyler, H. M. and Laki, K.:Fibrin clot stabilizing enzyme from guinea pig liver. Biochem. Biophys. Res. Commun., 24:506, 1966.
pubmed

29) 山田兼雄, 他:小児期におけるFibrin stabilizing factor (第XIII因子) の検討. 臨床血液, 9:22, 1968.

30) Stefani, M., et al.:Deficiency of fibrin stabilizing factor:report of a case, probably congenital, with observations on the effects of treatment with-aminocaproic acid and with prednisolone. Am. J. Clin. Path., 57:364, 1972.

31) 福井弘, 他:先天性第XIII因子 (fibrin stabilizing factor) 欠乏症の3症例. 臨床血液, 15:191, 1974.

32) Lorand, L. and Jacobson, A.:Studies on the polymerization of fibrin. The role of the globulin:fibrin stabilizing factor. J. Biol. Chem., 230:421, 1958.

33) MeDonagh, R. P., et al.:The influence of fibrin cross linking on the kinetics of urokinase-induced clotlysis. Brit. J. Haematol., 21:323, 1971.

34) Swigert, S., et al.:Selective inactivation of fibrin stabilizing factor contaminant in fibrinogen. Nature, 198:797, 1963.
pubmed

35) Lorand, L. and Bickenman, R. C.:Assay Inethod for the "fibrin-stabilizing factor". Analyt. Biochem., 15:45, 1966.

36) Finlayson, J. and Mosesson, M. W.:Heterogeneity of human firinogen. Biochemistry, 2:42, 1963.

37) Inoshita, K. and Shanberge, J. N.:A rapid quantitative assay method for fibrinstabilizing factor (Factor XIII). Am. J. Clin. Path., 61:85, 1974.
pubmed

38) Schwartz, M. L, et al. The effect of fibrin-stabilizing facfor in the subunit structure of human fibrin. J. Clin. Invest., 50:1506-1513, 1971.
pubmed

39) Bohn, H. and Haupt, H.:Eine quantitative Bestimlnung von Faktor XIII mit Anti-Faktor. XIII-Serum. Thromb. Diath. Haemorrh., 19:309, 1968.

40) Becker, W., et al.:Die immunologische Bestimmung des Faktor-XIII. Thromb. Diath. Haemorrh. 34:15, 1969.

41) 浮田実, 他:第XIII因子活性とフィブリン塊溶解試験について. 日血会誌, 40:963-968, 1977.

42) Lorand, L., et al.:Diagnostic and genetic studies on fibrin stabilizing factor with a new assay based on amine incorporation. J. Clin. Invest., 48:1054, 1969.
pubmed

43) 浦山功:フィブリン安定化因子の螢光学的測定. 日血会誌, 33:684, 1970.

44) Henrikson, P., et al.:Fibrin stabilizing factor (Factor XIII) in the fetus and newborn infant. Pediatr. Res., 879, 1974.

45) Cooke, R. S., et al.:Calcium and the assays of human plasma clotting Factor XIII. Biochem. J., 141:71, 1974.

46) 高橋芳右, 他:Dansylcadaverine incorporation法による血漿第XIII因子活性測定法の基礎的検討. 日血会誌, 42:516-524, 1979.

47) 小川和夫, 馬場節子, 他:ゲル濾過を利用した血漿第XIII因子の活性測定法, 投稿中.

48) 浦山功:XIII因子測定法の変遷. 医用酵素, 1:788-791, 1976.

49) 西村昇, 浦山功, 他:XIII因子のspot定量法および正常値. 医用酵素, 1:759-764, 1975.

50) Carlebjork, G.:A precise routine method for detemination of FXIII activity in plasma. Thromb. Res., 21:507-511, 1981.

51) Yamada, K. and Meguro, T.:A new assay method for factor XIII using a fluorescence polarization analyzer, based on change in the rotary brownian motion. Thromb. Res., 11:557-566, 1977.

52) Dvilanski, A., et al.:Factor XIII assay by an isotope method. Brit. J. Haematol., 18:399, 1970.

53) Lorand, L., et al.:A filter paper assay for transamidating enzymes using radioactive amine substrates. Anal. Biochem., 50:623, 1972.
pubmed

54) Egbring, R., et al.:Die vereinfachte radiologische Faktor-XIII-Bestimmung und ihre klinische Anwendung bei kongenitalem Faktor-XIII-Mangel. Blut, 27:6, 1973.
pubmed

55) Schmer, G.:A solid-phase radioassay for Factor-XIII activity (Fibrin stabilizing factor) in human plasma. Brit. J. Haematol., 24:735, 1973.

56) Nelson, J. C. and Lerner, R. G.:Detection of Factor XIIIa (active fibrin stabilizing factor) in normal plasma. Blood, 52:581-591, 1978.
pubmed

57) Curtis, C. G. and Lorand, L.:Fibrin-Stabilizing Factor (Factor XIII), Methods in Enzymology, Vol. XLV, Proteolytic Enzymes, Part B (Lorand, L., ed), N. Y.:Academic Press, 1976. p. 177.

58) Lorand, L., et al.:Thioester substrates for transamidating enzymes:studies on fibrinoligase. Proc. Natl. Acad. Sci., 69:2645, 1972.

59) Curtis, C. G., et al.:Titration and subunit localization of active center cysteine in fibrinoligase (thrombin-activated fibrin stabilizing factor). Biochem. Biophys. Res. Commun., 52:51, 1973.
pubmed

60) 吉峯徳, 他:Factor XIII (F. XIII) の定量に関する検討と2, 3病態における変動について. 血液と脈管, 9:116-120, 1978.

61) Laurell, C.-B.:Electroimmunoassay. Scand. J. Clin. Lab. Invest., 29 (Suppl. 124):21, 1972.

62) Bohn, H., et al.:Die moekulare struktur der fibrin-stabilisierenden Faktoren des Menschen. Blut, 26:303, 1973.
pubmed

63) Bohn, H.:Immunologische Untersuchungen uber Faktor XIII und des FSF-bindende Globulin. Blut, 18:81, 1974.

64) Barbui, T., et al.:Electroimmunoassay of plasma subunit-A and-S in a case offibrin stabilizing factor deficiency. Thromb. Diath. Haemorrh., 32:124, 1974.

65) 藤巻道男, 他:凝固因子の免疫学的測定 (2) II因子, VIII因子, IX因子, XIII因子. Immunohematology, 2:235-244, 1980.

66) 安部英, 風間睦美, 他:Factor XIII subunits法の同時分析泳動法とその臨床的応用. 血液と脈管, 8:622-627, 1977.

67) Francis, J. L.:The detection and measurement of factor XIII activity. A review. Med. Lab. Sci., 37:137-147, 1980.
pubmed

68) Sovia, J., Sovia, C. and Lafay, Ph.:Evaluation du facteur XIII de la coagulation. Pathol. Biol., 28:313-317, 1980.

69) Lopaciuk, S., Bykowska, K., McDonagh, J. M., et al.:Differences between type I autoimmune inhibitors of fibrin stabilization in two patients with severe hemorrhagic disorders. J. Clin. Invest., 61:1196-1203, 1978,

70) Godal, H. C., Ly, B.:An inhibitor of activated factor XIII inhibiting fibrin crosslinking but not incorporation of amine into casein. Scand. J. Haematol., 19:443-448, 1977.
pubmed

71) Lorand, L, Losowsky, M. S. and Miloszewski, K. J. M.:Human Factor XIII:Fibrin-stabilizing factor. Progress in Hemostasis and Thrombosis, Vol. 5 (Spaet, T. H., ed.), N. Y.:Grune & Stratton, p. 245.

P.425 掲載の参考文献

1) 松岡松三, 品田章二:血液凝固F:凝固亢進状態. 日本血液学全書13, 丸善, 1979. p. 486-490.

2) Kingdon, H. S., Lundblad, R. L., Veltkamp, J. J. and Aronson, D. L:Potentially thrombogenic materials in factor IX concentrates. Thromb. Diath. haemorrh (Stuttg), 33:617-631, 1975.

3) Speer, R. G. and Ridgway, H.:The formation and decay of XIII. Thromb. Diath. haemorrh., 18:259-267, 1967.

4) 松岡正三, 神保長三, 渡辺透:血液中にて活性化されている接触因子の測定法. 内科, 29:421-426, 1972.

5) Vinazzer, H.:Assay of total factor XIII and of activated factor XIIIin plasma with a chromogenic substrate. Thromb. Res., 14:155-166, 1979.

6) Vinazzer, H.:Diagnosis of intravascular coagulation by assays of activated factor X and XII with chromogenics substrate. Haematologica, 65:636-643, 1980.

7) Elodi, S. and Varadi, K.:Activation of clotting factors in prothrombin complex concentrates as demonstrated by clotting assays for factor IXa Xa and Xa. Thromb. Res., 12:797-807, 1978.
pubmed

8) Osterud, B. and Rapaport, S. I,:Activation of factor IX by the reaction product of tissue factor and factor VII:Additional pathway for initiating blood coagulation. Proc. Natl Acad. Sci. USA, 74:5260-5264, 1977.
pubmed

9) Thompson, A. R. and Davie, E. W.:Affinity chromatography of thrombin. Biochim. Biophys. Acta, 250:210-215, 1971.
pubmed

10) Fujikawa, K., Thompson, A. R., Legaz, M. E., Meyer, R. G. and Davie, E. W.:Isolation and characterization of bovine factor IX (Christmas factor). Biochemistry, 12:4938-4945, 1973.
pubmed

11) Holmberg, L. and Ljung, R.:Purification of F. VIII:C by antigen-antibody chromatography. Thromb. Res., 12:667-675, 1978.
pubmed

12) Osterud, B. and Flengsrud, R.:Purification and some characteristic of the coagulation factor IX from human plasma. Biochem. J., 145:469-474, 1975.
pubmed

13) Schiffman, S. I., Rapaport, SI. and Theodor, I.:Separation from Russell's viper venom of one fraction reacting with factor X and another reacting with factor V. Biochemistry (Wash.), 8:1397-1405, 1969.
pubmed

14) 櫻川信男:第V因子, 第VII因子, 第X因子, 実践止血凝固学-血小板・血液凝固・線溶検査法-. 医歯薬出版, 1980. P. 128-138.

15) Seligsohn, U., Kasper, C. K., Osterud, B and Rapaport, S. I.:Activated factor VII:Presence in factor IX (concentrates and persistence in the circulation after infusion. Blood, 53:828-837, 1979.
pubmed

16) U. S. Department of Health, Education, and Welfare. NIH:Minimum requirements:Dried thrombin, 2nd Rev., 1946.

17) 浅井紀一:最近の血液凝固検査法, 第II因子 (プロトロンビン), トロンビン. 臨床病理, 特集27号:143-157, 1976.

18) 福武勝博, 鈴木弘文:血液凝固B;第II相および第III相・日本血液学全書13, 丸善, 1979・P. 369-413.

19) Svendsen, L, Blomback, B., Blomback, M. and Olsson, P. I.:Synthetic chromogenic substrates for determination of trypsin, thrombin and thrombin-like enzymes. Thromb. Res., 1:267-278, 1969.

20) 加藤正俊, 矢野容子, 藤巻道男:chromogenic substratesによる凝血学的検査法-トロンビンおよび血漿カリクレインの測定-. 循環器科, 6:289-294, 1979.

21) Gaffney, P. J., Lord, K., Brasher, M. and Kirkwood, T. B. L.:Problems in the assay of thrombin using synthetic peptides as substrates. Thromb. Res., 10:549-556, 1977.

22) Lorand, L, Urayama, T., Dekiewiet, J. W. C. and Nossel, H. L.:Diagnostic and genetic studies on fibrin-stabilizing factor with a new assay based on amine incorporation. J. Clin. Invest., 48:1054-1063, 1969.

23) Gallimore, M. J. and Friberger, P.:Simple chromogenic peptide substrate assay for determining prekallikrein, kallikrein inhibition and kallikrein "like" activity in human plasma. Thromb. Res., 25:293-298, 1982.
pubmed

P.441 掲載の参考文献

1) Gormsen, J.:A technique for the heparin tolerance test. Brit. J. Haemat., 5:259-267, 1959.

2) Arre, N. T. and Mette, L.:Evaluation of amidolytic heparin assay method in creased sensitivity by adding purified antithrombin III. Thromb. Res., 10:399-404, 1977.

3) Gary, A. M., Robert, J. G., Rolf, M. H., Daniel, E. L., Sharom, P. P. and Jaime, A. S.:Assay for plasma heparin using a synthetic peptide substrate for thrombin:Introduction of the fluorophore aminoisophthalic acid, dimethyl ester. Thromb. Res., 13:47～52, 1978.

4) Biggs, R.:Antithrombin III, Antifactor Xa and heparin cofactor. Brit. J. Haemat., 19:283-306, 1970.

5) Biggs, R.:Human Blood Coagulation, Haelnostasis and Thrombosis. Blackwell Sci. Publ., 1972. p. 643-645.

6) 目黒嵩, 山田兼雄, 他:Antithrombin (antithrombin III α2-macroglobulin) の免疫学的測定法. 臨床病理, 23:635-638, 1975.

7) 山田兼雄, 白幡聡, 他:新生児の血管内凝固症候群. 小児科臨床, 28:402-411, 1975.

8) Egeberg, O.:Inherited antithrombin deficiency causing thrombophilia. Thrombos. Diathes. haemorrh. (Stuttg.), 13:516, 1965.

9) van der Meer, J., Stoepman-von Dalen, E. A., et al.:Antithrombin-III deficiency in a Dutch family. J. Clin. Path., 26:532, 1973.

10) Marciniak, E., Farley, C. H., et al.:Familial thrombosis due to antithrombin III deficiency. Blood, 43:219-231, 1974.

11) von Kaulla, E., von Kaulla, K. N.:Oral contraceptives and low antithrombin-III activity. Lancet, i:36, 1970.
pubmed

12) Gjonnaess, H. and Fagerhol, M. K.:Plasma concentrations of anti-thrombin III in untreated and estrogen-treated puerperal women. Proceedings of the 2nd Congress of the International Society on Thrombosis and Haemostasis, Oslo, 1971. p. 20.

13) von Kaulla, E., von Kaulla, K. N.:Antithrombinin and diseases. Amer. J. Clin. Path., 48:69, 1967.

14) Schilnpf, K. L.:Klinik des Antithrombins. Thrombos. Diathes haemorrh. Suppl., 54:17-38, 1971.

15) 吉田信彦:アンチトロンビンIII (AT-III). 医学のあゆみ, 109:855, 1979.

16) 中村節子, 滝沢徳正, 中西一夫, 五十嵐紀子:発色性ペプチド基質を用いた血漿抗トロンビンIII測定の検討. 臨床病理, 28:81-86, 1980.

17) 藤沢宗駿, 小屋原伊一郎, 山崎一成, 難波脩一, 松田保, 村上元孝:ラテックス凝集法によるヒト血漿中のアンチトロビンIIIの測定. 日血誌, 43:898-906, 1980.

18) 高橋薫, 桜川信男, 堀江幸男, 他:Antithrombin III 異常症の一家系. 日血会誌, 44:1195, 1981.

19) Sherman, LA., Goldstein, M. A. and Sise, H. S.:Circulating anticoagulant (antifactor VIII) treated with immunosuppressive drug. Thromb. Diath. Haemorrh., 21:249-258, 1969.

20) Michael, J. J., Boach, L. J., Van del Plas, P. M., Abela, J.:Factor VIII inhibitor postpartum. Scand. J, Haemat., 20:97-107, 1978.

21) 雨宮章, 浜田宏, 日黒. 嵩, 山田兼雄:分娩により第VIII因子に対するインヒビターを認めた1症例. 臨床血液, 23:63-70, 1982.

22) Shapiro, S. S. and Hultin, M.:Acquired inhibitors to the blood coagulation factors. Semin. Thromb. Hemostasis, 1:336-385, 1975.

23) Shapiro, S. S.:Antibodies to blood coagulation. Clinics in Haematology, WB. Saunders, 8:207-214, 1979.

24) 昭和55年度厚生省心身障害研究, 小児慢性疾患研究班:小児慢性疾患 (内分泌, 代謝, 血液系) に関する研究. 1980. p. 200.

25) Hardisty, R. M., Macpherson, J. C., Ingram, G. I. C.:A one-stage factor VIII (anti-haemophilic globulin) assay and its use on venous and capillary plasma. Thromb. Diath. Haemorrh., 7:251, 1962.

26) Biggs, R., Bidwell, E.:A method for the study of antihaemophilic globulin inhibitors with reference to six cases. Brit. J. Haemat., 5:379-394, 1957.

27) Kasper, C. K., Aledort, LM., Caunts, P. B., et al.:A more uniform measurment of factor VIII inhibitors. Thromb. Diath. Haemorrh., 34:869-872, 1975.

P.467 掲載の参考文献

1) Stefanini, M., et al.:The Hemorrhagic Disorders. 2nd ed., New York:Grune & Stratton, 1962. p. 510.

2) Sherry, S., et al.:Studies on enhanced fibrinolytic activity in man. J. Clin. Invest., 38:810-822, 1959.

3) 藤巻道男, 他:線維素溶解現象. 臨床病理, 22:234-241, 1974.

4) 藤巻道男:血液検査 (三輪史朗, 編), 1版. 東京:医学書院, 1972. p. 516-525.

5) Astrup, J., et al.:Fibrin plate method for estimating fibrinolytic activity. Arch. Biochem., 40:346-351, 1952.

6) 五十嵐紀子, 他:アフィニティークロマトグラフィーを用いる線溶能の検査. 臨床検査, 17:713-722, 1973.

7) 藤巻道男, 他:合成ペプチド基質による測定法. 凝固線溶因子をめぐって (山中學, 編), メディコピア2. 東京:テクノ1980. p. 102-112.

8) 藤巻道男:血液凝固, 線溶における新しい検査法. 臨床病理, 30:44-53, 1982.
Medical*Online

9) Sherry, S., et al.:The action of plasma on synthetic substrates. J. Biol. Chem., 208:85-94, 1954.

10) Hedner, V., et al.:Determination of plasminogen in human by a case in method. Thromb. Diath. Haemorrh., 14:545-561, 1965.

11) Philip, S. N.:Measurement of an activator in human serum. J. Exp. Med., 106:423-437, 1967.

12) Johnson, A. J., et al.:Assay methods and standard preparations for plasmin, plasminogen and urokinase in purified systems. Thromb. Diath. Haemorrh., 21:259-272, 1969.
pubmed

13) Robbins, K. C., et al.:Human plasminogen and plasmin. Method in enzymology, 19:184-199, 1970.

14) 藤巻道男, 他:血液凝固因子. 微生物検査必携. 免疫血清反応検査. 日本公衆衛生協会, 1978 p. 364-356.

15) 藤巻道男, 他:実践止血凝固学-血小板・血液凝固・線溶検査法-. 医歯薬出版, 1980. p. 215-228.

16) 藤巻道男, 他:FDP. 血液・尿・化学検査. その数値をどう読むか. 日本臨牀, 春季増刊:729-736, 1980.

17) 藤巻道男, 他:FDPの免疫学的測定法. 臨床免疫, 6:557-565, 1974.

18) 藤巻道男, 他:線溶療法にともなう検査の実際. 医用酵素, 1:100-107, 1974.

19) Mersky, C., et al.:Quantitative estimation of split products of fibrinogen in human serum relation to diagnosis and treatment. Blood, 28:1-18, 1966.

20) Mersky, C., et al.:A rapid, simple., sensitive, method for measuring fibrinolytic split products in human serum. Proc. Soc. Exp. Biol. Med., 131:871-875, 1969.

21) Das, P. C.:Assay of serum fibrin degradation products by agglutination inhibition of coated erythrocytes. J. clin. Path., 23:299-303, 1970.
pubmed

22) 池松正次郎, 他:FDP分画の免疫学的定量法について. 医用酵素, 1:30-38, 1974.

23) 藤巻道男, 他:フィブリン体分解物 (FDP) の検査法と意義づけ. モダンメディア, 19:584-593, 1973.

24) Allington, M. J., et al.:Detection of fibrin (ogen) degradation products by a latex clumping method. Scand. J. Haemat., 13:115-119, 1971.

25) Garrey, M. B., et al.:The detection of fibrinogen/fibrin degradation products by means of a new antibody coated latex particle. J. clin. Path., 25:680-682, 1972.

26) 池松正次郎, 他:FDP. 臨床病理, 特集27号:229-248, 1976.

27) 池松正次郎, 他:免疫電気泳動法によるFDPの検索. 第13回プラスミン研究報告集, 1973. p. 163-171.

28) 臼井美津子:免疫電気泳動法. 臨床病理, 特集11号:113-122, 1968.

29) 負仁田英明, 他:簡易かつ高感度な免疫学的測定法 counter immunoelectrophoresis について. ホルモンと臨床, 19:79-82, 1971.

30) Laurell, C. B.:Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Ann. Biochem., 15:45-52, 1966.

31) Marder, V., et al.:High molecular weight derivatives of human fibrinogen produced by plasmin (1) J. Biol. Clin., 244:2111-2119, 1969.

32) 緇莊和子, 他:SDSアガロースゲルを用いた二次元免疫電気泳動法によるFgDPとFDPの鑑別について. 血液と脈管, 13:183-190, 1982.

33) Hawiger, J., et al.:Measurement of fibrinogen and fibrin degradation products in serum by staphylococcal clumping test. J. Lab. Clin. Med., 73:93-108, 1970.

34) Allington, M. J.:Fibrinogen and fibrin degradation products and the clumping of staphylococci by serum. Brit. J. Haemat., 13:550-567, 1967.
pubmed

35) Lipinski, B., et al.:Detection of soluble test for fibrin monomer complex in blood by means of protamine sulfate test. Thromb. Diath. Haemorrh., 20:44-47, 1968.
pubmed

36) Sanfelippo, M. J., et al.:Protamine sulfate test for fibrin monomer. Am. J, Clin. Path., 56:166-169, 1971.

37) Niewiarowski, S., et al.:Laboratory identification of intravascular coagulation. J. Lab. Clin. Med., April:665-676, 1971.

38) Gurewich, V., et al.:The detection of fibrin degradation products. Application of serial dilution protamine sulfate (SDPS) test to fibrinolytic therapy. Thrombolytic Therapy. Stuttgart, New York:F. K. Schattaue, Verlag, 1971. p. 138-144.

39) 池松正次郎, 他:連続希釈硫酸プロタミン試験 (Serial Dilution Protamine Sulfate test:SDPS) によるFgDP, FDPの鑑別について. 血液と脈管, 7:141-145, 1976.

40) Hraeff, R., et al.:Estimation of soluble fibrin monomer complex by agarose gel filtration. Progress in chemical fibrinolysis and thrombosis. N. Y.:Reven Press, 1976.

41) Todd, A. S.:The histological localization of fibrinolysis activator. J. Path, Bact., 78:281, 1959.
pubmed

P.498 掲載の参考文献

1) Salzman, E. W.:Measurement of platelet adhesiveness. J. Lab. Clin. Med., 62:724, 1960.

2) 安永幸二郎:血小板粘着能, 最近の血液凝固検査法-新しい臨床検査法を中心として-. 臨床病理, 特集27号:1, 1976.

3) Hellem, A. J.:Platelet adhesiveness in von Willebrand's disease. A study with a new modification of the glass bead filter method. Scand. J. Haemat., 7:374, 1970.
pubmed

4) Hellem, A. J.:The adhesiveness of human platelet in vitro. Scand. J. Clin. Invest., 12 (Supple). 51:1, 1960.

5) 塚田理康, 他:血小板粘着能検査についての検討. 臨床病理, 20 (補):102, 1972.

6) 塚田理康, 他:ガラスビーズカラムによる血小板停滞能測定法の検討 (第2報). 採血後の時間経過および細分画採取法について. 臨床病理, 20 (補):97, 1974.

7) 田中隆一:血小板機能に関する研究, 特に血小板粘着能について. 日血会誌, 20:270, 1957.

8) Wright, H. P.:The adhesiveness of blood platelets in normal subjects with varing concentrations of anticoagulants. J. Path. Bacteriol., 53:255, 1941.

9) Moolten, S. E., Vroman, L.:The adhesiveness of blood platelets in thrombolism and hemorrhagic disorders. 1. Measurement of platelet adhesiveness by glass-wool filter. Amer. J. Clin. Path., 19:701, 1949.

10) Breddin, K.:Zur Messung der Thrombocytesadhesivitat. Thromb. Diath. Haemorrh., 12:269, 1964.
pubmed

11) Mason, R. G., Gilkey, J. M.:A simple test for quantitation of platelet adhesion to glass. Thromb. Diath. Haemorrh., 25:21, 1971.
pubmed

12) Baumgartner, H. R. and Handerschild, C.:Adhesion of platelets to subendothelium. Ann. N. Y. Acad. Sci., 201:22, 1972.

13) 稲垣稔, 山田兼雄:先天性血小板機能異常症-血小板・血管壁相互作用を中心として-. 臨床病理, 29:358, 1981.
Medical*Online

14) Borchgrevink, S. E.:A method for measuring platelet in vivo. Acta Med. Scand., 168:157, 1960.

15) 昭和48年度文部省科学研究班会議:「血小板機能検査標準化へのアプローチ」記録. 東京, 昭和48年2月.

16) Hardisty, R. M., Ingram, G. I. C.:Bleeding Disorders, Investigation and Management. Oxford:Blackwell Sci. 1965.

17) 寺田秀夫:血小板機能検査法. 臨床病理, 特集16号:48, 1969.

18) Jurgens, R., Nauman, W.:Klinische und experimentelle Untersuchungen uber Funktionen der Blutplattchen. Deutsch Arch. Klin. Med., 172:248, 1931.

19) 安西茂則:血小板の凝集について. 日血会誌, 9:68, 1946.

20) Sano, T., et al.:Platelet sensitivity to aggregation in normal and diseased groups. A method for assessment of platelet aggregability. Thromb. Diath. Haemorrh., 25:524, 1971.
pubmed

21) 佐野忠弘, 他:遠沈操作なしに微量検査で行える血小板凝集能測定の新法. 血液と脈管, 4:1305, 1973.

22) Born, G. V. R.:Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature, 194:927, 1962.

23) O'Brien, J. R.:Platelet aggregation. part II. Some results from a new method of study. J. Clin. Path., 15:452, 1962.

24) 安永幸二郎:凝固・線溶系に関する血液検査. 今日の医学, 41:15, 1970.

25) Charo, I. F., et al.:Interrelation of platelet aggregation and secretion. J. Clin. Invest., 60:866, 1977.
pubmed

26) 安部英, 他:血小板凝集計測定曲線の分析と評価. 血液と脈管, 3:1478, 1972.

27) 山中學:血小板機能測定の問題点. 臨床検査, 12 (臨時増刊):937, 1968.

28) 磯部淳一, 他:血小板collagen凝. 集能測定に関する検討. 血液と脈管, 10:267, 1979.

29) 山中學:血小板凝集能. 臨床病理, 特集27号:15, 1976.

30) Yamazaki, H., et al.:Hyperaggregability of platelets in thromboembolic disorders. Thromb. Diath. Haemorrh., 34:94, 1975.
pubmed

31) 安永幸二郎, 他:血小板凝集検査の標準化へのアプローチ, 「血小板異常の病態に関する検査学的研究」. 昭和56年度科学研究総合 (A) 班会議記録, 京都, 昭和57年2月.

32) Biggs, R., Douglas, A. S.:The thromboplastin generation test. J. Clin. Path., 6:23, 1953.

33) Bonnin, J. A., Cheney, K.:The PTF test:an improved method for the estimation of platelet thromboplastic function. Brit. J. Haemat., 7:512, 1961.
pubmed

34) Ultin, O. N., Karaca, M.:A study of the pathogenesis of thrombopathy using the platelet osmoticresistance test. Brit. J. Maemat., 5:302, 1959.

35) Stefanini, M., Damshek, W.:The Hemorrhagic Disorders, 2nd ed., New York:Grune & Stratton, 1962. p. 463.

36) Hardisty, R. H., Hutton, R. A.:The kaolin colotting time of platelet rich plasma. A test of platelet factor-3 availability. Brit. J. Haemat., 11:258, 1965.

37) Spaet, T. H., Cintron, J.:Studies on platelet factor-3 availability. Brit. J. Haemat., 11:269, 1965.
pubmed

38) Horowitz, H. I., Papayoanou, M. F.:Activation of platelet factor-3 by adenosine 5 diphosphate. Thromb. Diath. Haemorrh., 19:18, 1968.

39) Weiss, H. J.:Platelet aggregation, adhesion and adenosine diphosphate release in thrombopathia (Platelet factor-3 deficiency). A comparison with Glanzman's thrombathenia and von Willebrand's disease. Amer. J. Med., 43:570, 1967.

40) Hardisty, R. M., Hutton, R. A.:Bleeding tendency associated with "new" abnormality of platelet behaviour. Lancet, i:983, 1967.
pubmed

41) Weiss, H. J., Rogers, J.:Thrombocytopathia due to abnormalities in platelet release reaction-Studies on six unrelated patients. Blood, 39:187, 1972.
pubmed

42) David, J. L., Herion, F.:Method for the measurement of 14C-5HT uptake and release by platelets. Platelet Function & Thrombosis. A Review of Methods. Advances in Experimental Medicine and Biology, Vol. 34 (Mannuci, P. M. and Gorini, S., eds.), New York-London:Plenum Prees, 1972. p. 335.

43) Humphrey, J. H., Jaques, R.:The release of histamine and 5-hydroxytryptamine (serotonin) from platelets by antigen-antibody reactions (in vitro). J. Physiol., 128:9, 1955.
pubmed

44) 守屋邦男:14C 5-HTによる血小板抗体の診断. 臨床病理, 11:442, 1963.

45) 安永幸二郎, 大態稔:アレルギー性紫斑病. 診療, 20:1412, 1967.

46) Garg, S. K., et al.:The increased percentage of megathrombocytes in various clinical disorders. Ann. Int. Med., 77:361, 1972.
pubmed

47) 磯部淳一, 山中學:血小板のpopulation, 血小板-基礎と臨床-(山中學, 編), 科学評論社, 1979. p. 38-64.

48) 山崎博男, 本宮武司:血小板の組織性変態, XIII. 血小板荷電とその変化, 新版日血全書11, 出血性素因・基礎, 丸善, 1979. p. 128-130.

49) Phillips, D. R. & Poh Agin, P.:Platelet plasma membrane glycoproteins. Identification of a proteolytic substrate for thrombin. Biochem. Biophys. Res. Commun., 75:940, 1977.

50) 渡辺清明, 安藤泰彦:血小板膜の研究動向. 日本臨牀, 36:3776, 1978.
Medical*Online

51) Mills, D. C. B., et al.:Platelet receptors. Platelets in Biology and Pathology, (Gordon, I. I., ed.), North Holland, Amsterdam, 1976. p. 159.

52) 池田康夫, 他:血小板のレセプター. 血小板 (山中學, 植田穣, 編), 医歯薬出版, 1982 p. 96.

53) Kaplan, K. L., et al.:Platelet alphagranule proteins:Studies on release and subcellular localization. Blood, 53:604, 1979.
pubmed

54) 新井仁, 山田律爾:β-thromboglobulin. 血小板 (山中學, 植田穣, 編), 医歯薬出版, 1982 p. 150.

55) Chesterman, C. N., et al.:Plasma levels of platelet factor 4 measured by radioimmunoassay. Brit. J. Haematol., 40:489, 1978.

56) Holmsen, H. & Weiss, H. J.:Further evidence for a deficient storage pool of adenine nucleotides in platelets from some patients with thrombocytopathia-'storage pool disease'. Blood, 39:197, 1972.
pubmed

57) Homma, M., et al.:An ultrasensitive method for the simultaneous determination of cyclic AMP and cyclic GMP in small. volume samples from blood and tissue. Biochem. Med., 18:257, 1977.

58) Samuelsson, B., et al.:Prostaglandins and thromboxanes-biochemical and physiological considerations. Advances in Prostaglandin and Thromboxane Research, Vol. 4 (Coceani, F. & Olley, P. M., eds.), New York:Raven Press, 1978.

59) Okuma, M., et al.:A simple method for estimation of lipoxygenase and cyclo-oxygenase pathways in human platelets. The use of thiobarbituric acid reaction. Thrombos. Haemostas., 42:245, 1979.

60) Smith, JB., et al.:Malondialdehyde formation as an indicator of prostaglandin production by human platelets. J. Lab. Clin. Med., 88:167, 1976.
pubmed

P.513 掲載の参考文献

1) Kakkar, V.:The diagnosis of deep vein thrombosis using the 1251-fibrinogen test. Arch. Surg., 104:152-159, 1972.

2) Hobbs, J. T., Davies, J. W. L.:Determination of venous thrombosis with 1311-labelled fibrinogen in the rabbit. Lancet, ii:134-135, 1960.

3) Atkins, P., Howkins, LA.:Detection of venous thrombosis in the legs. Lancet, ii:1217-1219, 1965.

4) Flanc, C., Kakkar, V. V., Clarke, M. B.:The detection of venous thrombosis of the legs using 125I-labeled fibrinogen. Brit. J. Surg., 55:742-747, 1968.

5) Hirsh, J., Gallus, A. S., Cade, J. F.:Diagnosis of thrombosis. Evaluation of 125I-fibrinogen scanning and blood tests. Thrombos. Diathes. Haemorrh., 32:11-20, 1974.

6) Bettmann, M. A., Salzman, E. W.:Recent advances in the diagnosis of deep vein thrombosis and pulmonary embolism. Recent Advances in Blood Coagulation (Poller, L, ed.), Edinburgh, London, Melbourne and New York:Churchill Livingstone, 1981. p. 287-317.

7) Harris, W. H., Salzman, E. W., Athanasoulis, C. A., Waltman, A., Baum, S., De Sautis, R., Potsaid, M., Sise, H.:Comparison of 125I-fibrinogen count scanning with phlebography for detection of venous thrombi after elective hip surgery. New Engl. J. Med., 292:665-667, 1975.

8) Browse, N. L, Clapham, W. F., Croft, D. N., Jones, D. J., Thomas, M. L.:Diagnosis of established deep vein thrombosis with the 125I-fibrinogen uptake test. Brit. Med. J., 4:325-328, 1971.

9) Mavor, G. E., Mahaffry, R. G., Walker, M. G., Duthie, G. F.:Peripheral venous scanning with 125I-tagged fibrinogen. Lancet, i:661-663, 1972.

10) Coe, NP., Collins, R. E. C., Klein, L. A., Bettmann, M. A., Skillman, J. J., Shapiro, R. M., Salzman, E. W.:Prevention of deep vein thrombosis in urological patients:A controlled randomized trial of low dose heparin and external compression boots. Surgery, 83:232-234, 1978.

11) Kakkar, V. V.:Deep vein thrombosis. Detection and prevention. Circulation, 51:8-19, 1975.
pubmed

12) O:Brien, J. R.:Diagnosis of venous thrombosis. Progress in Hemostasis and Thrombosis. Vol. 2 (Spaet, T. H., ed.), New York and London:Grune & Stratton, 1974. p. 311-332.

13) Henkin, R. E., Yao, J. S., Quinn, J. L., Bergan, J. J.:Radionuclide venography (RNV) in lower extremity venous disease. J. Nucl. Med., 15:171-175, 1974.

14) 石井靖, 鳥塚莞爾:血栓の放射線診断, 放射性同位元素. Medicina, 16:842-845, 1979.

15) Harwig, S. L., Harwig, J. F., Coleman, RE., Welch, M. J.:In vivo behaviour of 99mTc-fibrinogen and its potential as a thrombus. imaging agent. J. Nucl. Med., 17:40-46, 1976.

16) Asavavekinkul, S., Forbes, C. D., McDougall, I. R.:Is 99mTc-Urokinase a useful agent for detection of deep venous thrombosis. Clin. Nucl. Med., 2:235-238, 1977.

17) Persson, BB. R., Kempi, V.:Labeling and testing Of 99mTc-streptokinase for the diagnosis of deep vein thrombosis. J. Nucl. Med., 16:474-477, 1975.

18) Harwig, S. L., Harwig, J. F., Sherman, LA., Coleman, RE., Welch, M. J.:Radioiodinated plasminogen:An imaging agent for pre-existing thrombi. J. Nucl. Med., 18:42-45, 1977.
pubmed

19) Chervu, LR.:Radiopharmaceuticals in cardiovascular nuclear medicine. Sem. Nucl. Med., 9:241-256, 1979.

20) Goodwin, D. A., Bushberg, J. T., Doherty, P. W., Lipton, M. J., Conley, F. K., Diamantic, C. I., Meares, C. F.:Indium. 111-labeled autologous platelets for location of vascular thrombi in human. J. Nucl. Med., 19:626-634, 1978.

21) Fenech, A., Dendy, P. P., Hussey, J. LC., Bennett, B., Douglas, A. S.:Indium-111-labelled platelets in diagnosis of leg-vein thrombosis:Preliminary findings. Brit. Med. J., 1:1571-1573, 1980.

22) Thakur, M. L., Welch, M. J., Joist, J. H., Coleman, R. E.:Indium-111-labeled platelets:studies on preparation and evaluation of in vitro and in vivo functions. Thrombos. Res., 9:345-357, 1976.

23) Grossman, Z. D., Wistow, B. W., McAfee, J. G., Subramaniar, G., Thomas, F. D., Henderson, R. W., Rohner, R. F., Roskopf, M. L.:Platelets labeled with oxine complexes of Tc-99m and In 111. Part 2. Localization of experimentally induced vascular lesions. J. Nucl. Med., 19:488～491, 1978.

24) Riba, A. L, Thakur, M. L, Gottshalk, A., Andriole, V. T., Zaret, B. L.:Imaging experimental infective endocarditis with indium-111-1abeled blood cellular components. Circulation, 59:336-343, 1979.

25) Davis, II, H. H., Siegel, B. A., Sherman, L. A., Heaton, W. A., Naidich, T. P., Joist, J. H., Welch, MJ.:Scintigraphic detection of carotid atherosclerosis with indium:111:labeled autologous platelets. Circulation, 61:982-988, 1980.

26) Siegel, B., Felix, W. R., Popky, G. L., Ipsen, J.:Diagnosis of low limb venous thrombosis by Doppler ultrasound technique. Arch. Sur., 104:174-179, 1972.

27) Wheeler, H. B., Pearson, D., O'Connell, D., Mullick, S. C.:Impedance phlebography. Technique, interpretation and results. Arch. Surg., 104:164-169, 1972.
pubmed

28) Didisheim, P.:Animal models useful in the study of thrombosis and antithrombotic agents. Progress in Hematology and Thrombosis. (Spaet, T. H., ed.), New York:Grune & Stratton, 1972. p. 165-197.

29) 小林紀夫, 前川正:血小板よりみた血栓症の成因. 脈管学, 14:575-579, 1974.

30) Maekawa, T., Arai, H., Kobayashi, N.:The effects of aspirin on platelets and experimental thrombosis. Thrombos. Diathes. Haemorrh., Suppl. 60:363-370, 1974.

31) 前川正:血栓症の治療と予防. 臨床血液, 5:268-275, 1964.

32) Wessler, S., Reiner, S. M., Sheps, M. C.:Biological assay of thrombosis:inducing activity in human serum. J. Appl. Physiol, 14:943-946, 1959.

33) Chandler, AB.:In vitro thrombotic coagulation of the blood. A method for producing a thrombos. Lab. Inv., 7:110-114, 1958.

34) 伊藤琢夫, 小林紀夫, 前川正:Chandlerの回転チューブ法による血小板凝集ならびに血栓形成に関する検討. 血液と脈管, 5:409-417, 1974.

P.529 掲載の参考文献

1) Jensen, F. and Pedersen, J. F.:The value of ultrasonic scanning in the diagnosis of intraabdominal abscess and hematomas. Surg. Gynecol. Obstet., 139:326-329, 1974.
pubmed

2) Nowotony, C., Niessner, H., Thaler, E. and Lechner, K.:Sonography:a method for localization of hematomas in hemophiliacs, Haemostasis, 5:129-135, 1976.

3) McVerry, B. A., Voke, J., Vicary, F. R. and Dormandy, K. M.:Ultrasonography in the management of hemophilia. Lancet, i:872-874, 1977.
pubmed

4) Forbes, C. D., Lowe, G. D. U. and Prentice, C. R. M.:Ultrasonography in hemophilia. Lancet, i:1064-1065, 1977.

5) Thomas, J. L. and Cunningham, J. J.:Echographic detection and characterization of abdominal hemorrhages in patients with altered coagulation states. Arch. Intern. Med., 138:1392-1393, 1978.
pubmed

6) Kumari, S., Fulco, J. D., Karayalcin, G. and Lipton, R.:Gray scale ultrasound:Evaluation of iliopsoas hematomas in hemophiliacs. Am. J. Roentgenol., 133:103-106, 1979.

7) Alfidi, R. J. and Haaga, J. R.:Computed body tomography. Radiol. Clin. North. Am., 14:563-570, 1976.
pubmed

8) Stanley, RJ., Sagel, S. S. and Levitt, R. G.:Computed tomography of the body:early trends in application and accuracy of the method. Am. J. Roentgenol, 127:53-67, 1976.

9) Milutinovich, J., Follette, W. C. and Scribner, B. H.:Spontaneous retroperitoneal bleeding in patients on chronic hemodialysis. Ann. Intern. Med., 86:189-192, 1977.
pubmed

10) Sagel, S. S., Siegel, M. J., Stanley, R. J. and Jost, R. G.:Detection of retroperitoneal hemorrhage by computed tomography. Am. J. Roentgenol., 129:403-407, 1977.

11) Adelman, M. L, Gishen, P., Dubbins, P. and Mibashan, P. S.:Localised intramesenteric haemorrhage-a recognisable syndrome in haemophilia? Brit. Med. J., 15 Sept. 1979.

12) Guilford, W. B., Mintz, P. D., Blatt, P. M. and Staab, E. V.:CT of hemophilic pseudotumors of the pelvis. Am. J. Roentgenol, 135:167-169, 1980.

13) Sundaram, M., Wolverson, M. K., Joist, J. H., Riaz, M. A. and Rao, B. J.:Case report 133. Skeletal Radiol., 6:54-57, 1981.
pubmed

14) Silverstein, A.:Intracranial bleeding in hemophilia. Arch. Neurol., 3:141-157, 1960.
pubmed

15) Van Trotsenburg, L.:Neurological complications of hemophilia. Handbook of hemophilia, vol. 1, Chap. 25. New York:American Elsevier Pub. Co., 1975. p. 389-404.

16) Blattner, R. J.:Recent developments in management of hemophilia with particular reference to intracranial bleeding. J. Pediatr., 70:449-452, 1967.
pubmed

17) Friedman, H., Guerry, R. and Wilkins, R. H.:Intracerebral hematoma in a hemophiliac:combined surgical and factor VIII treatment. J.A.M.A., 215:791-792, 1971.

18) Seeler, R. A. and Imana, R. B.:Intracranial hemorrhage in patients with hemophilia. J. Neuro. surg., 39:181-185, 1973.

19) Kinney, T. R., Zimmerman, R. A., Butler, R. B. and Gill, F. M.:Computerized tomography in the management of intracanial bleeding in hemophilia. J. Pediatr., 91:31-35, 1977.

20) Raggio, J. F., Fleischer, A. S. and Corley, C. C.:Posterior fossa subdural hematoma in a hemophiliac. Neurosurg., 3:213-215, 1978.

21) New, P. F., Scott, W. R., Schnur, J. A., Davis, K. R. and Taveras, J. M.:Computerized axial tomography with the EMI scanner. Radiology, 110:109-123, 1974.
pubmed

22) Meino-deVillasnte, J., Taveras, J. M.:Computerized tomography (CT) in acute head trauma. Am. J. Roentgenol., 126:765-785, 1976.

23) Butzer, J. F., Cancilla, P. A. and Corneil, S. H.:Computerized axial tomography of intracerebral hematoma. Arch. Neurol., 33:206-214, 1976.

24) Harwood-Nash, D. C. and Breckbill, D. L.:Computed tomography in children:Anew diagnostic technique. J. Pediatr., 89:343-357, 1976.

25) 飯塚敦夫:頭部外傷と頭蓋内出血. 血友病, 全国ヘモフィリア友の会, 1981. p. 397-408.

26) 藤野英世, 桑原武夫:血友病. 全国ヘモフィリア友の会, 1981. p. 409-425.

はじめての方へ

個人／法人会員登録のご案内